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The process of autophagy is situated at the intersection of multiple cell 
signaling pathways, including cell metabolism, growth, and death, and hence 
is subject to multiple forms of regulation. Misregulation of autophagy has 
been recognized to result in numerous pathological consequences including 
cancer; hence manipulation of autophagy has very important therapeutic 
implications.  
We have found that the inhibition of isoprenylcysteine carboxyl-
methyltransferase (Icmt), which catalyzes the final step in the post-
translational prenylation of so-called CAAX proteins, resulted in the induction 
of autophagy which enhances cell death in some cancer cells. To this end, we 
set out to identify Icmt substrates that mediate cysmethynil-induced 
autophagy, and to delineate how these CAAX proteins impact on the 
autophagy process. Using siRNA-mediated knockdown of a group of CAAX 
proteins that are predicted Icmt substrates, the Rac3 GTPase was identified as 
a negative regulator of the process of autophagy. Knockdown of Rac3, but not 
its closely related isoforms Rac1 and Rac2, resulted in induction of autophagy. 
Ectopic expression of Rac3 but not Rac1 and Rac2, significantly rescued cells 
from autophagy induced by Icmt inhibition, strengthening the notion of an 
isoform-specific autophagy regulatory function of Rac3. The impact of Rac3 
on autophagy was observed in multiple cell lines with varying Rac subtype  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expression profiles, suggesting its broad involvement in the process. The 
identification of this less-studied Rac member as a novel negative regulator of 
autophagy has provided new insight into autophagy and opened opportunities 
in identifying additional regulatory inputs of the process.  
Moreover, we have found that FoxO1 was up-regulated and FoxO3a was 
down-regulated upon the knockdown of Rac3, suggesting that FoxO proteins 
might be involved in the autophagy regulation process of Rac3. FoxO proteins 
are members of already known autophagy regulators. They regulate autophagy 
mainly by transcriptionally promoting the expression of autophagy related 
genes. One recent study also suggested that cytosolic FoxO1 participates in the 
regulation of autophagy. In the current study, we found that cytosolic FoxO1 
indeed stimulates cellular autophagy in multiple cancer cell lines, and that it 
regulates not only basal autophagy but also that induced by rapamycin and that 
in response to nutrient deprivation. These findings illustrate the importance of 
FoxO1 in cell metabolism regulation independent of its transcription factor 
function. In contrast to FoxO1, we found the closely related FoxO3a is a 
negative regulator of autophagy in multiple cancer cell lines, a previously 
unrecognized function for this protein, different from its function in benign 
fibroblast and muscle cells. Interestingly, the regulatory role of FoxO3a on 
autophagy was determined to be through its ability to transcriptionally 
suppress FoxO1. This complicated interplay of FoxO1 and FoxO3a suggests a  
IX
complex checks- and balances-relationship between FoxO3a and FoxO1 
in regulating autophagy and cell metabolism. This study has revealed an 
unexpected role of FoxO3a in autophagy, and highlight the complexity of 
FoxO signaling and its biological impact in different cell contexts. 
Taken together, these studies will provide us not only novel information 
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CHAPTER 1: INTRODUCTION 
!
1.1 Autophagy 
Autophagy is a highly conserved intracellular process in eukaryotic 
cells. It is essential for cellular homeostasis by degrading organelles (e.g., 
mitochondria and peroxisomes), infectious agents and bulk cytoplasm, and 
eliminating long-lived, misfolded, or aggregated proteins (1). Autophagy is 
mainly thought to serve as a stress-adaption and survival mechanism, as it is 
upregulated to generate the building blocks for cellular survival under stress 
condition such as nutrient deprivation (2). So far, three types of autophagy 
have been characterized in mammalian cells: chaperone-mediated autophagy 
(CMA), microautophagy, and macroautophagy (3). 
CMA is a selective autophagic process which serves to degrade 
specific proteins sequestered within lysosomes, and CMA hence is 
significantly different from other types of autophagy. In CMA, the proteins 
containing the KFERQ motif are selectively recognized by the heat shock 
protein HSP70 and its co-chaperones, and then are selectively delivered to 
lysosome via interacting with the lysosome-associated membrane protein 
LAMP2A (4). In contrast, microautophagy deals solely with cytoplasmic 
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materials via a process that involves the cytoplasm being directly engulfed 
into the lysosome through invagination of lysosomal membrane (5). 
Macroautophagy, herein referred to simply as “autophagy,” is the most 
widely studied form of autophagy and is used by cells for the degradation of 
proteins and organelles in a process initiated by their envelopment into double 
membrane vesicles (6). This process of autophagy is dissected into four steps 
in mammals as illustrated in Figure 1. 
(1). Nucleation involves the formation of a small flattened vesicle via a 
process controlled by a protein complex consisting of ULK1(Atg1), Atg13, 
Atg101, and FIP200 complex. This complex recruits membrane to grow to a 
cup-shaped isolation membrane, or phagophore, in a process is mediated by 
the Beclin 1(Atg6)/UVRAG (UV irradiation resistance-associated gene)/
Atg14/VPS34 complex.  
(2). In elongation, the edges of phagophores expand and close to form 
a double-membrane autophagosome. This process requires the conjugation of 
the proteins Atg5 and Atg12 and is catalyzed by Atg7. Meanwhile, pro-LC3 
(Atg8) is cleaved to form LC3-I, which is then lipidated to form LC3-II, which 
associates with the autophagosome. 
(3). In maturation/fusion, the outer membrane of the autophagosome 
directly fuses with lysosome to form an autolysosome.  
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(4). In the degradation phase, the sequestered organelles and proteins 
are degraded in the autolyosome via the action of acidic lysosomal hydrolases, 
and the breakdown products (amino acids, fatty acids, sugars, and nucleosides/
nucleotides etc.) are released back into the cytosol to be reused (7-9). 
 
Figure 1. Schematic diagram of autophagy process (reference 7).  
     
It is well-known that the whole autophagy pathway is controlled by the 
proteins encoded by the so-called autophagy-related-genes (ATGs). Since the 
first ATG gene was discovered in 1993 by Ohsumi’s group using the budding 
yeast, Saccharomyces cerevisiae, thirty ATG genes have been identified 
(10-11). The identification of ATG genes in budding yeast did not only bring 
about the breakthrough in knowledge on autophagy, but also significantly help 
researchers to decipher the molecular mechanisms of autophagy from yeast to 
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Figure 1: Schematic diagram of the steps of autophagy. Autophagy begins with the formation of the phagophore or isolation membrane (vesicle
nucleation step). The concerted action of the autophagy core machinery proteins at the phagophore assembly site (PAS) is thought to lead to the expansion
of the phagophore into an autophagosome (vesicle elongation). The autophagosome can engulf bulk cytoplasm nonspecifically, including entire organelles,
or target cargos specifically. When the outer membrane of the autophagosome fuses with an endosome (forming an amphisome before fusing with the
lysosome) or directly with a lysosome (docking and fusion steps), it forms an autophagolysosome. Finally, the sequestered material is degraded inside the
autophagolyosome (vesicle breakdown and degradation) and recycled.
1.2. Molecular machinery
As detailed in numerous reviews on yeast autophagy, several genetic screens led to the identification of
autophagy-related genes, or ATG genes, in Saccharomyces cerevisiae, Hansenula polymorpha, and Pichia pastoris.
The analyses of yeast atg mutants have provided the framework for dissecting the autophagic process into distinct
steps, including (Fig. 1): (a) induction, (b) cargo selection and packaging, (c) vesicle nucleation, (d) vesicle
expansion and completion, (e) retrieval, and (f) vesicle targeting, docking, and fusion (reviewed in Suzuki and
Ohsumi, 2007; Xie and Klionsky, 2007). Gene products have been identified that act at each of these steps, and that
are required for the formation of the sequestering membrane (Fig. 2).
Four enzymatic complexes are required for autophagosome formation (Fig. 2); a serine/threonine protein
kinase complex that responds to upstream inhibitory signals like the TOR kinase and induces autophagic activity; a
class III phosphatidylinositol 3-kinase (PI3K) lipid kinase enzymatic complex that acts in vesicle nucleation; two
novel ubiquitin-like conjugation pathways that lead to vesicle expansion and completion; and a protein retrieval
system. In yeast, the induction complex includes the kinase, Atg1, and its regulators, Atg13 and Atg17, and it may
interact with Atg23 and the integral membrane protein, Atg9, to recruit membrane to the nascent phagophore (Fig.
2A). Vesicle nucleation requires a lipid kinase complex, including: Atg6, Atg14, Vps15 and the class III PI3K
Vps34, which function to generate phosphatidylinositol 3-phosphate (PI3P) (Fig. 2B) (Kihara et al., 2001). This
class III PI3K complex functions in the localization of other autophagy proteins to the forming autophagosome
(Kihara et al., 2001). Two other enzymatic complexes are the Atg12 conjugation system (Atg12, Atg5, and Atg16),
and the Atg8 lipidation system (Atg8, Atg3, and Atg7) which mediate vesicle expansion, and vesicle completion
(Fig. 2C). The retrieval system includes Atg9 which is the only transmembrane protein in the core machinery of
autophagy proteins. Atg9 functions i the shuttling f membrane from the PAS to non-PAS structures, a process
required for the formation of the autophagosome (Reggiori and Klionsky, 2006; Reggiori et al., 2004; Yen and
Klionsky, 2007). The efficient delivery of Atg9 to the PAS involves the transport factors Atg23 and Atg27 (Legakis
et al., 2007; Tucker et al., 2003; Yen et al., 2007). Finally, the retrieval of Atg9 (Fig. 2D) from the PAS involves the
Atg1 kinase complex, as well as Atg2 and Atg18, two interacting peripheral proteins (Reggiori et al., 2004; Shintani
et al., 2001; Suzuki et al., 2007; Wang et al., 2001).
Autophagy in C. elegans
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mammals. To recognize the contribution of Professor Yoshinori Ohsumi on 
autophagy, he was awarded the 2016 Nobel Prize in Physiology or Medicine. 
!
1.1.1 Roles of Autophagy in Cancer 
Dysfunctional autophagy has been implicated in a number of diseases, 
including liver disease, infectious disease, neurodegenerative disorders, aging, 
myopathy, as well as cancer (12). In cancer, autophagy has been reported to 
have important roles in cancer metastasis, formation, growth, and dormancy. 
Moreover, the responses of cancer cells to various cancer therapies can be 
significantly affected by their autophagic capacity (13). 
Although the abnormal autophagy is thought to have a role in 
tumorigenesis, cumulative evidence indicates that the exact role of autophagy 
in cancer is complicated and context-dependent. Autophagy can be a double-
edged sword in cancer, because it can either promote or inhibit tumorigenesis 
depending on the cancer type and cellular context (14-17). 
In the early stage of cancer, autophagy appears to predominantly play a 
tumor suppression role by degradation of damaged macromolecules and 
dysfunctional organelles (particularly mitochondria), prevention of damaged 
DNA accumulation and genomic instability, and limitation of oxidative stress 
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(18, 19). However, in established cancers, autophagy is generally considered 
to provide a pro-survival role. Because of the unfavorable metabolic 
conditions arising from insufficient nutrients, hypoxia and the high demand of 
energy in established cancer, autophagy is an alternative survival pathway to 
provide the energy and metabolites to support tumor growth (20, 21). 
!
1.1.1.1 Tumor Suppressive Role of Autophagy 
A major piece of evidence for a tumor suppressive role of autophagy 
came from the study of mice with allelic loss of the essential autophagy gene 
BECN1/ATG6. These mice are partially defective for autophagy and develop 
hepatocellular carcinomas with advancing age (22-24). Many studies have also 
reported that BECN1/ATG6 was monoallelically lost in 40%, 50% and 70% of 
prostate, breast, and ovarian cancers, respectively, (25-27). Moreover, 
activation of autophagy by overexpression of Beclin 1 in MCF7 cells, which 
have extremely low levels of endogenous Beclin 1, was coincident with 
decreased proliferation and inhibition of tumorigenesis (28). Also, the 
deficiency of ATG4c in mice led to the decreased autophagy and increased 
incidence of tumor formation (29).  
In addition to autophagy proteins being involved in suppressing 
tumorigenesis, many tumor suppressor proteins, such as p53, LKB1, PTEN, 
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AMPK and Bif-1, have been shown to promote autophagy (30-32). 
Furthermore, cellular responses to autophagy deficiency include many known 
causes of cancer initiation, such as genome instability and oxidative stress 
(33). Collectively, these findings suggest that autophagy has a tumor 
suppressive role in cancer. 
!
1.1.1.2 Tumor Pro-survival Role of Autophagy 
In the established cancer, cancer cells are more autophagy dependent 
than normal cells and tissues, likely due to the increased biosynthetic and 
metabolic demands imposed by deregulated proliferation (34). In this case, 
autophagy is activated to maintain cellular biosynthesis and ATP levels in 
cancer cells. For example, in RAS-transformed cancer cells, autophagy is 
upregulated and it promotes cancer cell growth and survival by preserving 
mitochondria energy production and metabolism (35).  
Autophagy has also been reported to increase cell motility and 
migration, and thereby promote metastasis and invasion. For example, 
knockdown of autophagy-related genes in oncogenic RAS-driven epithelial 
cells led to the decrease of cell motility and invasion (36). Furthermore, 
autophagy may induce cytoprotective response to various cancer therapies, 
resulted in chemoresistance. Inhibition of autophagy through either 
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pharmacological means (e.g., chloroquine) or genetic means (e.g., knockdown 
of autophagy-related genes) sensitized cancer cells to chemotherapy (37, 38). 
!
1.1.2 Autophagic Cell Death 
Programmed cell death plays a vital role in the normal development and 
physiology of metazoans. According to the morphologically distinct cell death 
modalities, programmed cell death is characterized into apoptotic cell death 
(type I programmed cell death), autophagic cell death (type II programmed 
cell death) and necrotic cell death (type III programmed cell death) (39).  
Increasingly, autophagy is considered to present therapeutic 
opportunities in cancer, because it is recognized as a participant in autophagic 
cell death. For example, sustained autophagic activation, which leads to 
turnover of proteins and organelles beyond a survival threshold, can kill some 
cancer cells with high apoptotic thresholds, thus enhancing treatment efficacy 
(40). 
Autophagic cell death is morphologically defined as a type of cell death 
that occurs in the absence of chromatin condensation but is accompanied by 
large-scale autophagic vacuolization of the cytoplasm (41). Autophagic cell 
death is distinct from apoptotic cell death. It is caspase independent, and it has 
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been presented to occur in the presence of caspase inhibitors and when 
apoptosis machinery is defective (42-43). 
However, from a purely morphological perspective, the term 
“autophagic cell death” is highly prone to misinterpretation. Therefore, to 
define the cell death as autophagic cell death, autophagy should be assessed 
based on biochemical and functional considerations (44). Autophagy serving 
as a death mechanism should meet the following criteria: (1) the cell death 
occurs without apoptosis; (2) in addition to an increase of autophagic markers 
(e.g., LC3 II), there is also an increase of the autophagy flux in dying cells; 
and (3) suppression of autophagy through pharmacological inhibitors (e.g., 3-
MA) or genetic approaches (e.g., ATG5 or ATG7 knockdown) can rescue or 
prevent the cell death. In short, autophagic cell death is cell death by 
autophagy, not cell death with autophagy (45). 
!
1.1.3 Regulation of Autophagy by mTOR Signaling 
A major modulator of autophagy in mammal is the mammalian target of 
rapamycin (mTOR), which is a serine/threonine kinase and a key component 
that responds to environmental stress and cellular physiological conditions 
(46-47). The inhibition of mTOR activity promotes autophagy, and active 
mTOR suppresses autophagy (48). 
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mTOR forms two structurally and functionally distinct signaling 
complexes: mTOR complex 1 (mTORC1), which is sensitive to rapamycin; 
and mTOR complex 2 (mTORC2), which is rapamycin insensitive (49-50). 
The proteins mLST8, Tti1/Tel2 and DEPTOR exist in both mTORC1 and 
mTORC2 complex while RAPTOR and PRAS40 are specific to mTORC1 
complex, and RICTOR, PROCTOR1/2 and mSin1 are specific to mTORC2 
complex (51-54). 












Figure 5. mTOR signaling pathway.
function of mTORC1, but not that of mTORC2, and much
more is known about the function of the rapamycin-sensitive
complex.1,2,4 Activation of mTORC1 most prominently
results in the phosphorylation of two downstream targets,
the ribosomal S6Kinase (S6K) and 4E-BP (eukaryotic
translation-initiation factor 4E-binding protein), which
stimulate ribosome biogenesis and translation to increase
cell mass.6,7 Indeed, TOR and S6K mutant Drosophila are
much smaller than wild-type animals while the cell number is
unaltered.8,9 Another manner by which mTOR regulates cell
mass is by inhibiting autophagy, a physiological starving
mechanism that returns the cell mass through degradation to
the nutrient pool.2
TOR is regulated by different incoming signals
mTORC1 activation is regulated by a complex network of
partially opposing signaling inputs.2 mTORC1 is directly
activated by the Ras-related GTPase Rheb (Ras homolog
enriched in the brain), which associates with mTORC1 in
the perinuclear region on stimulation of RAG (Ras-related
GTP-binding protein) GTPases by amino acids.10 Activation
of mTORC1 by Rheb is repressed by the tuberous sclerosis
complex (TSC) that consists of hamartin (TSC1) and tuberin
(TSC2).11,12 On stimulation by growth factors and insulin
signaling, TSC2 is phosphorylated by AKT, ERK (extra-
cellular signal-regulated kinase 1), or RSK1 (ribosomal S6K)
at specific sites which render the TSC complex inactive and
allow Rheb to activate mTORC1.4 Conversely, during energy
depletion, TSC2 is phosphorylated at a different site by
AMPK (AMP-activated protein kinase), resulting in the
activation of the TSC complex, thereby inhibiting mTORC1
activity. Similarly, TSC2 is phosphorylated and activated by
GSK3 (glycogen synthase kinase 3).13 TSC2 phosphorylation
through GSK3 is inhibited by Wnt (wingless) signals, which
leads to the activation of mTORC1. In addition to indirect
mTORC1 control through the TSC complex and Rheb, direct
inputs exist at the level of the mTORC1 complex. Growth
factor signaling-activated AKT dissociates the inhibitor PRAS40
from mTORC1, resulting in activation of the complex.14–16
Conversely, AMPK signaling directly inhibits mTORC1 through
the phosphorylation of Raptor.17 How mTORC2 is activated










































Figure 1 |The mTOR pathway. The mTOR protein is part of two protein complexes: mTORC1 and mTORC2. mTORC1 is activated by growth
factor signaling and amino acids to phosphorylate 4E-BP and S6K, resulting in ribosome biogenesis and protein translation, and to
inhibit autophagy. mTORC1 is negatively regulated by the TSC complex. Activating proteins are shown in green, inhibiting proteins in red.
mTORC2 is activated through unknown mechanisms to phosphorylate AKT and to regulate the actin cytoskeleton through PKC. For details
see the main text. aa, amino acid; AKT, protein kinase B; AMPK, AMP-activated protein kinase; Deptor, DEP-domain containing mTOR-
interacting protein; 4E-BP, eukaryotic translation-initiation factor 4E-binding protein; ERK1/2, extracellular signal-regulated kinase 1/2;
FKBP12, FK506-binding protein of 12 kDa; FoxO, forkhead box O1; GSK3, glycogen synthase kinase 3; LKB1, serine threonine kinase 11;
mLST8, mammalian lethal with Sec13 protein 8; mSIN1, mammalian stress-activated protein kinase-interacting protein; mTORC, mammalian
target of rapamycin complex; PI3K, phosphoinositide-3 kinase; PKC, protein kinase C; PRAS40, praline-rich Akt substrate of 40 kDa;
PTEN, phosphatase and tensin homolog deleted on chromosome 10; RAG, Ras-related GTP-binding protein; Raptor, regulatory-associated
protein of TOR; Rheb, Ras homolog enriched in the brain; Rictor, rapamycin-insensitive companion of mTOR; RSK1, ribosomal S6 kinase;
S6K, p 70 ribosomal S6 kinase; TSC, tuberous sclerosis complex; TSC1, hamartin; TSC2, tuberin; Wnt, wingless.
Kidney International (2011) 79, 502–511 503
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ULK1
AMP/ATP
The accumulated evidences indicate that growth factors, cellular energy 
status (AMP/ATP ratio) and nutrients (e.g., amino acids) stimulate mTORC1 
(Figure 2). mTORC1 is activated by growth factors such as IGF and insulin, 
through the PI3K/PDK1/AKT signaling axis. Activated AKT phosphorylates 
TSC1/2, a GTPase-activating protein (GAP) for the Reb GTPase, and thereby 
inhibits TSC1/2 activity. When the TSC1/2 complex is inhibited, GTP-bound 
Rheb binds the mTOR catalytic domain leading to activate mTORC1 activity 
(55). AMP Kinase (AMPK) is a sensor of cellular energy levels and is 
activated by a high AMP/ATP ratio. AMPK phosphorylates either TSC2 
(Ser1387) or RAPTOR (Ser792), resulting in mTORC1 inhibition (56-57). 
Gag subfamily of small GTPases are the key mediators of mTORC1 activation 
by amino acids stimulation. The active Rag heterodimer mediates the 
translocation of mTORC1 from the cytoplasm to the surface of the lysosome, 
where mTORC1 encounters its upstream effector Rheb and is activated by it 
(58).  After activated in response to different environmental stimuli, mTORC1 
phosphorylates a range of substrates, such as 4E-BP, S6K, and ULK1 (59). 
Unlike mTORC1 signaling, mTORC2 signaling is only stimulated by 
growth factors. In contrast to mTORC1 signaling, the mechanisms of 
mTORC2 signaling is largely unknown (60). One study proposed that insulin/
PI3K signaling activates mTORC2 through promoting its interaction with 
ribosome (51, 61). mTORC2 phosphorylates several members of the AGC 
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subfamily of kinases, such as AKT, PKC-⍺ and SGK1 (Figure 2). mTORC2 
directly activates AKT by phosphorylating it at Ser473, which is the critical 
site for maximal activation of AKT, and AKT further phosphorylates FoxO1 
and FoxO3a, which are the direct targets of AKT to regulate cell cycle, 
apoptosis and autophagy (62-63). 
While inhibition of either mTORC1 or mTROC2 complexes induces 
autophagy, they regulate autophagy through different mechanism in response 
to environmental cues (46). 
 
!
Figure 3. Regulation of autophagy by mTORC1 (Reference 51). 
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As discussed above, it is not fully understood how mTORC2 
activity is regulated. However, it was proposed that insulin/PI3K 
signaling activates mTORC2 by promoting its interaction with 
ribosome, and subsequently mTORC2 phosphorylates AKT at 
the turn motif site, Thr450, during translation (48, 80). In addi-
tion, mTORC2 phosphorylates AKT at the hydrophobic motif site, 
Ser473, which can lead to the activation of the AKT/mTORC1 sig-
naling axis. Therefore, mTORC2 may indirectly suppress autoph-
agy by activating mTORC1. Further studies are needed to deter-
mine whether mTORC2 can directly regulate autophagy.
Pharmacologic regulation of mTOR and 
autophagy
Autophagy is a cellular process essential for development and tis-
sue homeostasis. Autophagy is implicated in various physiologic 
and pathologic processes (including exercise, metabolic adap-
tation, and disorders such as neurodegenerative diseases, infec-
tious diseases, cardiovascular diseases, cancer, and aging), and 
thus pharmacologic modulation of autophagy is of great interest 
(reviewed in refs. 81, 82). As a master regulator of cellular metabo-
lism and autophagy, mTORC1 is an appealing pharmacologic tar-
get to manipulate autophagy. In fact, deregulation of mTORC1 has 
been implicated in diseases that are associated with autophagy 
defects (1), and there are mTOR inhibitors already in clinical trials 
or approved for treatment of these diseases (reviewed in refs. 83–
86). There are also pharmacologic molecules that can induce or 
inhibit autophagy via mTOR-independent mechanisms (81). For 
example, agents such as bafilomycin A1 and hydroxychloroquine 
that increase lysosomal pH can block autophagy flux by inhibiting 
autolysosomal formation. Such inhibitors could be combined with 
mTOR inhibitors to finely modulate autophagy flux. In this section 
we discuss currently available mTOR inhibitors and their effects 
on autophagy. We also summarize some mTOR inhibitors and 
their use for autophagy induction in preclinical studies (Table 1).
Rapamycin and rapalogs. Rapamycin was originally isolated 
from the soil bacterium Streptomyces hygroscopicus as an antifun-
gal compound in 1975, and was later shown to be a strong immu-
nosuppressant with broad anti-proliferative effects in mammalian 
cells (reviewed in ref. 84). About 16 years after the isolation of 
rapamycin, an elegant yeast genetic screen to identify rapamy-
cin-resistant genes led to the discovery of TOR1 and TOR2 (87). 
mTOR was identified in the mid-1990s through biochemical isola-
also regulate the VPS34 complex, a class III PI3K whose activity 
is crucial for autophagosome formation. VPS34 forms multiple 
complexes and has critical roles in cellular vesicle trafficking and 
autophagy induction. The ATG14L-associated VPS34 complex 
is specifically involved in autophagy regulation. In response to 
nutrient stress, AMPK activates the proautophagy VPS34 com-
plex by phosphorylating Beclin 1, whereas it simultaneously 
inhibits the nonautophagy VPS34 complex via phosphorylation of 
Thr163/Ser165 in VPS34 (72). In contrast, mTORC1 phosphory-
lates ATG14L in the VPS34 complex and inhibits the lipid kinase 
activity of VPS34, providing another mTORC1-mediated mecha-
nism in autophagy inhibition (73).
mTORC1 also regulates autophagy at the transcriptional level 
by modulating localization of transcription factor EB (TFEB), 
a master transcriptional regulator of lysosomal and autophagy 
genes (reviewed in ref. 74). The transcriptional activity of TFEB 
is regulated by nutrient and phosphorylation-dependent cyto-
plasm-to-nucleus shuttling (75). Although other kinases may also 
phosphorylate TFEB, it has been shown that mTORC1 directly 
phosphorylates TFEB at Ser142 and Ser211, and these phospho-
rylation events result in cytoplasmic sequestration of TFEB (76, 
77). As a key signal transducer of amino acids, the Rag GTPases 
can bind and sequester TFEB in the lysosome, thereby inhibiting 
TFEB activity (78). Thus, TFEB is constitutively activated regard-
less of nutrient availability in RagA and RagB deficient cells (47). 
In conclusion, mTORC1 coordinates both anabolism and cat-
abolism to meet the needs of cell growth. In growing cells, high 
mTORC1 activity promotes biomolecule synthesis and simulta-
neously inhibits autophagy. mTORC1 tightly regulates autoph-
agy by suppressing autophagy induction via phosphorylation- 
dependent inhibition of ULK1/2 and the VPS34 complex and by 
preventing global expression of lysosomal and autophagy genes 
through TFEB phosphorylation.
Autophagy flux denotes the sum total of autophagic molecu-
lar events, from the induction of autophagy and autophagosome 
formation to the autolysosomal degradation and reformation of 
lysosome. Interestingly, although mTORC1 is inactivated during 
autophagy initiation, the kinase complex is reactivated by energy 
supplies generated by the degradation of autolysosomal products 
at the end of autophagy flux. Its reactivation is required for the 
reformation of functional lysosomes, indicating the critical role of 
mTORC1 in the completion of autophagy flux (79).
Figure 2. Regulation of autophagy by mTORC1. Activation of mTORC1 
by nutrients and growth factors leads to inhibition of autophagy through 
the phosphorylation of multiple autophagy-related proteins, such as 
ULK1, ATG13, AMBRA1, and ATG14L, which promote autophagy initia-
tion and autophagosome nucleation. mTORC1 also phosphorylates and 
prevents nuclear localization of the transcription factor TFEB, a master 
regulator of lysosomal and autophagy gene expression. Proper lysosome 
function is essential for autophagy completion.
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1.1.3.1 mTORC1 Signaling in Autophagy Regulation 
mTORC1 mediates several steps of the autophagy progress in 
mammalian cells (Figure 3). The underlying molecular mechanism of how 
mTOC1 regulates autophagy in mammalian cells has been elucidated recently. 
mTORC1 phosphorylates ULK1 at Ser758, preventing the interaction and 
phosphorylation of ULK1 by AMPK, which is essential for ULK1 activation. 
Therefore, mTORC1 inhibits autophagy (64). mTORC1 also regulates ULK1 
through inhibiting ULK1 stability by inhibitory phosphorylation of AMBRA1 
(65). In addition, mTORC1 inhibits ULK complex by directly phosphorylating 
and inhibiting ATG13, which positively regulates ULK1 (66). Moreover, 
mTORC1 also regulate autophagy by regulating the VPS34 complex (a class 
III PI3K), which is involved in autophagosome formation as aforementioned. 
mTORC1 also directly phosphorylates ATG14 on multiples sits in the VPS34 
complex, and thereby inhibits the lipid kinase activity of VPS34, resulted in 
autophagy inhibition (67). 
!
1.1.3.2 mTORC2 Signaling in Autophagy Regulation 
Like mTORC1 inhibition, mTORC2 inhibition also induces autophagy 
in cells, but the mechanism is different from that of mTORC1 inhibition. 
Autophagy induction by mTORC2 inhibition is mainly regulated by AKT/
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FoxO signaling axis. Suppression of mTORC2 decreases the phosphorylation 
of AKT (Ser473), which subsequently inhibits the phosphorylation of FoxO 
proteins and results in FoxO proteins retention in nucleus (68). The nuclear 
FoxO proteins transcriptionally increase the autophagy-related genes 
expression, such as LC3II, ATG12 and GABARAPL1, to induce autophagy 
(69). 
!
1.2 Aims of This Study 
Recently, autophagy has garnered increasing attention as a regulated 
physiological process. Autophagy is involved in the cell’s response to its 
nutritional environment, one of the most cardinal external factors to which the 
cell needs to adapt for survival, and as such autophagy is now recognized to be 
critically involved in cell growth and survival. Misregulation of autophagy has 
been recognized to result in numerous pathological consequences, including 
cancer. Either induction or inhibition of autophagy can be a therapeutic option 
for cancer, depending on the cell context, hence advancing our knowledge on 
autophagy regulation is of fundamental importance in oncology.  
Our lab has found that the inhibition of Icmt, which catalyzes the final 
step in the post-translational prenylation of CAAX proteins, results in the 
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induction of autophagy that enhances cell death in several types of cancer cells 
(70, 71). However, the molecular mechanisms by which Icmt inhibition 
promotes autophagy remain largely unknown. In this regard, the aims of my 
thesis are:  
(i) To identify the CAAX protein(s) that mediate Icmt inhibition-induced 
autophagy;  
(ii) To delineate the signaling pathway of Rac3, a CAAX protein identified in 
aim (i), in autophagy regulation;  
(iii) To study the interplay of FoxO1 and FoxO3a in autophagy regulation in 










CHAPTERS 2: MATERIALS AND METHODS 
!
2.1 Antibodies 
Antibodies recognizing Flag and human GAPDH, Atg5, p-AKT(S473), 
p62, FoxO1(C29H4), FoxO3a(75D8), p-FoxO1(T24), p-4EBP1(T37/46), p-
S6(S240/244), and Histone H3 were from Cell Signaling Technology (Danver, 
MA). HA and Myc antibodies were from Upstate (Waltham, MA), GFP 
antibody was from Fitzgerald Industries Intl (Concord, MA), and LC3 
(APG8A) antibody was from Abgent (San Diego, CA). 
!
2.2 Cell culture 
PC3, MDA-MB-231, U87, HCT116, HeLa, and H1299 cells were 
obtained from American Type Culture Collection (ATCC; Manassas, VA). 
Cells were maintained at 37 ˚C with 5% CO2 in DMEM (Sigma-Aldrich, St. 
Louis, MO) supplemented with 10% FBS (Hyclone, Novato, CA), 50 units/ml 
penicillin and 50 µg/ml streptomycin (Invitrogen, North Andover, MA). Cells 
were subcultured when reaching 70% to 90% confluence. Basically, cells were 
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detached by using 0.25% trypsin (Invitrogen) after washed once with PBS and 
spilt at the ratio from 1:4 to 1:10. Standard cell culture procedures and 
methods following ATCC Animal Cell Culture Guide were used. 
!
2.3 Cell viability assay 
The cell viability assays were performed using CellTiter® 96 AQueous 
One Solution Cell Proliferation Assay (Promega, Madison, WI). Briefly, 2×103 
cells per well were seed in 96-well plates with 200 µl cell culture medium.  In 
next day, cells then were subjected to different drugs treatment in 200µl 
culture medium for further 2 to 3 days. 20µl MTS reagent was added to each 
well at experimental end points. After three hours of incubation at 37 ˚C, 
cellular proliferative activity was measured using microplate spectro-
photometer (Bio-Rad, Hercules, CA) at absorbance 490 nm. Each condition 
was performed in triplicate, and data presented that obtained from at least 
three separate experiments. 
!
2.4 Cloning 
Rac1 and Rac3 coding sequence were amplified from PC3 cDNA, and 
Rac2 coding sequence was amplified from U87 cDNA using Taq DNA 
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polymerase (Thermofisher Scientific, Waltham, MA). Subsequently, PCR 
products were run in 0.7% agrose gel, and products in expected size were cut 
and then purified using QIAquick Gel extraction Purification Kit (QIAGEN, 
Hilden, Germany). Both pcDNA3.1-Myc and pcDNA-HA plasmids, and PCR 
products were digested using EcoRV and XhoI restriction enzymes (New 
England Biolabs, Ipswich, MA) at  37 ˚C for 3 hours. The double digested 
plasmids and PCR products were run on 0.7% agrose gel and purified using 
QIAquick Gel Extraction Kit. Next, double digested plasmids and PCR 
products were ligated at 1:10 molar mass ratio overnight at 16 ˚C using T4 
DNA ligase (Thermofisher Scientific). The ligation product was transformed 
into DH5α competent bacterial cells by heat shock, and bacterial cells were 
selected in ampicillin agar plate for overnight. A single positive clone was 
selected and inoculated for plasmid production. All plasmids were extracted 
using QIAprep Spin Miniprep Kit (QIAGEN) and verified by DNA 
sequencing. 
!
2.5 Site-directed mutagenesis 
Flag-FoxO1, Flag-FoxO1-DB (deletion of residues 208–220 of FoxO1) 
and Flag-FoxO3a expression plasmids were purchased from Addgene 
(Cambridge, MA). Flag-FoxO3a-3A (Alanine substitution of Thr 32, Ser 253 
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and Ser 315 of FoxO3a) was generated using Flag-FoxO3a as template by 
QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies, Santa 
Clara, CA). Briefly, Flag-FoxO3a-3A was generated from Flag-FoxO3a by 
three steps mutagenesis. Firstly, Flag-FoxO3a (T32A) was generated using 
primers T32A-Forward and T32A-Reverse from Flag-FoxO3a. Secondly, 
Flag-FoxO3a (T32A, S253A) was generated using primers S253A-Forward 
and S253A-Reverse from Flag-FoxO3a (T32A). Finally, Flag-FoxO3a-3A 
(T32A, S253A, S315A) was generated using primers S315A-Forward and 
S315A-Reverse from FoxO3a (T32A, S253A). In each step, plasmid sequence 
was verified by DNA sequencing. Flag-FoxO3a(r) (which is wide type 
FoxO3a protein coded by cDNA resistant to siFoxO3a) was generated by 
mutating five siRNA-1 of FoxO3a targeting base-pairs in the wild-type Flag-
FoxO3a plasmid using primers (siFoxO3a-Resistent-Forward and siFoxO3a-
Resistent-Reverse) by QuikChange II Site-Directed Mutagenesis Kit. All 
primers’ sequence were shown in Table 1. All plasmids were were extracted 
using QIAprep Spin Miniprep Kit (QIAGEN) and verified by DNA 
sequencing. 
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Table 1. Mutagenesis primers sequence 
!
2.6 Transfection of siRNA and DNA 
Transfections of siRNA or DNA were performed using Lipofectamine™ 
2000 (Invitrogen) based on manufacturer’s protocol. Briefly, 3×104 cells (for 
siRNA transfection) or 6×104 cells (for DNA transfection) per well in 500 µl 
of growth medium were seed in 24-well plate at one day before transfection. 
In the next day, cell confluence reached to 70% for siRNA transfection or 90% 
for DNA transfection, respectively. For each transfection sample in 24-well 
plate, siRNA or DNA/Lipofectamine 2000 complexes were prepared as 
follows: (1). Diluted 3 µl of 20 µM siRNA or 0.5 µg DNA in 60 µl Opti-MEM 
(Invitrogen) and incubated for 5 min at room temperature. Meanwhile, diluted 
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3 µl Lipofectamine 2000 in 12.5 µl Opti-MEM and also incubated for 5 min at 
room temperature. (2). Mixed the diluted siRNA or DNA with diluted lipid 
gently, and left for 20 min at room temperature to allow siRNA or DNA/
Lipofectamine 2000 complexes form. (3). Added 100 µl Opti-MEM into the 
mixture. (4) Discarded the medium, transferred the mixture to the 24-well 
plate and put the plate into cell culture incubator. (5). After 5 hr incubation in 
cell culture incubator, added fresh DMEM medium with 10% of FBS and 
incubated for overnight. (6) Discarded the medium and added fresh DMEM 
medium with 10% of FBS next day. (7). Passaged cells when cell confluence 
reached to 90%. The transfection efficiency were verified by either qRT-PCR 









Table 2. siRNA target sequence 
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Gene siRNA Target Sequence (5’ to 3’) Gene siRNA Target Sequence (5’ to 3’)
CENPF a.  CAGAATCTTAGTAGTCAAGTA b.  CAGGAAAGACTAGCCCATATA PRICKLE3
a. CCCTACAACCTAAGTCATAAA 
b. TCGGCTAATCTCGGACTTCCA
FNTB a.  CACGTCCATAGAACAGGCAAA b.  CAAGGTTTATACGTTTCAATA RAB3
a. CCCGTCACCCTTATTTATTAT 
b. CCGGACCATCACCACCGCATA
FOXO1 a. TTGTACAGGTGTCTTCACTTGGGTC b. ACATGCTCAGCAGACATCTGCAGTT RAC1
a. ACAAGCCTTCTTAAAGCCTTA 
b. ATGCATTTCCTGGAGAATATA
FOXO3A a. ATTGACCAAACTTCCCTGGTTAGGC b. GAGCTCTTGGTGGATCATC RAC2
a. AACTACTCAGCCAATGTGATG 
b. ACCGTGTTTGACAACTATTCA
GNA11 a.  CTACAAGTACGAGCAGAACAA b.  AACGTGACATCCATCATGTTT RAC3
a. CGCGCCCATGCAGGCCATCAA 
b. AACGTGATGGTGGACGGGAA
GNA12 a.  CCGGATCGGCCAGCTGAATTA b.  GTCCGTTTAACTCGATAGAAA RALB
a. CCCAAAGACGTGATGAGTTAA 
b. CAGGAATGGTGTGCATTATAA
GNA14 a.  GACAACGAGAATCGCATGGAA b. AGGGAATTCAACCTTGTCTAA RAP1A
a. AAGATCAATGTTAATGAGATA 
b. CAGGGCCAGAATTTAGCAAGA
GNAI1 a. ATGGACGATTACACTTAGAAA b. CTGCATAAGTGTAAATATGCA RAP1B
a. GACGAGTACTGTGGATGTGAA 
b. CAGTATAATGTCTTAGATTAA
GNAI2 a.  CCGGGCGGTTGTCTACAGCAA b.  CAGCCCAAGTCCAAATGTTTA RAP2B
a. AAGGTGGTCTTAGTAATATAA 
b. CTCACTTAAGTTTGATATCAA
GNAI3 a. ACCGATGTTAACTGTAGTAAT b. AAAGTGTGATTCGATCGTCAA RASD2
a. CTCCGTGTACACTATCAATAA 
b. TTCGTGTCATGTATAGTAGTA
GNAL a. ATGGGTTTAATCCCGAGGAAA b. CACCGGTGACGGCAAACATTA RASEF
a. CCGGAAGCTACATGACAGTAA 
b. CAGCCATATGAACATGTTATA
GNAQ a. CAGGAATGCTATGATAGACGA b. CAGGACACATCGTTCGATTTA RHEB
a. ATCCCTAGACCTTGACTGAAA 
b. TTGCCTGTCACTGTCCTAGAA
GNAS a. CAGAATTTGCTCGCTACACTA b. CCAAATTTAATTAAAGCCTTA RHOB
a. CCTGCTGATCGTGTTCAGTAA 
b. ACAAGGCATTCTCTAAAGCTA
GNAZ a. CGGGACACGTGTTGTACATAA b. ACGGATAGATTGCTAGGTAGA RHOC
a. CCCTACTGTCTTTGAGAACTA 
b.CACCATGGCTGCAATCCGAAA
GNG11 a. CAGAGAGTATCAGATGTACAA b. TTGGGAGAAACTGCATCCTAA RHOF
a. CCCATCGGTGTTCGAGAAGTA 
b. CTGGTAGTGGGTAAACGTAGA
GNG13 a. CCAGCGGGAGATGGCGTCCAA b. CACGTGATTACAGTCTGTAAA RHOG
a. ACCCACGATGCAGAGCATCAA 
b. CTGGGTATTCTCATGAGCTCA
HRAS a. CCGGAAGCAGGTGGTCATTGA b. AGGAGCGATGACGGAATATAA RHOH
a. TTCACTAACTACACTCTACAA 
b. TTGATCCTATGAGGAAATCAA
INPP5E a. CAGAAATGTGCCCGACACCAA b. CACGTACGACAGCACCTCCAA RHOJ
a. CCCGATTATAAGAAGACATGA 
b. CACGTGCCTTATGTCCTCATA
KRAS a. CAGACGTATATTGTATCATTT b.  AAGGAGAATTTAATAAAGATA RHOQ
a. AGGGAGAATAGTAATCCCTCA 
b. ATAGTTTACTATCTACGTAAA
C9ORF169 a. CAGGGTGATCTTCCTCCCAAA b. CAGGACCCAGACTTCAGCAAA RNF208
a. CACAGAGATCATTGTCAACCA 
b. TGAGGTCATTGTGAATCAGTA
MRAS a. CAGGAACAACGCTGCACCAAA b. CAGAAGGTAATGGGAACTGTA RRAS
a. CCGGGTCACTGCTGTATATAA 
b. CTCGGCCAAACTGCGTCTCAA
PDE6A a. CAGATGTATTATGAGCTCAAA b. CATGTGAAGTGTGACAATGAA STK11
a. GAGGATGACCTAGCACTGAAA 
b. AACGTGAAGAAGGAAATTCAA
PDE6B a. CCGGGAAATTGTCTTCTACAA b. CACGCTGCTCATGACCGGCAA UBL3
a. AAGGACGATTTCTACATGGAA 
b. CCCGGCGGATATGATAAATTT




Whole cell lysates were prepared by incubating cell pellets on ice for 20 
min in radio-immunoprecipitation assay (RIPA) buffer (Sigma-Aldrich) 
supplemented with phosphatase inhibitor cocktail settlement II and protease 
inhibitor cocktail set I (EMD Millipore, Billerica, MA) after cells were 
washed once with cold PBS. The cell lysates were subsequently sonicated on 
ice for 5 min with 10 second on and 10 second off using sonicator. Next, the 
lysate supernatant were collected by centrifugation at  20,000 g for 20 min at 4 
˚C.  Protein concentrations were measured using a Bicinchoninic acid (BCA) 
protein assay kit (Thermofisher Scientific). Protein samples were prepared in 
protein loading buffer and heated for 5 min to denature proteins before loading 
proteins into SDS-PAGE gel. Proteins were transferred onto polyvinylidene 
difluoride (PVDF) membrane after proteins were separated by SDS-PAGE gel. 
Membrane was blocked with 5% milk in TBST (tris-buffered saline 
supplemented with 0.1% (v/v) tween-20) for an hour at room temperature, 
followed by staining with the primary antibodies overnight at 4 ˚C. 
Membranes were subsequently washed three times in TBST before probing 
with secondary antibodies for an hour at room temperature. Finally, the 
membranes were washed three times in TBST before immunoblot analysis. 
Immunoblot analysis was performed using an enhanced chemiluminescence 
procedure (GE Healthcare, Piscataway, NJ). 
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2.8 siRNA screening of Icmt substrates 
Standard immunoblot analyses were employed to determine significance 
of findings for the select CAAX proteins. In the screen to identify targets, PC3 
cells were transfected with siRNAs targeting a group of CAAX proteins; two 
siRNAs for each target were employed. Cell lysates were prepared 96 h after 
transfection. The LC3-II value was normalized to GAPDH for each sample. In 
the end of screening, the mean value of the ratio of  LC3-II/GADPH for the 
whole group was calculated, which is called ‘MEAN”. The ratio of LC3-II/
GAPDH for each set of knockdowns is reported as the ‘SD’ (standard 
deviation) from the ‘MEAN’. The experiment has been repeated twice for 
each set of siRNAs.	
!
2.9 Confocal imaging and analysis 
After the desired drugs treatment or transfection, cells were fixed with 
4% paraformaldehyde, followed by permeabilization with cold methanol. For 
cells went through immunofluorescent labeling, the fixed and permeabilized 
cells were incubated with blocking buffer (5% normal goat serum, 0.3% Triton 
X-100 in PBS) for 1 h at room temperature, followed by incubation in the 
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appropriately diluted antibody in antibody dilution buffer (1% BSA, 0.3% 
Triton X-100 in PBS) overnight at 4 ˚C. Cells were then washed three times 
with PBS and subsequently incubated with either FITC-goat anti-rabbit 
(1:1000) or Rhodamine-goat anti-mouse IgG secondary antibodies (1:1000), 
as appropriate, in antibody dilution buffer for 1 h at room temperature. All 
confocal images were taken with a Carl Zeiss LSM 710 confocal microscope 
(Oberkochen, Germany). Imaging data were analyzed by Metamorph Analysis 
Software (Molecular Devices Inc., Sunnyvale, CA). Colocalization efficiency 
of mRFP to that of GFP fluorescent signals was measured using ImageJ 
software. 
!
2.10 Quantitative real-time PCR assay (qRT-PCR)	
Total RNA was extracted using RNeasy Mini Kit (QIAGEN) according 
to the manufacturer’s instructions. Subsequently, first-strand cDNA was 
synthesized under standard conditions with the Superscript First-strand 
Synthesis System (Invitrogen). Quantitative PCR was carried out using SYBR 
green supermix (Bio-Rad) in CFX96 Real-Time System (Bio-Rad) with qRT-
PCR primers (Table 2). The quantification of the transcripts for Rac3 in 
different cell lines was performed using a standard curve with 10-fold serial 
dilution of a cloned plasmid of the corresponding genes. Rac isoform specific 
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PCR reactions were verified by both melt-curve analysis and sequencing 
analysis. The quantity of the transcript was normalized to the level of 
ribosomal proteins 18S.	
Table 3. qRT-PCR primers sequence 
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Cysmethynil was synthesized by the Duke Small Molecule Synthesis 
Facility via established methods. Rapamycin, Chloroquine, and 
Cycloheximide, Bafilomycin, G418 were purchased from Sigma-Aldrich. 
Cysmethynil , Rapamycin and Bafilomycin were dissolved in 
dimethylsulfoxide (DMSO), and Chloroquine, Cycloheximide and G418 were 
dissolved in H2O. All reconstituted drugs were aliquoted and stored at -20  ̊C. 
For treatment of Cysmethynil, DMEM medium with 5% of FBS was used. 
DMEM medium with 10% of FBS was used for all other drugs treatment. 
!
2.12 Cytosol/nucleus fractionation 
Cells were trypsinized using 0.25% trypsin-EDTA solution (Invitrogen) 
and centrifuged at 800 g for 5 min at 4  ̊C. The supernatant was removed and 
cell pellet was washed with cold PBS before centrifugation at 800 g for 5 min 
at 4 ˚C. Cell pellet was resuspended in cold resuspension buffer (100 mM Tris-
HCl pH 7.6, 15 mM Mg(OAc)2, 10 mM KOAc, 10 mM PMSF, 0.5% NP40, 
1% protease inhibitor cocktail), and left on ice for 20 min before 
centrifugation at 2,500 g for 5 min at 4 ˚C. The supernatant fraction was 
"26
collected as the cytoplasmic extract. The pellet was washed once with the 
same buffer before being suspended at 4 ˚C in nuclei lyses buffer (100 mM 
Tris-HCl pH 7.6, 42 mM NaCl, 50 mM EDTA, 10 mM PMSF, 2% SDS, 1% 
protease inhibitor cocktail). Following 10 min incubation on ice, the 
suspension was sonicated for 3 min on ice before centrifugation at 12,000 g 
for 15 min at 4 ˚C. The supernatant fraction was collected as the nuclear 
extract. Protein concentrations were measured using a BCA protein assay kit 
(Thermofisher Scientific) before loading proteins into SDS-PAGE gel. 
!
2.13 Generation of stable cell lines 
The MDA-MB-231 cell with stable expression of tandem fluorescent 
mRFP-GFP-LC3 was generated using G418 selection.  Briefly,  6×104 MDA-
MB-231 cells per well were seed in 24-well plate at one day before 
transfection. The mRFP-GFP-LC3 plasmid, which was a gift from Dr. 
Tamotsu Yoshimori (72), was transfected using Lipofectamine™ 2000 based 
on our standard protocol. After 48 hr post-transfection, 6×104 transfected 
MDA-MB-231 cells per well were seed on 6-well plate and treated with 1000 
µg/ml G148 in the next day. After 7 days antibiotics selection, all cells had 
expression of mRFP-GFP-LC3 evaluated by fluoresce microscopy. The 
antibiotics were subsequently removed and fresh medium was added to 
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continue culturing MDA-MB-231 cells with stable expression of mRFP-GFP-
LC3, which were used for the autophagic flux assay.  
!
2.14 Data analysis 
Data was presented as Mean ± S.D. or Mean ± S.E.M. Statistical 
differences were assessed by Student’s t test. Differences were considered 
statistically significant at “*”, p<0.05 and “**”, p<0.01. All experiments have 










CHAPTER 3: A ROLE FOR RAC3 GTPASE IN THE 
REGULATION OF AUTOPHAGY 
!
3.1 Introduction 
3.1.1 CAAX Proteins 
CAAX proteins are a group of proteins which have carboxy-terminal 
CAAX motifs, in which “C” is an invariant cysteine, “A” is usually an 
aliphatic amino acid, and “X” can be any of several amino acids depending on 
different substrates specificity (73-75). CAAX proteins have essential roles in 
numerous cellular signaling pathways and regulatory events that are important 
in cell biological functions, such as cell differentiation, proliferation, and 
migration, spermatogenesis, embryogenesis, metabolism, apoptosis, and 
carcinogenesis (76). According to genomic, structural, biochemical and 
functional analysis, over 200 CAAX proteins are expressed in mammalian. 
These proteins include Ras superfamily of GTPases (Ras and Rho GTPases 
etc.), nuclear lamins (lamin A, lamina B1/B2), γ-subunit of heterotrimeric 
GTPasess, several protein tyrosine phosphatases and Ser/Thr protein kinases, 
etc. (77-79).  
!
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3.1.1.1 Prenylation Pathway 
Upon targeting with the plasma membrane or with other membrane 
compartments to function, the CAAX proteins are promoted by a well-
described series of post-translational modifications, which termed prenylation 
pathway, at c-terminal CAAX motifs (80). The prenylation pathway, which is 
briefly illustrated in Figure 4, consists of polyisoprenylation, proteolysis, and 
carboxyl methylation (81).  
In the first step, 15-carbon farnesyl diphosphate (FPP) or 20-carbon 
geranylgeranyl diphosphate (GGPP) are added to the cysteine residue of the 
CAAX motif by farnesyltransferase (FTase) or geranylgeranyltransferase type 
I (GGTase-I), respectively. The “X” of CAAX motif determines which 
enzyme recognizes on protein. FTase usually recognizes CAAX proteins with 
X = M, S, Q, A, or C, whereas GGTase-I recognizes CAAX proteins with X = 
L , I or F (82-83). Subsequently, the prenylated-CAAX proteins are anchored 
to the endoplasmic reticulum (ER), where the AAX is proteolytically removed 
by RCE1. Finally, the newly exposed carboxyl group of the prenylated 
cysteine residue is methylated by isoprenylcysteine carboxyl-
methyltransferase (Icmt) in ER using S-adenosyl-L-methionine (AdoMet) as 
methyl donor (84).  
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 Figure 4. Prenylation process of CAAX protein (Reference 81). !!!
The hydrophobic C-terminus provided from prenylation greatly increase 
the capacity of CAAX proteins to interact with cellular membranes, such as 
plasma membrane and endomembrane, which have a high concentration of 
signaling molecules. Except affecting CAAX protein locations in cells, protein 
prenylation also modulates protein stability and defines specific protein-
protein interactions (85). 
Because of the ubiquitous nature of the protein prenylation and its 




Figure 1. CAAX protein prenylation process. !!
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HMG-CoA reductase
(HMGCR). The rate-controlling 
enzyme of the mevalonate 
pathway of cholesterol and 
isoprenoid biosynthesis and 
the target of the widely-used 
statin drugs.
Sterols
The major biosynthetic end 
products of the isoprenoid 
biosynthetic pathway; sterols 
occur naturally in eukaryotic 
organisms, with the most 
well-recognized animal sterol 
being cholesterol.
Mevalonate
The direct product of the 
HMG-CoA reductase (HMGCR) 
reaction and the first 
committed intermediate in the 
biosynthetic pathway that 
produces isoprenoids and, 
subsequently, sterols.
the maturation of prelamin A depends on prenylation, 
combined with understanding of the biochemistry 
of prelamin A processing9,10, led to a swift translation
from bench to bedside. In the cancer field, the prenyl-
ation of RAS GTPases, which drive more than 30% 
of human cancers, has been the subject of an intense 
drug- development effort for more than two decades. 
There has been renewed interest of late in targeting 
these ‘undruggable’ RAS proteins, not only because of 
advances in the structural determination of RAS and its 
partners, but also owing to its importance as a potential 
anticancer target. Targeting RAS localization through 
the disruption of prenylation remains a viable way to 
render this protein ‘druggable’ (REF. 11).
A brief history of protein prenylation
The first evidence for the modification of proteins by 
isoprenoid lipids came in the late 1970s from chemical 
analysis of a fungal mating factor, rhodotorucine A, 
which identified a farnesyl isoprenoid linked to a Cys 
residue of the peptide by a thioether bond12. The exist-
ence of prenylated proteins in mammals was first sug-
gested by studies of inhibitors and of feedback regulation 
of HMG-CoA reductase (HMGCR)13 (FIG. 1). The inhibitors, 
known as statins, were found to block cell proliferation 
in a way that could not be reversed by adding sterols14,15 
to the media. This suggested that an early inter mediate 
(or intermediates) in the bi synthesis of sterols was 
involved in the control of cell proliferation. An impor-
tant clue came from the observation that 3H-labelled 
mevalonate was incorp rated into many cellular pro-
teins when it was added to the media of statin-treated 
cells; these labelled proteins were dubbed ‘prenylated 
proteins’ (REF. 16). Subsequently, the nuclear protein 
lamin B was the first prenylated protein to be identified 
in mammals17, although at that time the identity of the 
 isoprenoid attached to the protein was not known.
The important finding that brought prenylation 
to the attention of the broader cell biology commu-
nity was the ‘rediscovery’ in 1988 of the prenylation of 
 fungal mating peptides — specifically, the farnesylation 
of the mating pheromone a-factor of Saccharomyces 
 cerevisiae18. The recognition that the genes encoding 
the yeast  a-factor and lamin B both code for sequences 
that predict a CAAX motif at their C termini, and that 
disruption of genes in yeast that affected prenylation 
process ing of the mating factor also affected the function 
of another CAAX-type protein, Ras1 (REF. 8), prompted 
a flurry of activity to determine whether mamma-
lian RAS proteins are also processed in this manner. 














































Figure 1 | Isoprenoid metabolism and CAAX protein prenylation. a | The production of farnesyl diphosphate (FPP) and 
geranylgeranyl diphosphate (GGPP) share the early steps of the cholesterol synthesis pathway initiated by HMG-CoA 
reductase, which is an endoplasmic reticulum (ER)-associated enzym  a d the target of statin drugs. FPP can be 
converted either to squalene (which is the committed precursor of sterols) or to GGPP, by squalene synthase or GGPP 
synthase, respectively. b | Cytosolic protein farnesyltransferase (FTase) and protein geranylgeranyltransferase (GGTase), 
which are the CAAX protein prenyltransferases, add farnesyl or geranylgeranyl, respectively, to the Cys of the CAAX motif 
of substrate proteins such as RAS. The post-prenylation modifications occur on the cytosolic surface of the ER as a result 
of the actions of RAS-converting CAAX endopeptidase 1 (RCE1) and isoprenylcysteine carboxylmethyltransferase (ICMT), 
both of which are intrinsic ER membrane proteins. The fully processed prenylated proteins are then trafficked to the 
destination membrane. AdoHcy, S-adenosyl-ƃhomocysteine; AdoMet, S-adenosyl methionine; GPP, geranyl diphosphate; 
IPP, isopentenyl diphosphate.
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lots of diseases, including cancer, cardiovascular diseases, neurodegenerative 
disorders, aging, infectious disease and metabolic diseases (86). For relevance 
in my study, many prenylated CAAX proteins are in relation to various aspects 
of carcinogenesis, such as cell proliferation and migration, apoptosis, 
angiogenesis, metastasis and autophagy (87). For example, prenylation of Ras, 
centromere protein F (Cenp-F), and lamin B plays a critical role in the 
regulation of cell proliferation and migration; and prenylation of Rac, Rho and 
protein tyrosine phosphatase (PTP4A3) modulate apoptosis, angiogenesis, 
metastasis, and autophagy (88-89).  
!
3.1.1.2 Ras GTPases and Human Cancer  
The roles of Ras superfamily in carcinogenesis are particularly 
interesting, and their roles in carcinogenesis have been well studied (75, 90). 
Since Der et al. observed that human Ras proteins mutation can cause caner in 
1982, Ras mutation has been detected in ~30% human cancer (91). Mutation 
of genes in the Ras subfamily, consisting of KRas (KRas-4A and KRas-4B), 
NRas and HRas, has been reported to associate with different type of cancer. 
KRas is mainly mutated in pancreatic cancer, lung cancer, myeloma, and 
colorectal cancer; NRas mutation is mainly found in melanoma and myeloma; 
HRas mutation is found in bladder cancer and thyroid cancer (92-93). All 
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these mutations prevent GAP-stimulated GTP hydrolysis, therefore Ras is 
rendered in constitutively active GTP-bound state (94). Furthermore, 
amplified expression or mutation in upstream of Ras signaling is also found in 
many cancers, which leads to hyperactivation of Ras (95). 
In addition to Ras subfamily of GTPases, the Rho subfamily of GTPases 
also involves in cancer initiation and progression. Unlike Ras subfamily, Rho 
subfamily does not have mutated form proteins. In contrast, altered expression 
of Rho subfamily GTPases at mRNA or protein level is found in multiple 
human cancers . Overexpression of RhoA is found in bladder cancer, breast 
cancer and colon cancer; overexpression of RhoC is found in pancreatic 
cancer, melanoma and breast cancer; Rac GTPases (Rac1, Rac2, and Rac3) 
over expression are found in head and neck cancer, colorectal cancer and 
breast cancer (96). Although overexpression alone does not necessarily imply 
a functional role in carcinogenesis, increased levels of these Rho proteins 
consistently correlate with aggressive clinical behavior and histological 
features, which suggests an important role of Rho in tumorigenesis (97-98).  
!
3.1.1.3 Potential Strategies for Targeting Ras Signaling Pathway 
Given the high mutation frequency and important role of Ras in 
carcinogenesis, both academia and industry have pursued intensive effort and 
"33
interest on developing pharmacological Ras inhibitors since more than three 
decades ago. Because it is very challenging to directly target on Ras, targeting 
it indirectly as an alternative strategy is explored. The possible strategies on 
designing inhibitors targeting the Ras signaling pathway are shown in Figure 
5.  
Figure 5. Possible strategies for targeting post-translational modifications 





Figure 2. Possible strategies for targeting post-translational modifications and functional 

































tumour cells exposed to radiation therapy both in vitro 
and in vivo123. Even in tumours without RAS mutations, 
FTIs have proved to be potent radiation sensitizers. 
Increased oxygenation after FTI therapy and decreased 
prenylation of RHOB and RAS have been implicated in 
the radiosensitizing effects of FTIs.
As a proof-of-concept, a Phase I study of the dual 
FTase and GGTase I inhibitor L-778,123 in combina-
tion with radiotherapy was carried out in patients with 
locally advanced pancreatic cancer. L-778,123 was given 
by continuous intravenous infusion with concomitant 
radiotherapy to 59.4 Gy in standard fractions. Reversible 
inhibition of HDJ2 farnesylation and radiosensitization 
were demonstrated in a patient-derived cell line. The 
combination of L-778,123 at a dose of 280 mg per m2 per 
day over weeks 1, 2, 4 and 5 with radiotherapy showed 
acceptable toxicity; one out of eight patients showed a 
partial response of 6 months in duration124.
Targeting functional regulation
Several strategies have been developed for targeting the 
functional regulation of the RAS superfamily of GTPases 
(FIG. 5). These strategies focus either on compounds that 
inhibit the interaction between the RAS superfamily of 
GTPases and regulatory proteins (that is, GEFs, GAPs 
and GDIs) or on development of drugs that target indi-
vidual RAS superfamily GTPases or regulatory proteins, 
thereby blocking GDP/GTP exchange and inhibiting the 
activation of downstream effectors.
Targeting interactions between the RAS superfamily 
of GTPases and regulatory proteins. The exact role of 
the GAP, GEF and GDI regulatory proteins in carcino-
genesis depends on the type of cancer, tumour stage 
(early versus late/metastatic) and, most importantly, 
on the RAS superfamily of GTPases that they regulate. 
Although in most circumstances GEFs and GDIs act as 
oncogenes and GAPs act as tumour suppressor genes, 
there are many exceptions. For example, AMAP1/
PAG2 is an ARF-GAP that is overexpressed in highly 
invasive breast cancer cells and its short-interfering 
RNA (siRNA)-mediated silencing effectively blocks 
invasion125. Furthermore, various GDIs may be over- or 
underexpressed in human malignancies correspond-
ing to different types of tumours and different stages 
of disease. Last, regulatory proteins may regulate RAS 
superfamily GTPases that may be tumorigenic or not 
(RAS and RHOA, for instance, are tumorigenic, whereas 
RHOB has growth inhibitory activity)70. In light of the 
complex roles of regulatory proteins in the carcinogenic 
process, a deep understanding of the role of individual 
regulatory proteins in different tumour types and stages 
of the disease is required before targeting each regulatory 
protein for anticancer therapy.
There are several problems with identifying com-
petitive inhibitors of interactions between regulatory 
proteins and RAS superfamily GTPases. First, both 
regulatory proteins (that is, GEFs, GAPs and GDIs) and 
RAS superfamily GTPases exist as families with highly 
similar members, making the discovery of specific inhibi-
tors challenging. Second, many regulatory proteins have 
more than one RAS superfamily GTPase as targets, and 
conversely many RAS superfamily GTPases may be regu-
lated by more than one regulatory protein. Therefore, 
competitive inhibitors might non-selectively interfere 
with multiple pathways, inducing prohibitive toxicity.
A promising way to overcome these challenges is the 
development of interfacial inhibitors that bind at the 
interface of the RAS-superfamily-GTPase–regulatory-
protein macromolecular complex as it undergoes 
structural transitions from one stable conformation to 
another126,127. These transitions frequently generate struc-
tural and energetic ‘hot spots’ (usually contributed by a 
few amino-acid residues) that constitute excellent targets 
for the development of small-molecule inhibitors. These 
inhibitors bind to the hot spot of a transient intermediate 
RAS-superfamily-GTPase–regulatory-protein complex, 
preventing it from carrying out its biological function. 
An important characteristic of interfacial inhibitors is 
that they recognize both components of the complex (the 
RAS superfamily GTPase and the regulatory protein), 
resulting in superior specificity. Additionally, interfacial 
inhibitors target the two components only when they 
interact in a complex and not the RAS superfamily 
Figure 5 | Possible strategies for targeting post-translational modifications and 
functional regulation of the RAS superfamily of GTPases. Statins, biphosphonates 
and isoprenoids, alone or in combinations, target the mevalonate pathway, whereas 
farnesyltransferase inhibi ors (FTIs), g ranylgeranyltransferase inhibitors (GGTIs) and 
dual prenylation inhibitors (DPIs) target the prenylation process. Several strategies have 
been developed for targeting the functional regulation of the RAS superfamily of 
GTPases. These focus either on compounds that inhibit the interaction between the RAS 
superfamily of GTPases and regulatory proteins (for example, interfacial inhibitors), or on 
drugs that target individual RAS superfamily GTPases (for example, bacterial toxins, 
GTP analogues, small-interfering RNA (siRNA) inhibitors), or regulatory proteins (siRNA 
inhibition), thereby blocking GDP/GTP exchange and inhibiting activation of 
downstream effectors. GAP, GTPase-activating protein; GDI, guanine nucleotide 
dissociation inhibitor; GEF, guanine nucleotide exchange factor; ICMT, isoprenylcysteine 
carboxymethyltransferase; RCE1, RAS converting enzyme.
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One strategy for Ras inhibitors design is to interfere in CAAX protein 
prenyltransferases, most notably FTase. Many FPP analogues or CAAX 
peptidomimetics, which compete with FPP or Ras-CAAX motif for FTase, 
respectively, have been designed as FTase inhibitors (FTIs) since 1990 (100). 
These inhibitors show efficiently inhibitory activity on FTase, and have 
impressive anti-tumor activity both in vitro and in vivo. But the outcome of 
clinical trials is disappointing (101). One probable explanation is that 
alternative prenylation, in which GGTase I can modify the substrates of FTase 
in cancer when FTase activity is inhibited by FTIs, escapes the effect of FTIs 
(102). 
Therefore, targeting the post-prenylation pathway, which shared by both 
farnesylated and geranylgeranylated CAAX proteins, has become an attractive 
strategy in inhibitors design since last decade (Figure 5). In this scenario, 
Rce1 and Icmt, which are responsible for both farnesylated and 
geranylgeranylated CAAX proteins in post-prenylation, become potential 
targets. In this case, even the alternative prenylation happen, prenylated 
CAAX proteins are still sensitive to Rce1 and Icmt inhibitors (103-104). 
!
3.1.1.4 Icmt Inhibitor 
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Icmt is a highly-conserved integral ER membrane protein, and human 
Icmt is predicted to consist of 8 transmembrane domains and a cytoplasmic 
catalytic domain (84, 105). Numerous gene disruption studies have 
demonstrated that Icmt is the only enzyme that catalyses the carboxyl 
methylation of prenylated proteins (106). Many genetic experiments in mouse 
have indicated that ICMT is an essential gene in mouse development, and 
ICMT-deficient mouse dies around embryonic day 11.5 (107). 
Studies from genetic and pharmacological inactivation of Icmt have 
indicated that Icmt activity has profound effect on oncogenesis. For instance, 
conditional deletion of ICMT leads loss ability of oncogenic K-Ras to 
transform immortalized fibroblasts, and genetic inactivation of ICMT results 
in Ras mislocalization and Ras signaling inhibition (108-111). A recent study 
has also addressed that pharmacological inhibition of Icmt in breast cancer 
cells disrupts cell adhesion and migration which mediated by Rac1 and RhoA 
(112). Taken together, these data implicate that Icmt can be a potential good 
anticancer therapeutic target.  
For the importance of Icmt-catalyzed CAAX protein methylation in 
oncogenesis, there is a clear need for specific pharmacological agents to target 
this process. Analogues of the substrate prenylcysteine or the product S-
adenosylhomocysteine have been reported as inhibitors. However, all of these 
analogs have been reported to have pleiotropic effects (113-115). 
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In 2005, from a high-throughput screen of a diverse chemical library, 
Prof. Patrick Casey and colleagues discovered an indole-based small-molecule 
inhibitor of Icmt with an inhibition constant (Ki) of 150 nM against 
recombinant human Icmt (116). This novel selective Icmt inhibitor is termed 











Figure 6.  Structure of Cysmethynil (reference 116). 
!
In our lab, the sensitivity of a wide array of human cancer cells to 
cysmethynil was assessed, including hepatocellular, prostate, breast and 
glioblastoma cancer cells. It was found that cysmethynil reduces cancer cell 
viability in all tested lines, albeit at different sensitivities. More encouragingly, 
cysmethynil demonstrated in vivo efficacy in multiple human cancer xenograft 
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chemical library of !10,000 compounds. The library contained
70" subfamilies derived from unique scaffolds. We used an in
vitro screen in which Icmt activity was measured as the incor-
poration of a [3H]methyl group into a farnesylated, Rce1-
proteolyzed, K-Ras substrate (seeMaterials and Methods). Com-
pounds that showed #50% inhibition at 50 !M were subjected
to a secondary screen by using a small-molecule substrate of
Icmt, BFC. From this screen, we identified a group of com-
pounds with an indole core structure that had significant activity
against Icmt. The most potent of these compounds was what we
term cysmethynil (Fig. 1A). This compound was independently
synthesized and characterized to confirm identity and purity (see
Supporting Text and Scheme 1, which are published as supporting
information on the PNAS web site), and all studies described
below were performed by using the independently synthesized
compound.
In the initial in vitro assay using BFC as the prenylcysteine
substrate, the IC50 for Icmt inhibition by cysmethynil was
determined to be 2.4 !M (Fig. 1B). In this assay, the substrates
and the inhibitor were premixed, and the reaction was initiated
by the addition of enzyme. However, when the enzyme was
premixed with inhibitor and AdoMet for 15 min before initiation
of the reaction with BFC, a dramatic increase in inhibitor
potency was observed with a measured IC50 of $200 nM (Fig.
1B). These data suggest that cysmethynil is a time-dependent
inhibitor of Icmt. Importantly, even at concentrations up to 50
!M, cysmethynil did not inhibit the other enzymes in the
prenylation pathway (FTase, geranylgeranyltransferase type I,
and Rce1), nor did it inhibit an AdoMet-dependent DNA
methyltransferase or an unrelated protein methyltransferase
(the SssI DNA methyltransferase and PCMT1 protein methyl-
transferase, respectively) (data not shown).
Cysmethynil Treatment Impacts Cell Growth in an Icmt-Dependent
Fashion.To evaluate the potential cellular activity of cysmethynil,
we took advantage of a cell model of Icmt deficiency developed
from the gene-disruption studies (32). Reasoning that cells that
had adapted to grow in the absence of Icmt activity should be
resistant to the effects of the inhibitor, we treated Icmt%/%mouse
embryonic fibroblasts and matched wild-type cells with increas-
ing concentrations of the compound and monitored cell growth
for 6 days (Fig. 2). Treatment with cysmethynil resulted in a
dose-dependent inhibition of growth wild-type cells (Fig. 2A),
but Icmt%/% cells were largely unaffected (Fig. 2B). Further-
more, when the human ICMT gene was stably expressed in
Icmt%/% cells, the reconstituted cell line regained sensitivity to
cysmethynil (Fig. 2C). These results provide strong evidence for
an antiproliferative activity of cysmethynil that is mechanism-
based, i.e., directly due to an impact on Icmt activity.
Cysmethynil Treatment of Cells Results in Mislocalization of Ras and
Impairment of Growth Factor Signaling. Carboxylmethylation is
important for proper plasma membrane localization of Ras (24).
Based on this observation, we predicted that treatment of cells
with an Icmt inhibitor would lead to a loss of Ras from the
plasma membrane. To test this hypothesis, MDCK cells stably
Fig. 1. Cysmethynil, a small-molecule inhibitor of Icmt. (A) Structure of the
indole-based compound, cysmethynil. (B) Time-dependent inhibition of Icmt
by cysmethynil. Icmt activity was measured as the incorporation of [3H] from
[3H]AdoMet into the Icmt substrate BFC. The assay was performed either with
(E) or without (F) preincubating Icmt with cysmethynil as described inMate-
rials and Methods.
Fig. 2. Icmt-dependentgrowth inhibitionofmouse embryonicfibroblasts by
using cysmethynil. Mouse embryonic fibroblasts grown in media containing
8% serumwere treatedwith DMSO (■) or cysmethynil at concentrations of 15
(‚), 20 (!), or 30 (F)!M.Media and drugwere replaced daily, and cell growth
was monitored for 6 days as described in Materials and Methods. Data
represent themean and SDof four replicatewells. (A) Icmt"/" cells. (B) Icmt%/%
cells. (C) Icmt%/% cells stably transfected with a gene expressing human ICMT
(Icmt%/%!ICMT cells).
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models, including PC3 prostate cancer and HepG2 hepatocellular cancer. 
Interestingly, cysmethynil treatment markedly induced autophagy and 
autophagic cell death (70-71). 
!
!
3.2 Results and Discussion 
3.2.1 Icmt inhibition induces autophagy in cancer cells 
To study the role of Icmt in autophagy regulation in cancer cells, Icmt 
was inhibited by either genetic knockdown or Icmt pharmacological inhibitor. 
Upon suppression of Icmt by genetic knockdown using siIcmt in PC3 cells, 
there was a dramatic elevation of the LC3-II protein (Figure 7A), which is the 
marker for autophagy (117). The qRT-PCR result showed that siIcmt 
knockdown significantly reduced the Icmt expression level (Figure 7B). 
Furthermore, anti-LC3 immunofluorescence showed that LC3-II punctae 
markedly increased when Icmt was suppressed by sh-Icmt in compare to sh-






Figure 7. Icmt inhibition by genetic knockdown induces autophagy. (A). 
Immunoblot analysis of LC3-II levels in lysates from cells treated with 
siLuciferase (siLuc) or siIcmt. Cell lysates were prepared from PC3 cells 96 h 
after siRNA transfection. (B). qRT-PCR analysis of the knockdown 
efficiencies for Icmt. Total mRNA was isolated from PC3 cells 96 h after 
siRNA transfection. The 18S transcript level was employed as control. (C). 
Immunofluorescence of Anti-LC3 vesicles in PC3 cells following sh-Vector 
and sh-ICMT knockdown. Images were taken by confocal microscopy 96 h 
after transfection of the indicated shRNA, and more than 50 cells were 
analyzed for each population. (D). The quantities of LC3 positive vesicle per 
cells compared in the same analysis between shRNA transfected cells and un-
transfected cells. Analysis was performed using MetaMorph analysis software. 
More than 50 cells were analyzed for each population. Data was presented as 
Mean ± S.E.M. (‘‘*’’, p<0.05). All experiments have been performed three 










gauge of cellular energy status. Once activated, AMPK suppresses
anabolic activities, activates fuel catabolism and promotes
autophagy to increase energy stores.10,11
Indeed, the treatment of PC3 cells with cysmethynil elevated
levels of phosphorylated AMPK in a dose-dependent manner
(Figure 1a). We also observed increased inhibitory phosphoryla-
tion of acetyl-coA carboxylase (ACC) at serine 79, an AMPK
phosphorylation site, consistent with increased AMPK activity.
Aligned with our previous reports of autophagy induction, there
was also a dose-dependent accumulation of the autophagy
marker LC3 II, which paralleled the response of AMPK activation
(Figure 1a). Similar phenotype of elevated pAMPK level was
observed upon small interfering RNA (siRNA) suppression of Icmt
expression (Figure 1b). Further, we subjected wild-type mouse
embryonic ﬁbroblast (MEF) cells and Icmt-null MEF cells to
cysmethynil treatment. While Icmt-null MEFs exhibit higher basal
pAMPK and LC3 II levels, robust increases in pAMPK and LC3 II
levels are only observed in the wild-type MEFs upon cysmethynil
treatment (Figure 1c). These genetic suppression studies provided
compelling evidence that effect of cysmethynil on AMPK
activation and autophagy is Icmt dependent.
The parallel elevation of autophagy and activation of AMPK are
indications that Icmt-induced autophagy is mediated by AMPK
activation, which can be either a direct response to cellular energy
status or a result of modulation by upstream molecules. In the
investigation for possible etiology of Icmt-inhibition-mediated
AMPK activation, we analyzed the levels of nucleotide tripho-
sphates (NTPs) in cysmethynil-treated and control cells. Signiﬁcant
decreases in levels of ATP, GTP, CTP and UTP were observed in
cysmethynil-treated PC3 cells (Figure 1d). Although ATP is
considered the major energy currency in cells, it is important to
measure the other nucleoside triphosphates in the evaluation of
cell energy status, as there exists a dynamic balance between
different NTPs, energy currency molecules.12,13 The reduction of
NTPs in cysmethynil-treated cells suggests that AMPK activation is
likely the result of energy deﬁciency. It is worth noting that the
energy deplete state and associated signaling changes induced by
Icmt inhibition is not limited to PC3 cells; MDA-MB-231 cells
responded in a similar manner (Supplementary Figure 1),
suggesting a general regulatory mechanism by Icmt in cell energy
metabolism.
Cysmethynil treatment reduces mitochondrial respiratory capacity
To investigate the cause of cysmethynil-induced energy depletion,
we studied mitochondrial function in the cells. Cysmethynil-
treated cells exhibit markedly reduced basal/resting-respiration
rates (Figure 2a). In addition, cysmethynil-treated cells exhibited a
shallower drop in oxygen consumption rate (OCR) upon the
addition of oligomycin, an ATPase inhibitor, in comparison with
the untreated cells (Figure 2a), suggesting attenuated ATP
production before oligomycin addition. This result is consistent
with the NTP quantiﬁcation study and the phenotype of AMPK
activation shown above. Triﬂuorocarbonylcyanide phenylhydra-
zone (FCCP), uncoupling the electron transport system from
oxidative phosphorylation, is often used to assess the maximal
respiratory capacity of cells. Cysmethynil-treated cells displayed
lower FCCP-induced respiration in comparison with untreated
cells (Figure 2a), indicative of reduction in the maximal respiratory
capacity and potential rate for ATP production. Last, the
differences in respiration between cysmethynil-treated and
control cells are not likely from non-mitochondrial oxygen
consumption, as no signiﬁcant differences of OCRs relative to
the basal respirations were observed between these two cell
populations after the addition of rotenone and antimycin A
(Figure 2a). The table below panel a summarizes the OCR values,
illustrating the reduction in mitochondrial respiratory capacity and
mitochondrial ATP production, under the treatment of
cysmethynil.
To investigate whether the defect(s) in energy production in
response to Icmt inhibition is at a stage upstream of mitochondria,
we measured media acidiﬁcation as a surrogate for glycolytic
lactate production for PC3 cells. Upon glucose addition,
cysmethynil-treated cells demonstrated a markedly higher rate
of acidiﬁcation of media as compared with that of untreated cells
(Figure 2b), indicating a higher rate of glycolysis. This observation
suggests that the cells are poised to use glucose via anaerobic
glycolysis, and that neither glucose transport nor the glycolytic
pathway is compromised by Icmt inhibition. Subsequently, ATP
synthesis inhibitor oligomycin was added to assess maximal
gl colytic capacity of the cells. Upon addition of oligomycin,
control cells showed a signiﬁcant increase in extracellular
acidiﬁcation rate (ECAR), whereas cysmethynil-treated cells
exhibited no additional increase (Figure 2b). There was no
signiﬁcant difference in the maximal glycolytic capacity between
these two populations of cells, although the maximal glycolysis
was achieved with the addition of glucose in the cysmethynil-
treated cells, whereas in the control cells this required the addition
of oligomycin (Figure 2b). These observations suggest that Icmt
inhibition did not compromise glycolysis; hence, the reduction of
OCR and energy depletion is the results of cysmethynil-induced
dysfunction of mitochondria oxidative phosphorylation. The table
in Figure 2b presents the calculated values of glycolytic ﬂux and
capacity from the ECAR studies. Similar ﬁndings of OCR and ECAR
changes had been observed in cysmethynil-treated MDA-MB-231
cells, illustrating that this regulation by Icmt is not cell line speciﬁc
(Supplementary Figure 2).
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Figure 1. ICMT inhibition leads to AMPK activation and reduction of
nucleoside triphosphates. (a) AMPK activation and autophagy
induction in cysmethynil-treated PC3 ce l . Cells wer treated with
increasing doses of cysmethynil—0 (dimethyl sulfoxide (DMSO)),
17.5, 20 and 22.5 μM—for 24 h as described8 before preparation of
cell lysates and immunoblot analy is. (b) Suppression of Icmt
expression leads to AMPK activation. Left, pAMPK and LC3 levels in
PC3 cell lysates 96 h after transfection of siRNAs (Invitrogen)
targeting Icmt or luciferase ( s a c ntrol); right, analysis of Icmt
knockdown efﬁciency by RT–PCR. (c) Immunoblot of pAMPK d
LC3 in lysates from Icmt wild-type MEF (+/+) and Icmt-null MEF
(− /− ) cells (obtained from M Bergo) following 24 h of treatment
with either DMSO or the indicated conc n ration of cysmethynil.
(d) Quantitative analysis of nucleoside triphosphates in control and
cysmethynil-treated PC3 cells. The cells were treated with DMSO
(black bar), 20.0 μM cysmethynil (gray bar) or 22.5 μM cysmethynil
(white bar) for 24 h before being harvested and subjected to
nucleotide analysis as described.34 Error bars denote standard
deviation of the data from three technical repeats. A biologic repeat
of the study exhibited similar results.
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gauge of cellular energy status. Once activated, AMPK suppresses
anabolic activities, activates fuel catabolism and promotes
autophagy to increase energy stores.10,11
Indeed, the treatment of PC3 cells with cysmethynil elevated
levels of phosphorylated AMPK in a dose-dependent manner
(Figur 1a). We also observed increased inhibitory phosphoryla-
tion of ac tyl-coA carboxyla (ACC) at serine 79, an AMPK
phosphorylation site, consistent with increased AMPK activity.
Aligned with our previous reports of autophagy induction, there
was also a dose-dependent accumulation of the autophagy
marker LC3 II, which paralleled the response of AMPK activation
(Figure 1a). Similar phenotype of elevated pAMPK level was
observed upon s all interfering RNA (siRNA) suppre sion of Icmt
expression (Figure 1b). Further, we subjected wild-type mouse
embryonic ﬁbroblast (MEF) cells and Icmt-null MEF cells to
cysmethynil treatment. While Icmt-null MEFs exhibit higher basal
pAMPK and LC3 II levels, robust increases in pAMPK and LC3 II
levels are only observed in the wild-type MEFs upon cysmethynil
treatment (Figure 1c). These genetic suppression studies provided
compelling evidence that effect f cysmethynil on AMPK
activation an autophagy is Icmt d pendent.
The parallel elevation of autophagy and activation of AMPK are
indications that Icmt-induced autophagy is mediated by AMPK
activation, which can be either a direct response to cellular energy
status or a result of modulation by upstream molecules. In the
investigation for possible etiology of Icmt-inhibition-mediated
AMPK activation, we analyzed the level of ucleotide tripho-
sphates (NTPs) in cysmethynil-treated and control cells. Signiﬁcant
decreases in levels of ATP, GTP, CTP and UTP were observed in
cysmethynil-treated PC3 cells (Figure 1d). Although ATP is
considered the major energy currency in cells, it is important to
measure the other nucleoside triphosphates in the evaluation of
cell energy status, as there exists a dynamic balance between
different NTPs, energy currency molecules.12,13 The reduction of
NTPs in cysmethynil-treated cells suggests that AMPK activation is
likely th r sult of energy deﬁciency. It is worth noting that the
energy deplete state and associated signaling changes induced by
Icmt inhibition is not limited to PC3 cells; MDA-MB-231 cells
responded in a similar manner (Supplementary Figure 1),
suggesting a general regulatory mechanism by Icmt in cell energy
metabolism.
Cysmethynil treatment reduces mitochondrial respiratory capacity
To investigate the cause of cysmethynil-induced energy depletion,
we studied mitochondrial function in the cells. Cysmethynil-
treated cells exhibit markedly reduced basal/resting-respiration
rates (Figure 2a). In addition, cysmethynil-treated cells exhibited a
shallower drop in oxygen consumption rate (OCR) upon the
addition f oligomycin, a ATPase i hibitor, in comparis wi h
the untreated cells (Figure 2a), suggesting attenuated ATP
production before oligomycin addition. This result is consistent
with the NTP quantiﬁcation study and the phenotype of AMPK
activation shown above. Triﬂuorocarbonylcyanide phenylhydra-
zone (FCCP), uncoupling the electron transport system from
xidative phosphorylation, is often used to assess the maximal
respiratory apacity of cells. Cysmethynil-treated cells displayed
lower FCCP-induced respiration in comparison with untreated
cells (Figure 2a), indicative of reduction in the maximal respiratory
capacity and potential rate for ATP production. Last, the
differences in respiration between cysmethynil-treated and
control cells are not likely from non-mitochondrial oxygen
consumption, as no signiﬁcant diff rences of s relative to
the basal respirations were observed between se two cell
populations after the addition of rotenone and antimycin A
(Figure 2a). The table below panel a summarizes the OCR values,
illustrating the reduction in mitochondrial respiratory capacity and
mitochondrial ATP production, under the treatment of
cysmethynil.
To investigate whether the defect(s) in energy production in
response to Icmt inhibition is at a stage upstream of mitochondria,
we measured media acidiﬁcation as a surrogate for glycolytic
lactate production for PC3 cells. Upon glucose addition,
cysmethynil-treated cells demonstrated a markedly higher rate
of acidiﬁcation of media as compared with that of untreated cells
(Figure 2b), indicating a higher rate of glycolysis. This observation
suggests that the cells are ois to use gluc se via ana robic
glycolysis, and that neither glucose transport nor the glycolytic
pathway is compromised by Icmt inhibition. Subsequently, ATP
synthesis inhibitor oligomycin was added to assess maximal
glycolytic capacity of the cells. Upon addition of oligomycin,
control cells showed a signiﬁcant increase in extracellular
acidiﬁcation rate (ECAR), whereas cysmethynil-treated cells
exhibited no additional increase (Figure 2b). There was no
signiﬁcant difference in the maximal glycolytic capacity between
these two populations of cells, although the maximal glycolysis
was achieved with the addition of glucose in the cysmethynil-
treated cells, whereas in the control cells this required the addition
of oligomycin (Figure 2b). These observations suggest that Icmt
inhibition did not c mpromise glycolysis; nce, the reduction of
OCR and energy depletion is the results of cysmethynil-induced
dysfunction of mitochondria oxidative phosphorylation. The table
in Figure 2b presents the calculated values of glycolytic ﬂux and
capacity from the ECAR studies. Similar ﬁndings of OCR and ECAR
changes had been observed in cysmethynil-treated MDA-MB-231
cells, illustrating that this regulation by Icmt is not cell line speciﬁc
(Supplementary Figure 2).
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Figure 1. ICMT inhibition leads to AMPK activation and reduction of
nucleoside triphosphates. (a) AMPK activation and autophagy
induction in cysmethynil-treated PC3 cells. Cells were treated with
increasing oses of cysmethynil—0 (dimethyl sulfoxide (DMSO)),
17.5, 20 and 22.5 μM—for 24 h as described8 before preparation of
cell lysates and immunoblot analysis. (b) Suppression of Icmt
expression leads to AMPK activation. Left, pAMPK and LC3 levels in
PC3 cell lysates 96 h after transfection of siRNAs (Invitrogen)
targeting Icmt or luciferas (as a control); right, a alysis of Icmt
knockdown efﬁcienc by RT–PCR. (c) Immu oblot of pAMPK and
LC3 in lysates from Icmt wild-type MEF (+/+) and Icmt-null MEF
(− /− ) cells (obtained from M Bergo) following 24 h of treatment
with either DMSO or the indicated concentration of cysmethynil.
(d) Quantitative analysis of nucleoside triphosphates in control and
cysmethynil-treated PC3 cells. The cells were treated with DMSO
(black bar), 20.0 μM cysmethynil (gray bar) or 22.5 μM cysmethynil
(white bar) for 24 h before being harvested nd subjected to
nucleotide analysis as described.34 Error bars denote standard
deviation of the data from three technical repeats. A biologic repeat
of the study exhibited similar results.
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ga ge of cellular energy status. Once activated, AMPK suppresses
nabolic a tivities, activates fuel catabolism and promotes
autophagy to increase energy stores.10,11
Indeed, the treatment of PC3 cells with ysmethynil elevated
levels of phosphorylat d AMPK i a dose-dep dent ma ner
(Figure 1a). We also observed increased inhibitory phosphoryla-
tion of acetyl-coA carboxylase (ACC) at serine 79, an AMPK
phosphorylation site, consistent with increas d AMPK activity.
Aligned with our previous rep rts of autophagy i ucti , there
was l a dose-depen e t accumulation of th autophagy
marker LC3 II, which paralleled the response of AMPK ctivation
(Figure 1a). Similar phenotype of elevated pAMPK level was
observed upon small interfering RNA (siRNA) suppression of Icmt
expression (Figure 1b). Further, we subjected wild-type mouse
embryonic ﬁbroblast (MEF) cells and Icmt-null MEF cells to
cysmethynil t eatm nt. While Icmt-null MEFs exhibit higher basal
pAMPK and LC3 II levels, robust increases in pAMPK and LC3 II
levels are only observed i the wild-type MEFs upon cysmethynil
treatment (Figur 1c). These genetic suppression studies provided
compelling evidence that effect of cysmethynil on AMPK
activation and autophagy is Icmt dep ndent.
The p rallel elevation of autop agy a d activation of AMPK are
indic tions that Icmt-induced autophagy is mediated by AMPK
activ tion, which can be either a dir ct response to cellular e ergy
st tus or a re ult of dulation by upstream molecules. In the
investigation for possi le etiology of Icmt-inhibition-mediated
AMPK activation, we analyzed the levels of nucleotide tripho-
sphat s (NTPs) in cysmethynil-treated and control cells. Signiﬁcant
decreases in levels of ATP, GTP, CTP and UTP were observed in
cysmethynil-treated PC3 cells (Figure 1d). Although ATP is
consider d the major energy currency in cells, it is important to
measure the oth r ucleoside triphosphates in the evaluation of
c ll energy status, as there exists a dynamic balance between
different NTPs, energy curr ncy molecules.12,13 The reduction of
NTPs in cysmethynil-treated cells suggests that AMPK activation is
lik ly the result of energy deﬁciency. It is worth noting that the
energy deplete state and associated signaling changes induced by
Icmt inhibition is not limited t PC3 cells; MDA-MB-231 cells
responded in a simil r manner (Supplementary Figure 1),
suggesting general regulatory mechanism by Icmt in cell energy
metabolism.
Cysmethynil treat ent redu s mito hondrial respiratory capacity
To inv stigate the cause of c smethynil-induced energy depletion,
we studied mitochondrial function in the cells. Cysmethynil-
treated cells exhibit markedly reduced basal/resting-respiration
rates (Figure 2a). In addition, cysmethynil-treated cells exhibited a
shallower dr p in oxygen consumption rate (OCR) upon the
addition of olig mycin, an ATPase in ibitor, in comparison with
th untreated cells (Figure 2a), suggesting attenuated ATP
production before oligo ycin addition. This result is consistent
with the NTP quantiﬁcation study and the phenotype of AMPK
activati n sh wn abov . Triﬂuorocarbonylcyanide phenylhydra-
zon (FCCP), uncou ling the electron transport system from
oxidative phosph rylation, is often used to assess the maximal
respirat ry capaci y of cells. Cysmethynil-treated cells displayed
lower FCCP-induced respiratio in comparison with untreated
cells (Figure 2a), indicative of reducti n in the maximal respiratory
c pacity and potential rate for ATP production. Last, the
differences in respiration betwee cysmethynil-treated and
control cells are n t likely from on-mitochondrial oxygen
co sumption, as n signiﬁcan differences of OCRs relative to
the basal respirations were observed between these two cell
populations after the addition of rotenone and antimycin A
(Figure 2 ). The t ble below panel a summarizes the OCR values,
illustrating the reduction in mitochondrial respiratory capacity and
mitochondrial ATP productio , under the treatment of
cysmethynil.
To investigate whether the defect(s) in energy production in
response to Icmt inhibition is at a stage upstream of mitochondria,
we measured media acidiﬁcation as a surrogate for glycolytic
lactate production for PC3 cells. Upon glucose addition,
cys ethynil-tre ted cells demonstrated a markedly higher rate
of acidiﬁcation of media as compared with that of untreated cells
(Figure 2b), indi ating a igher rate of glycolysis. This observation
suggests that the cells are poised to use glucose via anaerobic
glycolysi , and that neither glucose transport nor the glycolytic
pathway is compromised by Icmt inhibition. Subsequently, ATP
s nthesis inhibitor ligomycin was added to assess maximal
glycolytic capacity of the cells. Upon addition of oligomycin,
control cells show d a signiﬁcant increase in extracellular
acidiﬁcation rate (ECAR), whereas cysmethynil-treated cells
exhibited no additional increase (Figure 2b). There was no
signiﬁcant difference in the maximal glycolytic capacity between
th se two populations of cells, although the maximal glycolysis
was achi v d with the addition of glucose in the cysmethynil-
treated cells, w ereas in the control cells this required the addition
of oligomycin (Figure 2b). These observations suggest that Icmt
inhibition did not compromise glycolysis; hence, the reduction of
OCR and energy depletion is th results of cysmethynil-induced
dysfunction of mitochondria oxidative phosphorylation. The table
in Figur 2b pr ents the cal ulated values of glycolytic ﬂux and
capacity from the ECAR studies. Similar ﬁndings of OCR and ECAR
cha ges had been obs rved in cysmethynil-treated MDA-MB-231
cells, illustrating that this regulation by Icmt is not cell line speciﬁc
(Supplementary Figure 2).
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Figure 1. ICMT inhibition leads to AMPK activation and reduction of
nucleoside riphosphates. (a) AMPK activation and autophagy
induction in cysm thynil-treated PC3 cells. Cells were treated with
increasing oses of cysmethynil—0 (dimethyl sulfoxide (DMSO)),
17.5, 20 and 22.5 μM—for 24 h s described8 before preparation of
cell lys te a d immu obl t analysis. (b) Suppression of Icmt
expression l ads to AMPK activation. Left, pAMPK and LC3 levels in
PC3 cell lysates 96 h after transfection of siRNAs (Invitrogen)
targeting Icmt r luciferas (as a control); right, analysis of Icmt
knockdown efﬁciency by RT–PCR. (c) Immunoblot of pAMPK and
LC3 in lysates from Icmt wild-type EF (+/+) and Icmt- ull MEF
(− /− ) cells ( btained from M Bergo) follow g 24 h of treatment
with ither DMSO or the indicated concentration of cysmethynil.
(d) Quantitative analysis of nucleoside triphosphates in control and
cysmethynil-treated PC3 cells. The cells were treated with DMSO
(black bar), 20.0 μM cysmethynil (gra bar) or 22.5 μM cysmethynil
(whit bar) for 24 h before being harvested and subjected to
nucleotide analysis as described.34 Error bars denote standard
deviation of the dat from three technical repeats. A biologic repeat
of the study exhibited similar results.
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gauge of cellular energy status. Once ac ivated, AMPK suppress
nabolic activities, activates fuel catabolism and promotes
autophagy to increas energy stor s.10,11
Indeed, t e treatment of PC3 cells with cysmethynil elevated
levels of phosphorylated AMPK in a ose-dependent manner
(Figure 1 ). We also observed increased inhibitory phosphoryla-
tion of ace yl-coA carboxylase (ACC) at serine 79, an AMPK
horylati n sit , consi tent with incre sed AMPK ac ivity.
Aligned with our pr vious reports of autophagy induction, t ere
w s also a dose-de endent accumulation the autophagy
marker LC3 II, which aralleled the r sponse of AMPK activation
(Figu e 1a). Similar phenotype of elevated pAMPK level was
observed upon small interfering RNA (siRNA) suppression of Icmt
xpression (Figure 1b). Fur her, we subj cted wild-type mouse
embryonic ﬁbroblast (MEF) cells and Icmt-null MEF cells to
cysmethy il treatment. While Icmt-null MEFs exhibit higher basal
pAMPK and LC3 II levels, robust increases in pAMPK and LC3 II
levels are only observed in th wild-ty e MEFs upon cysmethynil
treatment (Figure 1c). These g n tic suppre sion studies provided
comp lli g vid ce that effect of cysmethynil on AMPK
acti ation and autophagy is Icmt dependent.
The parallel elevatio of autophagy nd activation of AMPK are
indica i s t at I mt-induced utophagy is mediat d by AMPK
activati n, which can be either a direct response to c ll lar e ergy
status or a result of modula i n by pstream molecules. In he
nvestigation for possible etiology of Icmt-inhibiti n-mediated
AMPK activatio , we analyzed th levels of nu l otide tripho-
sphate (NTPs) in cysmethynil-treated a control cells. Signiﬁcant
decreases in levels of ATP, GTP, CTP and UTP were observed in
ysmethynil-tr ated PC3 cells (Figure 1d). Although ATP is
considered the major energy currency in cells, it is impor ant to
measur the other nucleoside triphosphates in the evaluation of
cell energy status, as there exists a dynamic balance between
differe t NTPs, energy currency molecules.12,13 The reduction of
NTPs in cysmethynil-tr ated cells suggests that AMPK activation is
lik ly the result of nergy deﬁciency. It is worth noting that the
ene gy deplete state and associa ed signaling changes induced by
Ic t inhibition is not limited PC3 cells; MDA-MB-231 cells
responded in a similar manner (Supplementary Figure 1),
suggesting a general regulatory mechanism by Icmt in cell energy
metabolism.
Cys ethynil treatment reduces mitocho rial respiratory capacity
To investigate the cause of cys ethynil-induced energ depletion,
w studi d mitochondrial function in the cells. Cysmethynil-
treated cells exhibit markedl reduced basal/resting-respiration
rates (Figure 2a). I addition, ysmethynil-tre d cells exhibited a
shallower drop in oxygen consumption ate (OCR) upon the
addition of oligomycin, an ATPase inhibitor, in comparison with
the ntreated c lls (Figure 2a), suggesting at enuated ATP
production before oligomycin a dition. This resul is c nsistent
wi h the NTP quantiﬁcation study nd the phenotype of AMPK
activation show above. Triﬂuoro a bonylcyanide phenylhydra-
zone (FCCP), uncou ling th electron transport syste from
oxidative pho phorylation, is often used o ssess the maximal
respi atory capacity of cells. Cysmethynil-treated cells display
lower FCCP-induced respiration in comparison with untreated
ells (Figure 2a), indicative of reduction in the maximal respiratory
capacity and potential rate for ATP production. Last, the
diffe ences i respiration betwe n cys ethynil-t eated and
trol cells re not likely from non-mitochondrial oxygen
consumption, as n signiﬁcant diff renc s of OCRs relative to
the b sal respirations were bserved between these two cell
pop lations after the addition of rotenone and antimycin A
(Figure 2a). The table below pa el a summarizes the OCR values,
illustrati g the reduction in mi ochondrial espiratory c pacity and
mitochondrial ATP production, under the treatment of
cysmethynil.
To investigate whether the defect(s) in energy production in
response to Icmt inhibition is at a stage up t eam of mitochondria,
we measur medi acidiﬁc tion as a surrogate for glycolytic
l ctat production for PC3 cells. Upon glucose addition,
cysmethynil-treated cells demonstrated a m rkedly higher rate
of acidiﬁcation of media as compared with that of untreated cells
(Fi ure 2b), indicating a higher rate of glycolysis. This observation
suggests that the cells ar poised to use glucose via anaerobi
glycolysis, d that neither glucose transport nor the glycolytic
pathway is compromised by Icmt inhibition. Sub equently, ATP
synthesis inhibitor ligomy in was added t assess maximal
glycolytic capacity of the cells. Upon addition of oligomycin,
control cells showed a signiﬁcant increase in x racellular
acidiﬁcatio r te (ECAR), whereas cysmethynil-treated cells
exhibit d no additio al increase (Figure 2b). There was no
signiﬁcant difference in the maximal glycolytic c pacity between
these two populations of cells, although the maximal glycolysis
was achi ved with the addition of glucose in th cysmethynil-
treated cells, whereas in the control cells this required the addition
of olig mycin (Figure 2b). Th se observatio s suggest that Icmt
inhibition did not compr m glycolysis; hence, the reduction of
OCR and energy depletion is the results of cysme hynil-induced
dysfunction of mitochondri oxidative pho phorylation. The table
in Figure 2b presents the calculated values of glycolytic ﬂux and
apacity from th ECAR stu ies. Similar ﬁndings of OCR and ECAR
hanges had been observ d in cysmethynil-treated MDA-MB-231
cells, illustra ing that this regulation by Icmt is not cell line speciﬁc
(Supplementary Figure 2).
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Figure 1. ICMT inhibition leads to AMPK activation and reduction of
nucleoside triphosphates. (a) AMPK acti atio and autophagy
induction in cysmethynil-treated PC3 cells. Cells ere treated with
incr asi g doses f cysmethynil—0 (dimethyl sulfoxide (DMSO)),
17.5, 20 and 22.5 μM—for 24 h as described8 before preparation of
cell lysates and im unoblot analysis. (b) Suppression of Icmt
expression leads o AMPK activation. Left, pAMPK and LC3 levels in
PC3 cell lysates 96 h after transfecti of siRNAs (Invitrogen)
targeting Icmt or lucif rase (as a control); right, analysis of Icmt
knockdown fﬁci ncy by RT–PCR. (c) Im unoblot of pAMPK and
LC3 in lysates from Icmt wild-type MEF (+/+) and Icmt-null MEF
(− /− ) cells (obtained from M Bergo) following 24 h of treatment
with either DMSO or the indicated concentration of cysmethynil.
(d) Quantitative analysis of nucleoside triphosphates in control and
cysmethynil-treated PC3 cells. The cells were treated with DMSO
(black bar), 20.0 μM cysmethynil (gray bar) or 22.5 μM cysmethynil
(white bar) for 24 h before being harvested and subjected to
nucleotide analysis as described.34 Error bars denote standard
deviation of the data fro three technical repeats. A biologic repeat
of the study exhibited similar results.
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gauge of cellular energy status. Once activated, AMPK suppresses
anabolic activities, activates fu l catabolism a d promotes
autophagy t i c ase energy stores.10,11
In eed, the tr atment of PC3 cells with cysmethynil el vated
levels of phosphorylated AMPK in a dose-dependent manner
(Figure 1a). We also observed increased inhibitory phosphoryla-
tion of acetyl-c A carboxylase (ACC) at serine 79, an AMPK
phosphorylation site, consistent with increased AMPK activity.
Aligned with our previous reports of auto hagy induction, th re
was also a dose-d pend nt accu ulation of the autophagy
marker LC3 II, w ich parall led the response of AMPK activation
(Figure 1a). Similar phenotype of elevated pAMPK level was
observ d upon small interfering RNA (siRNA) suppression of Icmt
expression (Figure 1b). Furt er, we subjected wild-type mouse
embryonic ﬁbroblast (MEF) cells and Icmt-null MEF cells to
cysm thynil tr atment. While Ic t-null MEFs exhibit higher basal
pAMPK and LC3 II l vel , robust increases i pAMPK and LC3 II
levels are only observ d i th wild-type MEFs upon cysmethynil
treatment (Figure 1c). These genetic suppression studies provided
compelling evi ence that effect of cysmethynil on AMPK
activation and autophagy is Icmt dependent.
The parallel levation f autophagy a d activation of AMPK are
indicati ns that Icmt-i duced autophagy is mediated by AMPK
activation, which can be eit er a direct response to cellular nergy
status or a r sult of modulation by upstream molecules. In the
investigation for possible etiology of Icmt-inhibition-mediated
AMPK activation, we analyzed the levels of nucleotide tripho-
sphates (NTPs) in cysmethynil-treated nd ontrol cells. Signiﬁcant
decreases in levels of ATP, GTP, CTP and UTP were obs rved in
cysmethynil-treated PC3 cells (Figure 1d). Although ATP is
consid red the major nergy currency in cells, it is importa t to
measur the other ucleosid triphosphates in the evaluatio of
cell n rgy status, s the e exists a dynamic balance between
different NTPs, energy curre cy molecules.12,13 The reduction of
NTPs in cysmethy il-tre ted cells suggests that AMPK activation is
likely the result of energy deﬁciency. It is worth noting that the
energy d plete stat and ssociated signaling changes induced by
Ic t inhibitio is not limited to PC3 cells; MDA-MB-231 cells
responded in a similar manner (Supplementary Figure 1),
suggesting a general regulatory mechanism by Icmt in cell energy
metabolism.
Cysmethynil treatment reduces mitochondrial respiratory capacity
To investigate the cause of cysmethynil-induced energy depletion,
we studi d mitochon rial function in he cells. Cysmethynil-
treated cells exhibit m rk dly reduced basal/resting-respiration
rates (Figure 2a). In additi n, cysmethynil-treated cells exhibited a
shallower drop in oxygen consumption rate (OCR) upon the
addition of ligomycin, an ATPase inhibitor, in comparison with
the untreate cells (Figure 2a), suggesting attenuated ATP
production before oligomycin addition. This result is consistent
with th NTP quantiﬁcation study and th phenotyp of AMPK
activation shown ab v . Triﬂuorocarbon lcyanide phenylhydra-
zone (FCCP), uncoupling the electron transport system from
oxidative phosphorylation, is often used to assess the maximal
respiratory capacity of cells. Cy methynil-treated cells displayed
lower FCCP-induced respiration in comparison with untreated
cells (Figur 2a), indicative of reduction in the maximal respiratory
capacity a d pote ti l rat for ATP producti n. Last, th
differences i r piratio between cysmethynil-treated and
contr l cells ar not likely from non-mitochondrial oxygen
consumption, as no signiﬁcant differences of OCRs relative to
the b sal respirations wer observed between these two cell
populations after the addition of rotenone and antimycin A
(Figure 2a). Th le below pan l a summarizes th OCR values,
illustrating the r ction in mitocho drial respiratory capacity and
mitochondrial ATP production, under the treatment of
cysmethynil.
To investigate whether the defect(s) in energy production in
response to Icmt inhibition i at a stage upstream of mitochondria,
we ea ured media aci iﬁcation as a surrogate for glycolytic
l ctate pro u ti for PC3 c lls. Upon glucose addition,
cysmethynil-tre cells demonstr ted a m rkedly higher rate
f acidiﬁcati n of edia as comp re with that of untreated cells
(Figure 2b), indicating a higher rate of glycolysis. This observation
suggests that the cells are poised to use glucose via anaerobic
glycolysis, and that neither glucose tr nsport nor the glycolytic
pathway is compromised by Icmt inhibition. Subsequently, ATP
synthesis i hibitor oligomycin was added t assess maximal
glycolytic capacity of the cells. Upon d ition of oligomycin,
co trol cells showed a signiﬁc nt increase in extracellular
acidiﬁcation rate (ECAR), whereas cysmethynil-treated cells
exhibited no additional increase (Figure 2b). There was no
signiﬁcant difference in the maximal glycolytic capacity between
these tw populations of cells, lthough the aximal glycolysis
was achieved with the dd tion of glucose in the ysmeth nil-
treat d cells, whereas in t control ells this required the addition
f olig mycin (Figure 2b). These observations suggest that Icmt
inhibition did not compromise glycolysis; hence, the reduction of
OCR and energy depletion is the results of cysmethynil-induced
dysfunction of mitochondria oxidative phosphorylation. The table
in Figure 2b presents th calculated valu s of glycolytic ﬂux and
cap city from the ECAR studies. Similar ﬁndings of OCR and ECAR
cha ges had been observed i cysmethynil-treated MDA-MB-231
cells, illustrating that this regulation by Icmt is not cell line speciﬁc
(Supplementary Figure 2).
Cysm (µM) 0 20 22.5










































ATP GTP CTP UTP
Figure 1. ICMT inhibition l ads to AMPK activation and reduction of
nucleoside triphosphates. (a) AMPK ac ivation and autopha y
induction in cysmethynil-treated PC3 cells. Cells were treated with
increasi g doses of cysm thynil—0 (dimethyl sulfoxide (DMSO)),
17.5, 20 a d 22.5 μM—for 24 h as described8 before preparation of
ell lysates and immunoblot analysis. (b) Suppression of Icmt
expre sion leads to AMPK activation. Left, pAMPK and LC3 levels in
PC3 cell lysates 96 h after transfection of iRNAs (Invitrogen)
targeting Icmt or lucif ras (as a control); right, analysis of Icmt
knockdown efﬁciency by RT–PCR. (c) Immunoblot of pAMPK and
LC3 in lysates from Icmt wild-typ MEF (+/+) and Icmt- ull MEF
(− /− ) cells (obtained from M Berg ) following 24 h of treatment
with either DMSO or the indicated concentration of cysmethynil.
(d) Quantit tive analysis of nu leoside triphosphates in control and
cysmethynil-treat d PC3 cell . The cells were treated with DMSO
(black bar), 20.0 μM cysmethynil (gray bar) or 22.5 μM cysmethynil
(w it bar) for 24 h before being harvested and subjected to
nucleotide analysis as described.34 Error bars denote standard
d viation of the data fr m three technical repeats. A biol gic repeat
of th study exhibited similar results.
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Consistently, pharmacologic inhibition of Icmt by cysmethynil also 
resulted in a dramatic elevation of LC3-II in both PC3 cells (Figure 8A) and 
HeLa cells (Figure 8B). Moreover, upon treatment with cysmethynil, HeLa 
cells stably expressing GFP-LC3 showed increased autophagosome formation 
(Figure 8C). Image analysis provided further quantitative information on 
autophagy induced by cysmethynil in these cells. There were significant 
increases in the number of LC3-II-positive vesicle per cell and the quantity of 
LC3-II protein on the vesicles as determined by fluorescence intensity (Figure 
8D). Similar results were observed in PC3 cells when endogenous LC3-II was 
visualized by immunofluorescence of this protein (70). Taken together, these 
findings provide strong evidence that inhibition of Icmt induces autophagy in 
HeLa cells in a fashion similar to that observed with PC3 cells, and validate 
the use of both PC3 cells and GFP-LC3-expressing HeLa cells for the loss-of-








Figure 8. Cysmethynil treatment induces autophagy. (A). Immunoblot 
analysis of LC3-II levels in lysates from PC3 cells treated with either control 
(DMSO) or cysmethynil (20 µM) for 24 and 48 h. GAPDH levels were 
determined as control. (B). Immunoblot analysis of LC3-II levels in lysates 
from HeLa cells as described in A. (C). Microscopy analysis of LC3-II 
localization in cysmethynil-treated cells. HeLa cells stably expressing GFP-
LC3 were treated similarly as in B. Following 48 h of treatment with 
cysmethynil or vehicle, the cells were analyzed by confocal microscopy. (D). 
Analysis of the images from the experiment shown in panel C using 
MetaMorph software to determine the average number of GFP-positive 
particles per cell and average particle GFP fluorescent intensities in control 
and cysmethynil-treated cells. More than 50 cells were analyzed for each 
population. Data was presented as Mean ± S.D. (‘‘**’’, p<0.01). All 
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ization (Fig. 1D). Rapamycin treatment results in increased ini-
tiation and progression of autophagy, therefore while there
are more LC3 II positive particles the progression into
autophagolysosomes continues, as demonstrated by similar
fluorescence colocalization as in the control but more numer-
ous and with higher fluorescent intensity (Fig. 1D). Cysmethy-
nil treatment results inmore autophagosomes (Fig. 1, B andC),
but clearly theGFP/RFP colocalization pattern is similar to that
of rapamycin (Fig. 1D), indicating that cysmethynil treatment
induces initiation and progression of autophagy. ImageJ analy-
sis showed significant differences between cysmethynil- and
bafilomycin-treated cells in term of the colocalization of RFP
and GFP, while there were no significant differences between
those of cysmethynil- and rapamycin-treated cells (Fig. 1E). As
supportive evidence, using the DQ-BSA dequenching method
(27, 28), cysmethynil treatment significantly increased the vol-
ume of the proteolytic compartment as represented by the area
of fluorescence inHeLa cells treated with the drug (not shown).
Taken together, these findings provide strong evidence that
inhibition of Icmt induces autophagy in HeLa cells in a fashion
similar to that observed with PC3 cells, and validate the use of
both PC3 cells andGFP-LC3-expressingHeLa cells for the loss-
of-function screen detailed below.
siRNA Screening of CAAX Proteins Identifies Rac3, but Not
Rac1 or Rac2, as a Negative Regulator of Autophagy—To iden-
tify the Icmt substrates that mediate cysmethynil-induced
autophagy, we performed siRNA knockdown on a collection of
the CAAX proteins. As an initial test of the feasibility of the
screen, we used siRNAs to target a small group of CAAX pro-
teins; we included Rheb, a recognized negative regulator of
autophagy, as an internal positive control (29–31). Using this
method, the level of LC3-II in the cells transfected with siRNA
targeting Rheb was two standard deviations higher than the
mean of all the siRNAs tested (Fig. 2A). This experiment was
repeated using two different sets of siRNAswith similar results,
providing confidence that the method had the sensitivity and
specificity to yield possible target CAAX protein(s) involved in
autophagy.
The subsequent screen to identify negative regulator(s) of
autophagy employed siRNAs targeting 46 Icmt substrates (see
supplemental Table S1). To reduce the possibility of off-target
effects of the siRNAs, two sets of siRNAs for every target gene
were employed, and the experiments were performed several
times. The two strongest hits from this expanded screen were
the afore-mentioned Rheb and, quite interestingly, Rac3 (Fig.
2B). The involvement of Rac GTPases in the autophagy process
is novel, and it was considered particularly interesting that this
appeared to be a Rac3-specific function.
Using isoform-specific primers, PCR analysis showed that
the siRNAs employed effectively and selectively reduced the
expression of the appropriate Rac isoforms (Fig. 3A). Only
knockdown of Rac3 resulted in induction of autophagy, as
determined by both induction of LC3-II expression in PC3 cells
(Fig. 3B) and the formation of LC3-positive punctae in HeLa
cells expressing GFP-LC3 (Fig. 3C). Data analysis revealed a
markedly increased number of GFP-LC3-positive punctae
structures when Rac3 was knocked down, but not in cells
FIGURE 1. Cysmethynil treatment induces autophagy in HeLa cells. A, immunoblot analysis of LC3-II levels in lysates from HeLa cells treated with either
control (DMSO) or cysmethynil (20!M) for 24 and 48 h. GAPDH levels were determined as control. B, microscopy analysis of LC3-II localization in cysmethynil-
treated cells. HeLa cells stably expressing GFP-LC3 were treated similarly as in A. Following 48 h of treatment with cysmethynil or vehicle, the cells were
analyzed by confocal microscopy. C, analysis of the images from the experiment shown in panel B using MetaMorph software to determine the average
number of GFP-positive particles per cell and average particle GFP fluorescent intensities in control and cysmethynil-treated cells. **, p ! 0.01.
D, assessment of autophagy flux in HeLa cells treatedwith DMSO (control), 20!Mof cysmethynil, 25!Mof bafilomycin or 200 nM of rapamycin.mRFP-GFP-LC3
tandem-tagged fluorescent protein (tf-LC3) construct was used to transfect HeLa cells. Cells were subjected to treatment 24 h after transfection. After 48 h of
treatment, cells were examined using confocal microscopy for mRFP and GFP fluorescence. Colocalization of mRFP and GFP, an indicator of autophagy flux,
was analyzed using ImageJ software. Representative dotplots depicting extent of colocalization appears under each corresponding image; the horizontal axis
measures the intensity of red fluorescence while the vertical axis measure that of the green fluorescence. E, quantitative summary of colocalization. Pearson
Coefficients are plotted for each treatment condition;"100 cells were analyzed for each population. **, p! 0.01.
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To investigate whether cysmethynil-induced elevation of LC3-II was the 
result of increased initiation and progression of autophagy or the inhibition of 
autophagosome-lysosome fusion and the inhibition of proteolysis, the 
autophagy flux upon cysmethynil treatment was assessed. In this autophagy 
flux assay, the co-localization of tandem fluorescent mRFP-GFP-LC3 
expression vector were analyzed (72). The principle in this assay is that RFP 
and GFP have different chemical properties, and GFP fluorescence is 
attenuated and subsequently proteolysed at acidic pH while RFP is much more 
stable under similar conditions. Briefly, in normal condition, both GFP-LC3 
and RFP-LC3 fluorescence are co-localized in autophagosomes. However, in 
autophagolysosomes, which are much more acidic, the green fluorescence 
(GFP-LC3) weakens and eventually disappears. Therefore, progression from 
autophagosomes to autophagolysosomes presents as less colocalization and 
stronger red fluorescence. 
In DMSO-treated control cells, the lower basal level of autophagy 
presents as low intensity fluorescence but poorly colocalized (Figure 9A), 
since autophagosomes progress to merge with acidic compartment. In 
bafilomycin-treated cells, the inhibition of fusion of autophagosomes with 
lysosomes resulted in the accumulation of RFP-GFP-LC3 on autophagosomes, 
therefore high level of GFP and RFP fluorescence and their co-localization 
(Figure 9A). Rapamycin treatment resulted in increased initiation and 
"42
progression of autophagy. While there were more LC3 II positive particles, the 
progression into autophagolysosomes continued, as demonstrated by similar 
fluorescence colocalization as in the control but more numerous and with 
higher fluorescent intensity (Figure 9A). Cysmethynil treatment resulted in 
more autophagosomes, but clearly the GFP/RFP colocalization pattern was 
similar to that of rapamycin (Figure 9A), indicating that cysmethynil treatment 
induces initiation and progression of autophagy. ImageJ analysis showed 
significant differences between cysmethynil- and bafilomycin-treated cells in 
term of the colocalization of RFP and GFP, while there were no significant 
differences between those of cysmethynil- and rapamycin-treated cells (Figure 









 Figure 9. Cysmethynil treatment induces autophagy flux. (A). Assessment 
of autophagy flux in HeLa cells treated with DMSO (control), 20 µM of 
cysmethynil, 25 µM of bafilomycin or 200 nM of rapamycin. mRFP-GFP-
LC3 tandem-tagged fluorescent protein construct was used to transfect HeLa 
cells. Cells were subjected to treatment 24 h after transfection. After 48 h of 
treatment, cells were examined using confocal microscopy for mRFP and GFP 
fluorescence. Colocalization of mRFP and GFP, an indicator of autophagy 
flux, was analyzed using ImageJ software. Representative dotplots depicting 
extent of colocalization appears under each corresponding image; the 
horizontal axis measures the intensity of red fluorescence while the vertical 
axis measure that of the green fluorescence. (B). Quantitative summary of 
colocalization. Pearson Coefficients are plotted for each treatment condition. 
More than 100 cells were analyzed for each population. Data was presented as 
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3.2.2 siRNA screening of CAAX proteins to identify the regulator of Icmt 
mediated autophagy 
To identify the Icmt substrates that mediate cysmethynil-induced 
autophagy, siRNA knockdown on a collection of the CAAX proteins was 
performed. As an initial test of the feasibility of the screen, siRNAs targeting a 
small group of CAAX proteins was employed, in which Rheb, a recognized 
negative regulator of autophagy, was included as an internal positive control 
(118-120). Using this method, the level of LC3-II in the cells transfected with 
siRNA targeting Rheb was two standard deviations higher than the mean of all 
the siRNAs tested (Figure 10). This experiment was repeated using two 
different sets of siRNAs with similar results, providing confidence that the 
method had the sensitivity and specificity to yield possible target CAAX 






Figure 10. Feasibility analysis of siRNA screening on CAAX proteins. PC3 
cells were transfected with siRNAs targeting a group of CAAX proteins. Cell 
lysates were prepared 96 h after transfection, and LC3 and GAPDH levels 
were assessed by immunoblot analysis. The upper portion shows the 
immunoblots, while the lower portion presents the normalized LC3-II levels 
for each target knockdown. As positive control, the response to cysmethynil 
(cysmeth) was determined in parallel. The three horizontal lines mark the 
mean, and one and two S.D. above the mean, of the LC3-II/GAPDH ratio of 
the group, excluding the cysmethynil-treated sample. Shown is a 
representative experiment which has been repeated twice with similar results.  
!
!
Subsequently, siRNAs targeting 46 Icmt substrates were employed to 
screen to identify negative regulator(s) of autophagy. Two sets of siRNAs for 
"46
treated with control siRNA or with siRNA targeting Rac1 or
Rac2 (Fig. 3D).
We then investigated whether the regulatory role of Rac3 in
autophagy extended beyond HeLa and PC3 cells. Analysis of
Rac isoform expression in HCT116 colon cancer and MDA-
MB231 breast cancer cell lines was performed, alongwithHeLa
and PC3 lines; these four cell lines represented a range of Rac1,
Rac2, and Rac3 expression profiles (Fig. 4A). For example,
HCT116 exhibited highest Rac3 expression with low levels of
Rac1 and Rac2, while PC3 and MDA-MB231 cells expressed
much lower level of Rac3. Despite their differing ratios of Rac
isoform expression, Rac3 knockdown in all these cells induced
autophagy significantly, while knockdown of Rac1 andRac2 did
not (Fig. 4B). We speculate that the reason the induction of
LC3-II is not as robust in HCT116 cells by Rac3 siRNA knock-
down may be due to its high Rac3 expression level. These data,
in addition to suggesting a broad role in autophagy regulation
by Rac3, provide increased confidence in the Rac3 subtype-
specific regulatory role of this process.
To investigate the impact of Rac3 function on autophagic
flux, we used two approaches. First we assessed RFP/GFP colo-
calization in MDA-MB231 cells stably expressing the afore-
mentioned tandem fluorescent fused LC3 (mRFP-GFP-LC3);
this was the only cell line in whichwewere successful in achiev-
ing stable expression of this construct.Using this stable cell line,
the Rac3 knockdown cells developedmore LC3 positive puncta
(not shown) similar to that observed in Fig. 3C. In addition,
image analysis of GFP and RFP fluorescence demonstrated a
small but significant decrease in colocalization, indicatingmore
attenuation and proteolytic degradation of GFP upon down-
regulation of Rac3 (Fig. 4C). The substantial increase in total
LC3-II positive punctae, and continued autophagy flux as
measured by the colocalization of GFP and RFP, indicates up-
regulated initiation and progression of the autophagy process
(26, 32). In the second approach,we took advantage of the prop-
erty of free GFP production from the LC3 fluorescent fusion
protein as an indicator of autophagy flux; this approach assesses
the autophagy-related proteolysis directly (32, 33). In the same
experiment usingRac3 knockdown inMDA-MB231 cells stably
expressing mRFP-GFP-LC3 as shown in Fig. 4C, immunoblot
analysis was performed with cell lysates 72 h and 96 h after
siRNA transfection. The analysis showed both an increased
endogenous LCII level, and increased GFP-LC3 cleavage to
generate free GFP, in Rac3 knockdown cells compared with
mock knockdown cells (Fig. 4D), again indicating increased
autophagy progression with Rac3 knockdown.
Ectopic Expression of Rac3, but Not Rac1 or Rac2, Confers
Resistance to the Increased Autophagy and Cell Death Induced
by Icmt Inhibition—To provide further evidence for the sup-
pressive role of Rac3 on autophagy, we assessed the impact of
Rac protein overexpression on the ability of the Icmt inhibitor
cysmethynil to induce autophagy. HeLa cells transiently trans-
fected withMyc-Rac1, Myc-Rac2, or Myc-Rac3 were subjected
to cysmethynil treatment, and autophagy scored by quantitat-
ing GFP-LC3-positive particles as described above. Cells over-
expressing Rac3 exhibitedmuch lower level of autophagy, indi-
cating a resistance to cysmethynil-induced autophagy; while
those cells expressing Rac1 or Rac2 had similar levels of
autophagy induction as parental cells (Fig. 5). We then probed
several cancer cell lines for Rac3 transcript and basal autophagy
levels. Interestingly we observed a trend that the higher the
Rac3 expression, the lower the basal autophagy asmonitored by
expression of LC3-II (Fig. 6A). For example, HCT116 had the
highest level of Rac3 transcripts and the lowest basal levels of
LC3-II, while MDA-MB231 and PC3 have low Rac3 but high
LC3-II.
To further investigate the inhibitory effect of Rac3 on
autophagy, we transfected PC3 cells with pcDNA3.1-HA-Rac3
FIGURE 2. siRNA screening to identify negative regulators of autophagy.
A, feasibility analysis. PC3 cells were transfected with siRNAs targeting a
groupof CAAXproteins; cell lysateswereprepared96h after transfection and
LC3 and GAPDH levels assessed by immunoblot analysis. The upper portion
shows the immunoblots, while the lower portion presents the normalized
LC3-II l vels for each tar e knockdown. As positive control, the re p n e to
cysmethynil (cysmeth) was determined in parallel. The three horizontal lines
mark the mean, and one and two S.D. above the mean, of the LC3-II/GAPDH
ratio of the group, excluding the cysmethynil-treated sample. Shown is a
representative experiment which has been repeated twice with similar
results. B, screening. A panel of siRNAs targeting selected Icmt substrates (see
supplemental Table S1) was obtained; two siRNAs for each target were
employed. The standard deviation of GADPH corrected LC3 II levels was plot-
ted against each target. Cell lysates were prepared 96 h after transfection for
standard SDS-PAGE and immunoblot analysis, as detailed under “Experimen-
tal Procedures.” The LC3-II value was normalized to GAPDH for each sample,
and themean and standard deviation of the LC3- II/GAPDH ratio determined
and plotted. Zero on the y axis represents the mean of the ratio of the entire
panel of siRNAs tested, and the values above and below zero represent pos-
itive and negative deviation from the mean. The two circled points represent
the values from Rac3 and Rheb knockdown as indicated. The data presented
in the graph are the composite results from four separate knockdown points,
i.e. two experiments each with the two siRNAs against individual target in
each experiment.
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tr ated with control siRNA or with siRNA targeting Rac1 or
Rac2 (Fig. 3D).
We the investigated whether th regulato y role of Rac3 in
autophagy xten ed beyond HeLa and PC3 cells. Analysis of
Rac isoform expressio in HCT116 colon cancer and MDA-
MB231 breast cancer cell lines was pe formed, alongwithHeLa
and PC3 lines; these four cell lines represented range of Rac1,
Rac2, and Rac3 expression profiles (Fig. 4A). For example,
HCT116 exhibited ighest Rac3 expression with low levels of
Rac1 and Rac2, while PC3 and MDA-MB231 cells expr ssed
much lower level of Rac3. Despi e their differing rati s of Rac
isoform expression, Rac3 knockdow in all thes cells induced
autophagy significantly, while knockdown of Rac1 andRac2 did
not (Fig. 4B). We specula e that th reason the induction of
LC3-II is not as robust in HCT116 cells by Rac3 siRNA knock-
down may be due to its igh Rac3 expression level. These data,
in addition to suggesting a broad role in autophagy regulation
by Rac3, provide increased confidence in the Rac3 subtype-
spe ific regulato y role of this process.
To investiga e the impact of Rac3 function on autophagic
flux, we used two approaches. First we a ssed RFP/GFP colo-
calizatio in MDA-MB231 cells stably expressing the afore-
mentioned tandem fluorescent fused LC3 (mRFP-GFP-LC3);
this was the only cell line in w ich e were successful in achiev-
ing stable expressi n of this construct.Using this stabl cell line,
the Rac3 knockdown cells developedmore LC3 positive puncta
(not shown) s milar o that observed in Fig. 3C. In addition,
image nalysis of GFP and RFP fluorescence demons rated a
small but significant d crease in colocalizatio , indicatingmore
attenuation and pr teolytic degr dation of GFP upon down-
regulation of Rac3 (Fig. 4C). The substantial increase in total
LC3-II positive punctae, and co tinued autophagy flux as
measured by the colocalization of GFP and RFP, indicates up-
regulated ini atio and progression of the autophagy process
(26, 32). In th second approach,we took advantage of the prop-
erty of free GFP production from the LC3 fluorescent fusion
protein s a indicat r of autophagy flux; this approach a ses
the autophagy-related pr teolysis directly (32, 33). In the same
experiment usingRac3 knockdow inMDA-MB231 cells stably
expressing mRFP-GFP-LC3 as show in Fig. 4C, immun blot
nalysis was pe formed with cell lysates 72 h and 96 h after
siRNA transfection. The nalysis showed both a increased
endogenous LCII level, and increased GFP-LC3 cleavage to
g nerate free GFP, in Rac3 knockdown cells compared with
mock knockdown cells (Fig. 4D), agai indicating increased
autophagy progression with Rac3 knockdown.
Ectopic Expression of Rac3, but Not Rac1 or Rac2, Confers
Resistance o the Increased Autophagy and Cell Death Induced
by Icmt Inhibition—To provide furth r evidence for the sup-
pressive role of Rac3 on autophagy, we a ssed the impact of
Rac protein overexpression on the ability of the Icmt inhibitor
cysmethynil to induce autophagy. HeLa cells transiently trans-
f cted withMyc-Rac1, Myc-Rac2, or Myc-Rac3 were subj cted
to cysmethynil treatment, and autophagy scored by quantitat-
ing GFP-LC3-positive particle as described above. Cells over-
expressing Rac3 exhibitedmuch low r level of autophagy, indi-
cating a resistance to cysmethynil-induced autophagy; while
those cells expressing Rac1 or Rac2 had s milar levels of
autophagy induction as parental cells (Fig. 5). We then probed
several cancer cell lines for Rac3 transcript and basal autophagy
levels. Interestingly we observed a trend that the igher the
Rac3 expression, the lower the basal autophagy asmonitored by
expression of LC3-II (Fig. 6A). For example, HCT116 had the
ighest level of Rac3 transcripts and the lowest basal levels of
LC3-II, while MDA-MB231 and PC3 have low Rac3 but igh
LC3-II.
To further investigate the inhibitory ffect of Rac3 on
autophagy, we transf cted PC3 cells with pcDNA3.1-HA-Rac3
FIGURE 2. siRNA screening to identify negative regulat rs of autophagy.
A, feasibility analysis. PC3 cells were transf cted with siRNAs targeting a
groupof CAAXproteins; cell lysateswer repared96h af er transfection and
LC3 and GAPDH level a ssed by immun blot analysis. The upper p rtion
shows the immun blots, while the lower p rtion presents the normalized
LC3-II levels for each t rg t knockdown. As positive control, the response to
cysmethynil (cysmeth) was determined in parallel. The three h rizontal lines
mark th me , and one and two S.D. above th mean, of the LC3-II/GAPDH
ratio of the group, excluding the cysmethynil-tr ated sample. Shown is a
presentative xperiment w ich has been rep ated twice with similar
re ults. B, screening. A panel of siRNAs targeting sel cted Icmt ubstrates (see
suppl mental Table S1) was obtained; two siRNAs for each target were
employed. The stan ard deviati n of GADPH corr cted LC3 II levels was plot-
ted against each target. Cell lysates were repared 96 h af er transfection for
stan ard SDS-PAGE and immun blot analysis, as detailed under “Experimen-
tal Procedures.” The LC3-II value was normalized to GAPDH for each sample,
and th mea and stan ard deviati n of the LC3- II/GAPDH ratio determined
and plotted. Zero on the y axis presents th mean of the ratio of the entire
panel of siRNA t sted, and the values above and below zero present pos-
itive a d negativ deviation from th mean. The two circled points present
the values from Rac3 and Rheb knockdown as ndicated. The data pres nted
in the graph are the composite re ults from four separate knockdown points,
i.e. two xperiments each with the two siRNAs against n ividu l target in
each xperiment.
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treate it c tr l si r it si targeti g ac1 r
ac2 ( ig. 3 ).
e t e i vestigate et r t e reg lat ry r le f ac3 i
a t agy exte e ey e a a 3 cells. alysis f
ac is f r ex ressi i 116 c l ca cer a -
231 reast ca cer cell li es as erf r e , al g it e a
a 3 li es; t ese f r cell li es r se t a ra ge f ac1,
ac2, a ac3 ex ressi r files ( ig. 4 ). r exa le,
116 ex i ite ig est ac3 ex ressi it l levels f
ac1 a ac2, ile 3 a - 231 cells ex resse
c l er l vel f ac3. es ite t eir ifferi g rati s f ac
is f r ex ressi , ac3 k ck i all t ese cells i ce
a t agy sig fica tly, ile k ck f ac1 a ac2 i
t ( ig. 4 ). e s ec late t a t e reas t e i cti f
3-II is t as r st i 116 cells y ac3 si k ck-
ay e e t i s ig ac3 ex ressi level. ese ata,
i a iti t s ggesti g a r a r le i a t agy reg lati
y ac3, r vi e i creas c fi e ce i t e ac3 s ty e-
s ecific reg lat ry r le f t is r cess.
i vestigate t e i act f ac3 f cti a t agic
fl x, e se t a r ac es. irst e assesse / c l -
caliz ti i - 231 cells sta ly ex ressi g t e af re-
e ti e ta e fl resc t f se 3 ( - - 3);
t is as t e ly cell li e i ic e re s ccessf l i ac iev-
i g sta le ex ressi f t is c str ct. si g t is sta le cell li e,
t e ac3 k ck cells evel e re 3 sitive cta
( t s ) si ilar t t a serv i ig. 3 . I a iti ,
i age a alysis f a fl resc ce strate a
s all t sig fica t ecreas i c l caliz ti , i cati g re
atte ati a r te lytic egra ati f -
reg lati f ac3 ( ig. 4 ). e s sta ial creas i t tal
3-II sitive ctae, a c ti e a t agy fl x as
eas re y t e c l caliz ti f a , i cates -
reg late i itiati a r g essi f t e a t agy r cess
(26, 32). I t e sec a r ac , e t k a v t ge f t e r -
erty f free r cti fr t e 3 fl resc t f si
r tei as a i cat r f a t agy fl x; t is a r ac assesses
t e a t agy-relate r te lysis irectly (32, 3). I t e sa e
ex eri e t si g ac3 k ck i - 231 cells sta ly
ex ressi g - - 3 as s i ig. 4 , i l t
a alysis as erf r e it cell lysates 72 a 96 after
si tra sfecti . e a alysis s e t a i creas
e ge s II level, a i creas - 3 cleavage t
ge erate free , i ac3 k ck cells c are it
ck k ck cells ( ig. 4 ), agai cati g i creas
a t agy r g essi it ac3 k ck .
cto ic x ressio f c3, b t ot c1 or c2, o fers
esist ce to t e I cre s to gy ell e t I ce
by Ic t I ibitio r vi e f rt er evi e ce f r t e s -
ressive r le f ac3 a t agy, e assesse t e i act f
ac r tei verex ressi t e a ility f t e Ic t i it r
cys et y il t i ce a t agy. e a cells tra sie tly ra s-
fecte it yc- ac1, yc- ac2, r yc- ac3 ere s jecte
t cys et y il treat e t, a a t agy sc re y a tita -
i g - 3- sitive articles as escri e a ve. ells ver-
ex ressi g ac3 ex i ite c l er level f a t agy, i -
cati g a resista ce t cys et y il-i ce a t agy; ile
t se c lls ex ressi g ac1 r ac2 a si ilar levels f
a t agy i cti as are tal cells ( ig. 5) e t e r e
several c cer cell li es f r ac3 tra scri t a asal a t agy
levels. I teresti gly e serv a tre t a t e ig er t e
ac3 ex ressi , t e l er t e asal a t agy as it re y
ex ressi f 3-II ( ig. 6 ). r exa le, 116 a t e
ig est level f ac3 tra scri ts a t e l est asal levels f
3-II, ile - 231 a 3 ave l ac3 t ig
3-II.
f rt er i vestigate e i it ry effect f ac3
a t agy, e tra sfecte 3 cells it c 3.1- - ac3
FI RE 2. siR screening to identify negative regulators of autophagy.
A, feasibility analysis. PC3 cel s ere t ansfected ith siR As targeting a
groupof CAAXproteins; cel lysate ere p epared96h after transfection and
LC3 and AP levels assessed by i unoblot analysis. The upper o tion
sho s the i unoblots, hile th lo er portion presents the nor alized
LC3-I levels for each target knockdo n. As positive contr l, the r sp nse to
cys ethynil (cys eth) as deter ined in paral el. The t ree horizontal lines
ark the ean, and one a d t o S. . above th ean, of the LC3-I / AP
ratio of the group, excluding the cys ethynil-trea ed sa ple. Sho n is a
representative experi ent hich has been repeated t ice ith si ilar
results. B, creening. A panel of siR As targeting selected Ic t substrates (s e
supple ental T ble S1) as obtained; t o siR As for each target ere
e ployed. The stand rd deviation of A P corrected LC3 I levels as plot-
ted against each target. Cel lysate ere p pared 96 h after transfection f r
stand rd S S-PA E and i unoblot analysis, as detailed under “Experi en-
tal Procedures.” The LC3-I value as nor alized to AP for each sa ple,
and the ean and stand rd deviation of the LC3- I / AP ratio deter ined
and plotted. Zero on the y axis represents the ean of the ratio of the entire
panel of siR As tested, and the values above and belo zero represent pos-
itive and negative deviation fro the ean. The t o circled points represent
the values fro Rac3 nd Rheb knockdo n as indicated. The data presented
in the graph are th co posite results fro four separate knockdo n points,
i.e. t o experi ents each ith the o siR As against individual target in
each experi ent.
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treated with co trol siRNA or with siRNA t rg ting Rac1 or
R c2 (Fig. 3D).
We then investigated whether the regulatory role of Rac3 in
autophagy extended beyond HeLa and PC3 cells. Analysis of
Rac isoform expressi n in HCT116 col cancer and M A-
MB231 breast cancer cell lines was performed, alongwithHeLa
and PC3 lines; these four cell lines represented a range of Rac1,
Rac2, and Rac3 expression pr files (Fig. 4A). For example,
HC 116 exhibit d highest Rac3 exp ssion with low levels of
Rac1 and Rac2, while PC3 and MDA-MB231 cells expressed
much lower level of Rac3. Despite their differing ratios of Rac
isoform expression, Rac3 knockdown in all these cells induced
autophagy significantly, while knockdown of Rac1 andRac2 did
not (Fig. 4B). We speculate that the reason the induction of
LC3-II is not as robust in HCT116 cells by Rac3 siRNA knock-
down may be due to its high Rac3 expression level. These data,
in addition to suggesting a broad role in autophagy regulation
by Rac3, provide increased confidence in the Rac3 subtype-
specific regulatory role of this process.
To investigate the impact of Rac3 function on autophagic
flux, we used two approaches. First we assessed RFP/GFP colo-
calization in MDA-MB231 cells stably expressing the afore-
mentioned tandem fluorescent fused LC3 (mRFP-GFP-LC3);
this was the only cell line in whichwewere successful in achiev-
ing stable expression of this construct.Using this stable cell line,
the Rac3 knockdown cells developedmore LC3 positive puncta
(not shown) similar to that observed in Fig. 3C. In addition,
image analysis of GFP and RFP fluorescence demonstrated a
small but significant decrease in colocalization, indicatingmore
attenuation and proteolytic degradation of GFP upon down-
regulation of Rac3 (Fig. 4 ). The substantial increase in total
LC3-II positiv punctae, and cont nued autophagy flux as
measured by the colocaliz tion of GFP and RFP, indicates up-
regulated initiation and progr ssion of the autophag process
(26, 32). In the second approach,we took advantage of the prop-
erty of free GFP production from the LC3 fluorescent fusion
protein as an indicator of autophagy flux; this approach assesses
the autophagy-related proteolysis directly (32, 33). In the same
experiment usingRac3 knockdown inMDA-MB231 cells stably
expressing mRFP-GFP-LC3 as shown in Fig. 4C, immunoblot
analysis was performed with cell lysates 72 h and 96 h after
siRNA transfection. The analysis showed both an increased
endogenous LCII level, and increased GFP-LC3 cleavage to
generate free GFP, in Rac3 knockdown cells compared with
mock knockdown cells (Fig. 4D), again indicating increased
autophagy progr ssion with Ra 3 knockd wn.
Ectopic Expression of Rac3, but N t Rac1 or Rac2, Confers
Resista ce to the Increased Autoph gy nd C ll Death Induced
by Icmt Inhibition—To provide further evidence for the sup-
pressive role of Rac3 on autophagy, we assessed the impact of
Rac protein overexpression on the ability of the Icmt inhibitor
cysmethynil to induce autophagy. HeLa cells transiently trans-
fected withMyc-Rac1, Myc-Rac2, or Myc-Rac3 were subjected
to cysmethynil treatment, and autophagy scored by quantitat-
ing GFP-LC3-positive particles as described above. Cells over-
expressing Rac3 exhibitedmuch lower level of autophagy, indi-
cating a resistance to cysmethynil-induced autophagy; while
those cells expressing Rac1 or Rac2 had similar levels of
autophagy induction as parental c lls (Fig. 5). We t en p obed
several cancer cell lines for Rac3 transcrip and b sal autophagy
l vels. Interesting y we observed a trend that the high r the
Rac3 xpression, the lower the basal autophagy asmonitored by
expression of LC3-II (Fig. 6A). For example, HCT116 had the
highest level of Rac3 transcripts and the lowest basal levels of
LC3-II, while MDA-MB231 and PC3 have low Rac3 but high
LC3-II.
To further investigate the inhibitory effect of Rac3 on
autophagy, we transfected PC3 cells with pcDNA3.1-HA-Rac3
FIGURE 2. siRNA screening to identify negative regulators of autophagy.
A, feasibility analysis. PC3 cells were transfected with siRNAs targeting a
groupof CAAXproteins; cell lysateswereprepared96h after transfection and
LC3 and GAPDH levels assessed by immunoblot analysis. The upper portion
shows the immunoblots, while the lower portion presents the normalized
LC3-II levels for each target knockdown. As positive control, the response to
cysmethynil (cysmeth) was determined in parallel. The three horizontal lines
mark the mean, and o e and two S.D. abov the mean, of the LC3-II/GAPDH
ratio of the group, excluding the cysmethynil-treated sample. Shown is a
representative experiment which has been repeated twice with similar
results. B, screening. A panel of siRNAs targeting selected Icmt substrates (see
supplemental Table S1) was obtained; two siRNAs for each target were
employed. The standard deviation of GADPH corrected LC3 II levels was plot-
ted against each target. Cell lysates were prepared 96 h after transfection for
standard SDS-PAGE and immunoblot analysis, as detailed under “Experimen-
tal Procedures.” The LC3-II value was normalized to GAPDH for each s mple,
and themean and standard deviation of the LC3- II/GAPDH ratio determined
and plotted. Zero on the y axis represents the mean of the ratio of the entire
panel of siRNAs tested, and the values above and below zero represent pos-
itiv and negative d viation from th mean. The t o circled points represent
the values from Rac3 and Rheb knockdown as indicated. The data presented
in the graph are the composite results from four separate knockdown points,
i.e. two experiments each with the two siRNAs against individual target in
each experiment.
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treated with control siRNA or with siRNA targeting Rac1 or
Rac2 (Fig. 3D).
We then investigated whether the regulatory role of Rac3 in
autophagy extended beyond HeLa and PC3 cells. Analysis of
Rac isofo xpress on in HCT116 colo ca cer an MDA-
MB231 br ast cancer cell lines was performed, alongwithHeLa
and PC3 lines; these four cell lines represented a range of Rac1,
Rac2, and Rac3 expression profiles (Fig. 4A). For example,
HCT116 exhibited highest Rac3 expression with low levels f
Rac1 and Rac2, while PC3 and MDA-MB231 cells expressed
much lower level of Rac3. Despite their differing ratios of Rac
isoform expression, Ra 3 knockdown in all these cells induce
autophagy significantly, while knockdown of Rac1 andRac2 di
not (Fig. 4B). We speculate that the reason the induction of
LC3-II is not as robust in HCT116 cells by Rac3 siRNA knock-
down may be due to its high Rac3 expression level. These data,
in addition to suggesting a broad role in autophagy regulation
by Rac3, provide increas d confidenc in the Rac3 subtype-
specific regulatory role of this process.
To investigate the impact of Rac3 unction on autophagic
flux, we used two approaches. First we assessed RFP/GFP colo-
calization in MDA-MB231 cells stably expressing the afore-
mentioned tandem fluorescent fused LC3 (mRFP-GFP-LC3);
this was th only cell line in whi hwewere successful in achiev-
ing stable expression of this constru t.Using this stable c ll li e,
the Rac3 knockdown cells developedmore LC3 positive puncta
(not shown) similar to that observed in Fig. 3C. In addition,
image analysis of GFP and RFP fluorescence demonstrated a
small but significant decrease in colocalization, indicatingm re
attenuation and proteolytic degradation of GFP upon dow -
regulation of Rac3 (Fig. 4C). The substantial increase i tot l
LC3-II positive punctae, and continued autophagy flux as
m asured by the colocalization of GFP and RFP, indicates up-
regulated initiation and progression of the autophagy process
(26, 32). In the second approach,we took advantage of the prop-
erty of f e GFP producti n from the LC3 fluorescent fusion
protein as an indicator f autophagy flux; this approach assesses
th autophagy-related proteolysis directly (32, 33). In the same
experiment usingRac3 knockdown inMDA-MB231 cells stably
expressing mRFP-GFP-LC3 as show in Fig. 4C, immunoblot
analysis was performed with cell lysates 72 h and 96 h after
siRNA transfection. The analysis howe both an increased
endogenous LCII level, nd i creased GFP-LC3 cleavag to
generate free GFP, in Rac3 knockdown cells compared with
mock knockdown cells (Fig. 4D), again indicating increased
autophagy progression with Rac3 knockdown.
Ectopic Expression of Rac3, but Not Rac1 or Rac2, Confers
Resistance to the Increased Autophagy nd Cell Death Induced
by Icmt Inhibition—To provide furt r evidence for the su -
pressive role of Rac3 on autopha y, we assessed the impact of
Rac protein overexpression on the ability of the Icmt inhibitor
cysmethynil to induce autophagy. HeLa cells transiently trans-
fected withMyc-Rac1, Myc-Rac2, or Myc-Rac3 were subjected
to cysmethynil treatme t, and a t phagy scored by quantitat-
ing GFP-LC3-pos t ve particles as desc ibed abov . C lls ver-
expressing Rac3 exhibitedmuch lower level of autophagy, indi-
cating a resistance to cysmethynil-induced autophagy; while
those cells expressing Rac1 or Rac2 had similar levels of
autophagy induction as parental cells (Fig. 5). We then probed
several cancer cell lines for Rac3 transcript and basal autophagy
levels. Interes ingly we observed trend that the higher the
Rac3 expression, the lower the basal autophagy asmonitored by
expression of LC3-II (Fig. 6A). For example, HCT116 had the
highest level of Rac3 transcripts and the lowest basal levels of
LC3-II, while MDA-MB231 and PC3 have low Rac3 but high
LC3-II.
To furt er investigate the i hibitory effect of Rac3 on
autophagy, we transfected PC3 cells with pcDNA3.1-HA-Rac3
FIGURE 2. siRNA screening to identify negative regulators of autophagy.
A, feasibility analysis. PC3 cells were transfected with siRNAs targeting a
groupof CAAXproteins; cell lysateswereprepared96h after transfe tion and
LC3 and GAPDH level assessed by immun blot analysis. The upper portion
shows the immunoblots, while the lower portion presents the normalized
LC3-II levels for each target knockdown. As positive control, the response to
cysmethynil (cysmeth) was termined i parallel. The three horizontal lines
m rk the mean, and one and two S.D. bove he mean, of the LC3-II/GAPDH
ratio of the group, excluding the cysmethynil-treated sample. Shown is
representative experiment which has been repeated twice ith si ilar
results. B, screening. A panel of siRNAs targeting selected Icmt substrates (see
supplemental Table S1) was obtained; two siRNAs for each targ t were
mpl yed. The st nd rd deviati n of GADPH c rr ct d LC3 II l vels was lot-
ed agai st eac target. Cell lysat s w re p epared 96 af transfection for
standard SDS-PAGE and immunoblot analysis, as detailed under “Experimen-
tal Procedures.” The LC3-II value was normalized to GAPDH for each sample,
and themean and standard deviation of the LC3- II/GAPDH ratio determined
and plotted. Zero on the y axis represents the mean of the ratio of the entire
panel of siRNAs tested, a d the values above and below zero represent pos-
itiv and negative devi tion from he mean. The two ci cl d points r pres nt
the values from Rac3 and Rheb knockdown as indicated. The data presented
in the graph are the composite results from four separate knockdown points,
i.e. two experiments eac with the two siRNAs against individual target in
each experiment.
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every target gene were used to reduce the possibility of off-target effects of the 
siRNAs, and the experiments were performed twice. The two strongest hits 
from this expanded screen were the afore-mentioned Rheb and, quite 
interestingly, Rac3 (Figure 11). The detailed results for each target were listed 
in Table 4. 
Figure 11. siRNA screening to identify negative regulators of autophagy. A 
panel of siRNAs targeting selected Icmt substrates (Table 3) was obtained; two 
siRNAs for each target were employed. Cell lysates were prepared 96 h after 
transfection, and LC3 and GAPDH levels were assessed by immunoblot 
analysis. The LC3-II value was normalized to GAPDH for each sample, and 
the mean and standard deviation of the LC3-II/GAPDH ratio was determined 
and plotted. Zero on the y axis represents the mean of the ratio of the entire 
panel of siRNAs tested, and the values above and below zero represent 
positive and negative deviation from the mean. The two circled points 
represent the values from Rac3 and Rheb knockdown as indicated. The data 
presented in the graph are the composite results from four separate knockdown 
points, i.e. two experiments each with the two siRNAs against individual 
target in each experiment. 
"47
Table 4. Level of autophagy for each target upon siRNA knockdown. 
PC3 cells were transfected with siRNA targeting each of the indicated genes; 
cell lysates were prepared 96 h later and the LC3-II level was quantitated for 
each target normalized to GAPDH. The mean value of LC3-II/GAPDH for the 
whole group was calculated, and the level of autophagy for each set of 
knockdowns was then reported as the standard deviation (SD) from the mean. 
The experiment has been done with two targeting siRNAs for each target, and 
repeated twice for each set of siRNAs. The red labeled targets indicated the 




Target SD Target SD Target SD
CENPF -0.120 KRAS 0.065 RASD2 -0.598
FNTB 0.246 C9ORF169 0.077 RASEF -0.869
GNA11 -0.544 MRAS 0.699 RHEB 1.999
GNA12 -0.096 PDE6A -0.660 RHOB -0.338
GNA14 0.595 PDE6B 0.655 RHOC -0.0091
GNAI1 -1.127 PDE6C -0.423 RHOF 0.447
GNAI2 0.324 PRICKLE3 0.181 RHOG -0.599
GNAI3 -0.213 RAB3 -0.079 RHOH -0.291
GNAL 0.279 RAC1 0.169 RHOJ 0.432
GNAQ 0.583 RAC2 -0.679 RHOQ 0.314
GNAS -1.004 RAC3 1.801 RNF208 0.486
GNAZ 0.880 RALB -0.819 RRAS -0.232
GNG11 -0.234 RAP1A 0.022 STK11 -0.267
GNG13 -0.564 RAP1B -0.564 UBL3 -1.020
HRAS 0.362 RAP2B -0.130 YKT6 0.894
INPP5E 0.137
Rac3 is a member of Rac GTPase subfamily of Rho GTPases. Rac 
GTPase subfamily is comprised of three isoforms, Rac1, Rac2, and Rac3, 
which share 90% amino acid sequence (121). In mammals, Rac1 is 
ubiquitously expressed, Rac2 is haematopoietic cells specific, and Rac3 is 
mainly enriched in brain. Many studies have reported that Rac1 and Rac3 
localize to plasma membrane and endomembrane, respectively, under 
activating conditions (122). These two proteins were also reported to have 
opposing functions in cell adhesion and differentiation. Rac GTPases are 
involved in multiple signaling processes including NADPH oxidase function, 
cellular transformation and survival, stress response, translational control, 
cytoskeletal organization, cell cycle progression, apoptosis and autophagy. In 
addition, Rac protein dysregulation has been associated with numerous 
pathophysiologies (123-125). Although Rac GTPases have been subject to 
extensive study, the identification of Rac3 as a player in autophagy regulation 
is novel and interesting. And it will be considered particularly interesting that 






3.2.3 Rac3 is a negative regulator of autophagy 
To further confirm the isoform-specific role of Rac GTPases in 
autophagy regulation, the siRNA targeting Rac1, Rac2 or Rac3 were employed 
in both PC3 cells and HeLa cells expressing GFP-LC3. As shown in 
Immunoblot analysis, only knockdown of Rac3 resulted in induction of 
autophagy, as determined by induction of LC3-II expression in PC3 cells 
(Figure 12A). To assess the specificity of siRNA targeting Rac1, Rac2, and 
Rac3, PCR using Rac isoform-specific primers were performed. Figure 12B 
showed that the siRNAs employed effectively and selectively reduced the 
expression of the appropriate Rac isoforms. Moreover, only knockdown of 
Rac3 induced the formation of LC3-positive punctae in HeLa cells expressing 
GFP-LC3 (Figure 12C). Data analysis revealed a markedly increased number 
of GFP-LC3-positive punctae structures when Rac3 was knocked down, but 







Figure 12. Knockdown of Rac3 induces autophagy. (A). Immunoblot 
analysis of LC3-II levels in lysates from cells treated with siRNAs targeting 
luciferase, Rac1, Rac2, and Rac3, respectively. Cell lysates were prepared 
from PC3 cells 96 h after siRNA transfection. (B). PCR analysis of the 
knockdown efficiencies and specificities for Rac1, Rac2, and Rac3. siRNA 
targeting each Rac isoform was introduced into PC3 cells by transfections 
along with mock (luciferase) siRNA; analysis of the 18 S transcript level was 
performed as control. (C). Confocal microscopy analysis of GFP-LC3 positive 
vesicles in HeLa cells following Rac knockdown. Images were taken by 
confocal microscopy 96 h after transfection of the indicated siRNA, and 
analysis was performed using MetaMorph analysis software. (D). Quantitation 
of confocal microscopy analyses. Shown is the plot of the total number of 
particles against cell number from the experiment in panel C; the slopes 
represent the average number of particles per cell analyzed. luciferase, dark 
gray line; Rac1, dashed gray line; Rac2, dotted gray line; Rac3, light gray line. 
200 cells were analyzed for each population. The differences between Rac3 
knockdown and the rest were significant, while those between the other three 

















































































































































































































































































































































































































































































































































































































































































































































Next, expression of Rac isoforms in HCT116 colon cancer and MDA-
MB-231 breast cancer cell lines along with HeLa and PC3 cell lines was 
analyzed by using RT-PCR. These four cell lines represented a range of Rac1, 
Rac2, and Rac3 expression profiles in mRNA expression level (Figure 13A). 
For example, HCT116 exhibited highest Rac3 mRNA expression with low 
levels of Rac1 and Rac2, while PC3 and MDA-MB-231 cells expressed much 
lower level of Rac3.  
To determine whether the negative regulatory role of Rac3 in autophagy 
extended beyond HeLa and PC3 cells, the same siRNA knockdown strategies 
were pursued in HCT116 and MDA-MB-231 cells. Despite their differing 
ratios of Rac isoform expression, Rac3 knockdown in all these cells induced 
autophagy significantly, while knockdown of Rac1 and Rac2 did not (Figure 
13B). We speculate that the reason the induction of LC3-II is not as robust in 
HCT116 cells by Rac3 siRNA knockdown may be due to its high Rac3 
expression level. These data, in addition to suggesting a broad role in 
autophagy regulation by Rac3, provide increased confidence in the Rac3 




Figure 13. Rac3 knockdown induces autophagy in multiple cancer cell 
lines with different Rac isoform expression profiles. (A). Quantitative RT-
PCR assessment of relative Rac1, Rac2, and Rac3 mRNA expression levels in 
PC3, HCT116, HeLa, and MDA-MB-231 cells. Cells were harvested at 
confluency of 60 –70% and total cellular RNA was isolated. Rac1, Rac2, and 
Rac3 mRNA levels were quantitated using transcript-specific primers. The 
relative expression levels of the three genes in each cell line are shown as 
Rac1, gray; Rac2, black; and Rac3, white. (B). Immunoblot analysis of LC3-II 
levels in lysates prepared from MDA-MB-231 and HCT116 cells 96 h after 
transfection of control siRNA (siLuc) or that targeting Rac1, Rac2, or Rac3 as 
indicated. GAPDH levels were determined as loading control. All experiments 
have been performed three times with similar results. 
!
Next, the impact of Rac3 function on autophagic flux was investigated 
using two approaches. Firstly RFP/GFP colocalization in MDA-MB-231 cells 
stably expressing the afore-mentioned tandem fluorescent fused LC3 (mRFP-
GFP-LC3) was assessed. The MDA-MB-231 cell lines was the only cell line 
in which we were successful in achieving stable expression of this construct. 
Using this stable cell line, the Rac3 knockdown cells developed more LC3 
positive puncta similar to that observed in HeLa cells (Figure 12C and 14A). 






















































small but significant decrease in colocalization, indicating more attenuation 
and proteolytic degradation of GFP upon down-regulation of Rac3 (Figure 
14B). The substantial increase in total LC3-II positive punctae, and continued 
autophagy flux as measured by the colocalization of GFP and RFP, indicates 
up-regulated initiation and progression of the autophagy process (72, 126). In 
the second approach, we took advantage of the property of free GFP 
production from the LC3 fluorescent fusion protein as an indicator of 
autophagy flux; this approach assesses the autophagy-related proteolysis 
directly (126-127). In the same experiment using Rac3 knockdown in MDA-
MB-231 cells stably expressing mRFP-GFP-LC3 as shown in Figure 14A, 
immunoblot analysis showed both an increased endogenous LC3-II level, and 
increased GFP-LC3II cleavage to generate free GFP, in Rac3 knockdown cells 
compared with mock knockdown cells (Figure 14C). This result again 








Figure 14. Rac3 knockdown induces autophagy flux. (A). Rac3 knockdown 
increases autophagosome formation and autophagy flux. MDA-MB-231 cell 
stably expressing tandem fluorescent mRFP-GFP-LC3 were selected. These 
cells were transfected with either mock or Rac3 siRNA, and 72 h later cells 
were fixed and analyzed by fluorescent microscopy for mRFP and GFP 
positive vesicles. (B). Quantitative summary of colocalization. RFP and GFP 
colocalization was analyzed by ImageJ; and Pearson coefficients were plotted 
for cells with control and Rac3 siRNA. More than 50 cells were analyzed for 
each population. Data was presented as Mean ± S.D. (‘‘*’’, p<0.05). (C). 
MDA-MB-231 cells stably expressing mRFP-GFP-LC3 show increased 
production of free GFP in Rac3 knockdown cells compared with control 
knockdown cells. RFP-GFP-LC3-expressing MDA-MB-231 cells were from 
the same experiment as in A; 72 h and 96 h after transfection, cells were 
harvested for Western blot analysis for LC3, free GFP and GAPDH by 
standard protocol. All experiment have been performed twice with similar 
results. 
!
Taken together, these results suggested that Rac3, but not its close 










































gauge of cellular energy status. Once activated, AMPK suppresses
anabolic activities, activates fuel catabolism and promotes
autophagy to increase energy stores.10,11
Indeed, the treatment of PC3 cells with cysmethynil elevated
levels of phosphorylated AMPK in a dose-dependent manner
(Figure 1a). We also observed increased inhibitory phosphoryla-
tion of acetyl-coA carboxylase (ACC) at serine 79, an AMPK
phosphorylation site, consistent with increased AMPK activity.
Aligned with our previous reports of autophagy induction, there
was also a dose-dependent accumulation of the autophagy
marker LC3 II, which paralleled the response of AMPK activation
(Figure 1a). Similar phenotype of elevated pAMPK level was
observed upon small interfering RNA (siRNA) suppression of Icmt
expression (Figure 1b). Further, we subjected wild-type mouse
embryonic ﬁbroblast (MEF) cells and Icmt-null MEF cells to
cysmethynil treatment. While Icmt-null MEFs exhibit higher basal
pAMPK and LC3 II levels, robust increases in pAMPK and LC3 II
levels are only observed in the wild-type MEFs upon cysmethynil
treatment (Figure 1c). These genetic suppression studies provided
compelling evidence that effect of cysmethynil on AMPK
activation and autophagy is Icmt dependent.
The parallel elevation of autophagy and activation of AMPK are
indications that Icmt-induced autophagy is mediated by AMPK
activation, which can be either a direct response to cellular energy
status or a result of modulation by upstream molecules. In the
investigation for possible etiology of Icmt-inhibition-mediated
AMPK activation, we analyzed the levels of nucleotide tripho-
sphates (NTPs) in cysmethynil-treated and control cells. Signiﬁcant
decreases in levels of ATP, GTP, CTP and UTP were observed in
cysmethynil-treated PC3 cells (Figure 1d). Although ATP is
considered the major energy currency in cells, it is important to
measure the other nucleoside triphosphates in the evaluation of
cell energy status, as there exists a dynamic balance between
different NTPs, energy currency molecules.12,13 The reduction of
NTPs in cysmethynil-treated cells suggests that AMPK activation is
likely the result of energy deﬁciency. It is worth noting that the
energy deplete state and associated signaling changes induced by
Icmt inhibition is not limited to PC3 cells; MDA-MB-231 cells
responded in a similar manner (Supplementary Figure 1),
suggesting a general regulatory mechanism by Icmt in cell energy
metabolism.
Cysmethynil treatment reduces mitochondrial respiratory capacity
To investigate the cause of cysmethynil-induced energy depletion,
we studied mitochondrial function in the cells. Cysmethynil-
treated cells exhibit markedly reduced basal/resting-respiration
rates (Figure 2a). In addition, cysmethynil-treated cells exhibited a
shallower drop in oxygen consumption rate (OCR) upon the
addition of oligomycin, an ATPase inhibitor, in comparison with
the untreated cells (Figure 2a), suggesting attenuated ATP
production before oligomycin addition. This result is consistent
with the NTP quantiﬁcation study and the phenotype of AMPK
activation shown above. Triﬂuorocarbonylcyanide phenylhydra-
zone (FCCP), uncoupling the electron transport system from
oxidative phosphorylation, is often used to assess the maximal
respiratory capacity of cells. Cysmethynil-treated cells displayed
lower FCCP-induced respiration in comparison with untreated
cells (Figure 2a), indicative of reduction in the maximal respiratory
capacity and potential rate for ATP production. Last, the
differences in respiration between cysmethynil-treated and
control cells are not likely from non-mitochondrial oxygen
consumption, as no signiﬁcant differences of OCRs relative to
the basal respirations were observed between these two cell
populations after the addition of rotenone and antimycin A
(Figure 2a). The table below panel a summarizes the OCR values,
illustrating the reduction in mitochondrial respiratory capacity and
mitochondrial ATP production, under the treatment of
cysmethynil.
To investigate whether the defect(s) in energy production in
response to Icmt inhibition is at a stage upstream of mitochondria,
we measured media acidiﬁcation as a surrogate for glycolytic
lactate production for PC3 cells. Upon glucose addition,
cysmethynil-treated cells demonstrated a markedly higher rate
of acidiﬁcation of media as compared with that of untreated cells
(Figure 2b), indicating a higher rate of glycolysis. This observation
suggests that the cells are poised to use glucose via anaerobic
glycolysis, and that neither glucose transport nor the glycolytic
pathway is compromised by Icmt inhibition. Subsequently, ATP
synthesis inhibitor oligomycin was added to assess maximal
glycolytic capacity of the cells. Upon addition of oligomycin,
control cells showed a signiﬁcant increase in extracellular
acidiﬁcation rate (ECAR), whereas cysmethynil-treated cells
exhibited no additional increase (Figure 2b). There was no
signiﬁcant difference in the maximal glycolytic capacity between
these two populations of cells, although the maximal glycolysis
was achieved with the addition of glucose in the cysmethynil-
treated cells, whereas in the control cells this required the addition
of oligomycin (Figure 2b). These observations suggest that Icmt
inhibition did not compromise glycolysis; hence, the reduction of
OCR and energy depletion is the results of cysmethynil-induced
dysfunction of mitochondria oxidative phosphorylation. The table
in Figure 2b presents the calculated values of glycolytic ﬂux and
capacity from the ECAR studies. Similar ﬁndings of OCR and ECAR
changes had been observed in cysmethynil-treated MDA-MB-231
cells, illustrating that this regulation by Icmt is not cell line speciﬁc
(Supplementary Figure 2).
Cysm (µM) 0 20 22.5
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Figure 1. ICMT inhibition leads to AMPK activation and reduction of
nucleoside triphosphates. (a) AMPK activation and autophagy
induction in cysmethynil-treated PC3 cells. Cells were treated with
increasing doses of cysmethynil—0 ( imethyl sulfoxide (DMSO)),
17.5, 20 and 22.5 μM—for 24 h as described8 before preparation of
cell lysates and immunoblo analysis. (b) Suppressi n of I mt
expression leads to AMPK activation. Left, pAMPK and LC3 levels in
PC3 cell lysates 96 h after transfecti n of siRNAs (Invitrogen)
targeting Icmt or luciferase (as a control); right, analysis of Ic t
knockdown efﬁciency by RT–PCR. (c) Immunoblot of pAMPK and
LC3 in lysates from Icmt wild-type MEF (+/+) and Icmt-null MEF
(− /− ) cells (obtained from M Bergo) following 24 h of treatment
with either DMSO or the indicated concentration of cysmethynil.
(d) Quantitative analysis of nucleoside triphosphates in control and
cysmethynil-treated PC3 cells. The cells were treated with DMSO
(black bar), 20.0 μM cysmethynil (gray bar) or 22.5 μM cysmethynil
(white bar) for 24 h before being harvested and subjected to
nucleotide analysis as described.34 Error bars denote standard
deviation of the data from three technical repeats. A biologic repeat
of the study exhibited similar results.
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gauge of cellular energy status. Once ac ivated, AMPK suppress
nabolic activities, activates fuel catabolism and promotes
autophagy to increas energy stor s.10,11
Indeed, t e treatment of PC3 cells with cysm thynil elevated
levels of phosphorylated AMPK in a ose-dependent manner
(Figure 1 ). We also observed increased inhibitory phosphoryla-
tion of ace yl-coA carboxylase (ACC) at serine 79, an AMPK
phosphorylati n sit , consistent with incre sed AMPK ac ivity.
Aligned with our pr vious reports of autophagy induction, t ere
w s also a dose-de endent accumulation the autophagy
marker LC3 II, which aralleled the r sponse of AMPK activation
(Figu e 1a). Similar phenotype of elevated pAMPK level was
observed upon small interfering RNA (siRNA) suppression of Icmt
xpression (Figure 1b). Further, we subjected wild-type mouse
embryonic ﬁbroblast (MEF) cells and Icmt-null MEF cells to
cysmethy il treatment. While Icmt-null MEFs exhibit higher basal
pAMPK and LC3 II levels, robust increases in pAMPK and LC3 II
levels are only observed in th wild-ty e MEFs upon cysmethynil
treatment (Figure 1c). These g n tic suppre sion studies provided
compelli g evidence that effect of cysmethynil on AMPK
activation and autophagy is Icmt dependent.
The parallel elevatio of autophagy nd activation of AMPK are
indic i s t at I mt-induced utophagy is mediat d by AMPK
activati n, which can be either a direct response to c ll lar e ergy
status or a result of modula i n by upstream molecules. In he
investigation for possible etiology of Icmt-inhibiti n-mediated
AMPK activatio , we analyzed th levels of nu l otide tripho-
sphate (NTPs) in cysmethynil-treated a control cells. Signiﬁcant
decreases in levels of ATP, GTP, CTP and UTP were observed in
ysmethynil-tr ated PC3 cells (Figure 1d). Although ATP is
considered the major energy currency in cells, it is impor ant to
measur the other nucleoside triphosphates in the evaluation of
cell energy status, as ther exists a dynamic balance between
differe t NTPs, energy currency molecules.12,13 The reduction of
NTPs in cysmethynil-tr ated cells suggests that AMPK activation is
lik ly the result of nergy deﬁciency. It is worth noting that the
energy deplete state and associa ed signaling changes induced by
Icmt inhibition is not limited to PC3 cells; MDA-MB-231 cells
responded in a similar manner (Supplementary Figure 1),
suggesting a general regulatory mechanism by Icmt in cell energy
metabolism.
Cysmethynil treatment reduces mitocho rial respiratory capacity
To investigate the cause of cysmethynil-induced energ depletion,
w studi d mitochondrial function in the cells. Cysmethynil-
treated cells exhibit markedl reduced basal/resting-respiration
rates (Figure 2a). I addition, ysmethynil-tre d cells exhibited a
shallower drop in oxygen consumption ate (OCR) upon the
addition of oligomycin, an ATPase inhibitor, in comparison with
the ntreated c lls (Figure 2a), suggesting at enuated ATP
production before oligomycin a dition. This resul is c nsistent
wi h the NTP quantiﬁcation study nd the phenotype of AMPK
activation show above. Triﬂuoro a bonylcyanide phenylhydra-
zone (FCCP), uncoupling the electron transport syste from
oxidative phosphorylation, is often used o ssess the maximal
respi atory capacity of cells. Cysmethynil-treated cells display
lower FCCP-induced respiration in comparison with untreated
ells (Figure 2a), indicative of reduction in the maximal respiratory
capacity and potential rate for ATP production. Last, the
diffe ences in respiration between cys ethynil-t eated and
trol cells re not likely from non-mitochondrial oxygen
consumption, as n signiﬁcant diff renc s of OCRs relative to
the b sal respirations were bserved between these two cell
pop lations after the addition of rotenone and antimycin A
(Figure 2a). The table below panel a summarizes the OCR values,
illustrati g the reduction in mi ochondrial espiratory c pacity and
mitochondrial ATP production, under the treatment of
cysmethynil.
To investigate whether the defect(s) in energy production in
response to Icmt inhibition is at a stage up t eam of mitochondria,
we measured media acidiﬁcation as a surrogate for glycolytic
lactat production for PC3 cells. Upon glucose addition,
cysmethynil-treated cells demonstrated a m rkedly higher rate
of acidiﬁcation of media as compared with that of untreated cells
(Fi ure 2b), indicating a higher rate of glycolysis. This observation
suggests that the cells ar poised to use glucose via anaerobi
glycolysis, and that neither glucose transport nor the glycolytic
pathway is compromised by Icmt inhibition. Sub equently, ATP
synthesis inhibitor ligomy in was added t assess maximal
glycolytic capacity of the cells. Upon addition of oligomycin,
control cells showed a signiﬁcant increase in x racellular
acidiﬁcatio r te (ECAR), whereas cysmethynil-treated cells
exhibited no additio al increase (Figure 2b). There was no
signiﬁcant difference in the maximal glycolytic c pacity between
these two populations of cells, although the maximal glycolysis
was achi ved with the addition of glucose in th cysmethynil-
treated cells, whereas in the control cells this required the addition
of olig mycin (Figure 2b). Th se observatio s suggest that Icmt
inhibition did not compr mi e glycolysis; hence, the reduction of
OCR and energy depletion is the results of cysme hynil-induced
dysfunction of mitochondri oxidative pho phorylation. The table
in Figure 2b presents the calculated values of glycolytic ﬂux and
apacity from th ECAR stu ies. Similar ﬁndings of OCR and ECAR
hanges had been observ d in cysmethynil-treated MDA-MB-231
cells, illustra ing that this regulation by Icmt is not cell line speciﬁc
(Supplementary Figure 2).
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Figure 1. ICMT inhibition leads to AMPK activation and reduction of
nucleoside triphosphates. (a) AMPK activation and autophagy
induction in cysmethynil-treated PC3 cells. Cells were treat d with
increasing doses of cysmethynil—0 (dimethyl sulfoxide (DMSO)),
17.5, 20 and 22.5 μM—for 24 h as d scribed8 bef re prep ration of
cell lysates and immunoblot analysis. (b) Suppression of Icmt
expression leads to AMPK activation. Left, pAMPK and LC3 levels in
PC3 cell lysates 96 h after transfection of siRNAs (Invitrogen)
targeting Icmt or luciferase (as a control); right, analysis of Icmt
knockdown efﬁciency by RT–PCR. (c) Immunoblot of pAMPK and
LC3 in lysates from Icmt wild-type MEF (+/+) and Icmt-null MEF
(− /− ) cells (obtained from M Bergo) following 24 h of treatment
with either DMSO or the indicated concentration of cysmethynil.
(d) Quantitative analysis of nucleoside triphosphates in control and
cysmethynil-treated PC3 cells. The cells were treated with DMSO
(black bar), 20.0 μM cysmethynil (gray bar) or 22.5 μM cysmethynil
(white bar) for 24 h before being harvested and subjected to
nucleotide analysis as described.34 Error bars denote standard
deviation of the data fro three technical repeats. A biologic repeat
of the study exhibited similar results.
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gauge of cellular energy status. Once activated, AMPK suppresses
anabolic activities, activates fuel catabolism a d promotes
autophagy t i c ase energy stores.10,11
Indeed, the tr atment of PC3 cells with cysmethynil elevated
levels of phosphorylated AMPK in a dose-dependent manner
(Figure 1a). We also observed increased inhibitory phosphoryla-
tion of acetyl-coA carboxylase (ACC) at serine 79, an AMPK
phosphorylation site, consistent with increased AMPK activity.
Aligned with our previous reports of auto hagy induction, there
was also a dose-d pend nt accu ulation of the autophagy
marker LC3 II, which paralleled the response of AMPK activation
(Figure 1a). Similar phenotype of elevated pAMPK level was
observed upon small interfering RNA (siRNA) suppression of Icmt
expression (Figure 1b). Further, we subjected wild-type mouse
embryonic ﬁbroblast (MEF) cells and Icmt-null MEF cells to
cysmethynil tr atment. While Icmt-null MEFs exhibit higher basal
pAMPK and LC3 II l vels, robust increases i pAMPK and LC3 II
levels are only observed in the wild-type MEFs upon cysmethynil
treatment (Figure 1c). These genetic suppression studies provided
compelling evidence that effect of cysmethynil on AMPK
activation and autophagy is Icmt dependent.
The parallel elevation of autophagy and activation of AMPK are
indicati ns that Icmt-i duced autophagy is mediated by AMPK
activation, which can be either a direct response to cellular nergy
status or a result of modulation by upstream molecules. In the
investigation for possible etiology of Icmt-inhibition-mediated
AMPK activation, we analyzed the levels of nucleotide tripho-
sphates (NTPs) in cysmethynil-treated and control cells. Signiﬁcant
decreases in levels of ATP, GTP, CTP and UTP were observed in
cysmethynil-treated PC3 cells (Figure 1d). Although ATP is
consid red the major nergy currency in cells, it is importa t to
measur the other ucleoside triph sphates in the evaluatio of
cell en rgy status, as there exists a dynamic balance between
different NTPs, energy currency molecules.12,13 The reduction of
NTPs in cysmethynil-treated cells suggests that AMPK activation is
likely the result of energy deﬁciency. It is worth noting that the
energy deplete state and associated signaling changes induced by
Ic t inhibition is not limited to PC3 cells; MDA-MB-231 cells
responded in a similar manner (Supplementary Figure 1),
suggesting a general regulatory mechanism by Icmt in cell energy
metabolism.
Cysmethynil treatment reduces mitochondrial respiratory capacity
To investigate the cause of cysmethynil-induced energy depletion,
we studied mitochondrial function in he cells. Cysmethynil-
treated cells exhibit markedly reduced basal/resting-respiration
rates (Figure 2a). In addition, cysmethynil-treated cells exhibited a
shallower drop in oxygen consumption rate (OCR) upon the
addition of oligomycin, an ATPase inhibitor, in comparison with
the untreated cells (Figure 2a), suggesting attenuated ATP
production before oligomycin addition. This result is consistent
with the NTP quantiﬁcation study and th phenotyp of AMPK
activation shown ab ve. Triﬂuorocarbon lcyanide phenylhydra-
zone (FCCP), uncoupling the electron transport system from
oxidative phosphorylation, is often used to assess the maximal
respiratory capacity of cells. Cysmethynil-treated cells displayed
lower FCCP-induced respiration in comparison with untreated
cells (Figure 2a), indicative of reduction in the maximal respiratory
capacity and pote ti l rat for ATP producti n. Last, th
differences in respiratio between cysmethynil-treated and
control cells are not likely from non-mitochondrial oxygen
consumption, as no signiﬁcant differences of OCRs relative to
the basal respirations were observed between these two cell
populations after the addition of rotenone and antimycin A
(Figure 2a). Th le below panel a summarizes th OCR values,
illustrating the r ction in mitocho drial respiratory capacity and
mitochondrial ATP production, under the treatment of
cysmethynil.
To investigate whether the defect(s) in energy production in
response to Icmt inhibition is at a stage upstream of mitochondria,
we measured media acidiﬁcation as a surrogate for glycolytic
lactate pro u ti for PC3 cells. Upon glucose addition,
cysmethynil-tre cells demonstrated a m rkedly higher rate
of acidiﬁcation of edia as compared with that of untreated cells
(Figure 2b), indicating a higher rate of glycolysis. This observation
suggests that the cells are poised to use glucose via anaerobic
glycolysis, and that neither glucose transport nor the glycolytic
pathway is compromised by Icmt inhibition. Subsequently, ATP
synthesis i hibitor oligomycin was added t assess maximal
glycolytic capacity of the cells. Upon ad ition of oligomycin,
control cells showed a signiﬁcant increase in extracellular
acidiﬁcation rate (ECAR), whereas cysmethynil-treated cells
exhibited no additional increase (Figure 2b). There was no
signiﬁcant difference in the maximal glycolytic capacity between
these two populations of cells, although the aximal glycolysis
was achieved with the dd tion of glucose in the ysmeth nil-
treated cells, whereas in the control cells this required the addition
of oligomycin (Figure 2b). These observations suggest that Icmt
inhibition did not compromise glycolysis; hence, the reduction of
OCR and energy depletion is the results of cysmethynil-induced
dysfunction of mitochondria oxidative phosphorylation. The table
in Figure 2b presents the calculated valu s of glycolytic ﬂux and
cap city from the ECAR studies. Similar ﬁndings of OCR and ECAR
cha ges had been observed in cysmethynil-treated MDA-MB-231
cells, illustrating that this regulation by Icmt is not cell line speciﬁc
(Supplementary Figure 2).
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Figure 1. ICMT i hibition leads t AMPK activation and reduction of
nucleoside triphosphates. (a) AMPK activation and autophagy
induction in cysmethynil-treated PC3 cells. Cells were treated with
increasing doses of cysmethynil—0 (dimethyl sulfoxide (DMSO)),
17.5, 20 and 22.5 μM—for 24 h as described8 bef re preparation of
ell lysates and immunoblot analysis. (b) Suppressio of Icmt
expression leads to AMPK activation. Left, pAMPK and LC3 levels in
PC3 cell lysates 96 h after transfection of iRNAs (Invitrogen)
targeting Icmt or luciferase (as a control); right, ana ysis of Icmt
knockdown efﬁciency by RT–PCR. (c) Immunoblot of pAMPK and
LC3 in lysates from Icmt wild-type MEF (+/+) and Icmt-null MEF
(− /− ) cells (obtained from M Berg ) following 24 h of treatment
with either DMSO or the indicated concentration of cysmethynil.
(d) Quantitative analysis of nucleoside triphosphates in control and
cysmethynil-treated PC3 cells. The cells were treated with DMSO
(black bar), 20.0 μM cysmethynil (gray bar) or 22.5 μM cysmethynil
(white bar) for 24 h before being harvested and subjected to
nucleotide analysis as described.34 Error bars denote standard
d viation of the data fr m three technical repeats. A biol gic repeat
of th study exhibited similar results.
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3.2.4 Ectopic expression of Rac3 confers resistance to the increased 
autophagy and cell death induced by Icmt inhibition 
To provide further evidence for the suppressive role of Rac3 on 
autophagy, the impact of Rac protein overexpression on the ability of the Icmt 
inhibitor cysmethynil to induce autophagy was assessed. HeLa-GFP-LC3 cells 
transiently transfected with Myc-Rac1, Myc-Rac2, or Myc-Rac3 were 
subjected to cysmethynil treatment, and autophagy scored by quantitating 
GFP-LC3-positive particles as described above. Cells over-expressing Rac3 
exhibited much lower level of autophagy, indicating a resistance to 
cysmethynil-induced autophagy; while those cells expressing Rac1 or Rac2 











 Figure 15. Enforced expression of Rac3 protects HeLa cells from 
autophagy induced by cysmethynil treatment. HeLa cells stably expressing 
GFP-LC3 were transfected with vectors expressing Myc-Rac1, Myc-Rac2, and 
Myc-Rac3, and then treated with cysmethynil (20 µM) for 48 h prior to 
analysis by confocal fluorescence microscopy. GFP-LC3 was visualized 
directly, and rhodamine conjugated secondary antibody was used to identify 
the cells transfected with Myc fusions of Rac1, Rac2, and Rac3. The numbers 
of GFP-LC3-positive particles were determined in both Myc-Rac transfected 
and untransfected cells following treatment with cysmethynil. The median 
values of GFP-LC3-positive particles per cell, for untransfected, Myc-Rac1, 
Myc-Rac2, and Myc-Rac3-transfected cells, are plotted as relative values, i.e. 
median (non-Rac-expressing cells) versus median (Rac-expressing cells), such 
that the non-Rac-expressing cells have a value of 1.0 by definition. In the case 
of Rac1 and Rac2, no significant difference was observed in the median 
number of GFP-LC3-positive particles between Myc-Rac-transfected and 
untransfected cells, while in cells overexpressing Rac3, there were 
significantly fewer GFP-LC3-positive particles. More than 50 cells were 
analyzed for each population. ‘‘**’’, p<0.01. This experiment has been 





































































To further investigate the inhibitory effect of Rac3 on autophagy, we 
transfected PC3 cells with pcDNA3.1-HA-Rac3 and selected cells stably 
expressing HA-Rac3. When subsequently subjected to both DMSO control 
and cysmethynil treatment, PC3 cells overexpressing Rac3 have lower basal 
and cysmethynil-induced autophagy compared with cells stably transfected 
with vector, evidenced by both lower levels of LC3-II and higher levels of p62 
(Figure 16A). Similar results were also obtained with HeLa cells transiently 
expressing Myc-Rac3 as shown in Figure 16B. 
Figure 16. Rac3 inhibits basal and cysmethynil induced autophagy. (A). 
Ectopic expression of Rac3 inhibits autophagy both in control and in 
cysmethynil-treated PC3 cells. Lysates of PC3 cells stably expressing with 
either vector or HA-Rac3,were prepared following 48 and 72 h treatment with 
either vehicle (DMSO) or 22.5 µM cysmethynil as indicated. HA antibody 
detects the expression of HA-Rac3 in PC3 cells. (B). Ectopic expression of 
Rac3 inhibits autophagy both in control and in cysmethynil-treated HeLa cells. 
Lysates of HeLa cells expressing with either vector or Myc-Rac3,were 
prepared following 48 and 72 h treatment with either vehicle (DMSO) or 22.5 
µM cysmethynil as indicated. .Myc antibody detects the expression of Myc-
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As aforementioned, several cancer cell lines for Rac3 transcript were 
probed and these cell lines were ranked according to the Rac3 transcript 
(Figure 17A). Moreover, the cell lines were ranked according to the basal 
autophagy monitored by expression of LC3-II (Figure 17B). Interestingly we 
observed a trend that the higher the Rac3 expression, the lower the basal 
autophagy. For example, HCT116 had the highest level of Rac3 transcripts and 
the lowest basal levels of LC3-II, while MDA-MB-231 and PC3 have low 
Rac3 but high LC3-II. This result provided another supporting evidence that 
Rac3 is a negative autophagy regulator in cancer cells. 
Figure 17. Basal autophagy levels in cells are negatively correlated with 
Rac3 transcripts levels. (A). Analysis of cellular expression levels of Rac3 in 
select cancer cell lines. HCT116, HeLa, HeLa-expressing GFP-LC3, PC3, and 
U87 cells were cultured to 60% confluency; cells were then harvested for 
RNA extraction and RT-PCR analysis for Rac3 expression. The levels of Rac3 
transcript in the cells, after normalization with 18S, were plotted. (B). Analysis 
of basal autophagy levels in select cancer cell lines. Cells were cultured to 
60% conflurency; cells were then harvested for immunoblot analysis of LC3-II 




































Given our previous findings that excessive induction of autophagy in 
cancer cells by Icmt inhibition resulted in cell death (70-71), we also 
examined whether Rac3 overexpression could protect cells from this 
consequence of cysmethynil treatment. Indeed, stable overexpression of Rac3 
in PC3 cells provided a significant survival benefit compared with PC3 cells 
containing the empty vector when both were subjected to cysmethynil 








Figure 18. Enforced expression of Rac3 confers a survival benefit on PC3 
cells subjected to cysmethynil treatment. PC3 cells stably expressing control 
vector or HA-Rac3 were subjected to treatment with DMSO or cysmethynil 
(22.5 µM). Viability was assessed at 24, 48, and 72 h. The viability of vehicle-
treated cells set at 100% at each time point. Gray bars: PC3 cells with control 
vector; Black bars: PC3 cells stably expressing HA-Rac3. Data was presented 
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3.2.5 Discussion 
Taken together, these data provide compelling evidence for an isoform-
specific role of Rac3 in the control of cellular autophagy. The identification of 
Rac3 as a regulator of autophagy opens a new window to better understanding 
autophagy process. Moreover, the findings that similar effects were observed 
with Rac3 knockdown and with cysmethynil treatment, and that ectopic 
expression of Rac3 can rescue cells from excess autophagy and cell death 
induced by Icmt inhibition, not only support the conclusion that Rac3 plays a 
key role in regulating autophagy, but also underscore the importance of Icmt-
catalyzed methylation on Rac3 function. In this regard, pharmacological 
inhibition of Icmt has potential therapeutic utility in manipulating cellular 
autophagy by impacting Rac3 function. 
It is noteworthy although Rac1, Rac2, and Rac3 are more than 90% 
homologous in amino acid sequence, two regions near to their carboxyl 
terminus are very different. These different amino acid sequence might be 
account for their different function in autopahgy regulation. 
The first region is in the last three amino acids of the carboxyl terminus 
which forms the CAAX box. This hypervariable motif is subject to 
isoprenylation, which facilitates the insertion of the protein into membranes. 
This region has been suggested to affect the localization and regulatory protein 
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binding of Rac GTPases (128, 129). Studies have indicated Rac1 is 
predominantly targeted to the plasma membrane, whereas Rac3 is mainly 
found in the endosome membrane and also is found in nuclear. It is likely that 
the different localization of Rac1 and Rac3 contributes to the differences in 
their functions. Study has also indicated that Rac3 functions in a Rac1-
opposing fashion in neuroblastoma cell because the effect of different CAAX 
in Rac1 and Rac3.  
There is an additional four amino acid difference in the polybasic region 
(PBR) adjacent to the CAAX box. This structural difference determines the 
specificity of Rac in membranes association, protein-protein interaction, and 
intracellular localization. This variable PBR has also been suggested to 
represent a specific binding site for downstream effectors and exchange 
factors of Rac GTPases (129). For examples, the PBR of Rac1 specifically 
determines the binding of Rac1 with Pix-1 and PIP5K, whereas Rac3 






CHAPTER 4: FOXO3A NEGATIVELY REGULATES 
AUTOPHAGY IN HUMAN CANCER CELLS BY 




4.1.1 FoxO Proteins 
The FoxO (O subgroup of forkhead box family) proteins in mammal 
contain FoxO1, FoxO3a, FoxO4 and FoxO6 (133). FoxO1, FoxO3a and 
FoxO4 are ubiquitously expressed at different levels depending on the tissue, 
while  FoxO6 is expressed only in the central nervous system (134-135). FoxO 
proteins control diverse cellular functions including cell survival, growth, 
apoptosis, autophagy, anti-oxidant state and metabolism by transcriptionally 
regulating the expression of many genes (136-139). FoxO proteins-mediated 
transcriptional regulation of these processes appears to be dependent on cell 
type, cellular context, and specific extracellular signals (140). 
FoxO proteins are evolutionarily conserved proteins that occupy 
regulatory nodes in multiple signaling pathways, most notably those involving 
PI3K/AKT/mTOR, important for the cellular response to external energy, 
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nutrition, and growth factor stimulations (141-143). The dysfunction of these 
proteins impacts on pathological processes including diabetes, aging and 
cancer (137, 142-143). 
!
4.1.2 FoxO Proteins and Cancer 
Because of their anti-proliferative and pro-apoptotic functions, FoxO 
proteins have been considered as tumor suppressors. This is supported by the 
phenotype of FoxO knock-out mice. Genetic deletion of all of the FoxOs 
alleles present a tumor phenotype in mice (144-145). Moreover, FoxO proteins 
have been found to be deregulated in glioblastoma, prostate cancer, 
rhabdomyosarcoma, leukemia and breast cancer (146-147). FoxO3a 
overexpression has been shown to inhibit breast tumor growth and tumor size 
(148). In addition, inhibition of FoxO3a’s transcriptional activity promotes 
tumor progression, cell transformation, and angiogenesis during tumor 
development (149). Therefore, increasing the activity of FoxO proteins may 
provide an effective therapeutic strategy because of the importance of FoxO 
proteins in carcinogenic transformation. 
!
4.1.3 Regulation of FoxO Proteins by AKT 
"64
One important focus of the regulation of FoxO proteins has been on their 
cellular localization, which is reversibly regulated by their post-translational 
modifications, primarily that of phosphorylation (62, 150-152), and 
acetylation (153-154) in response to environmental stimuli. These post-
translational modifications are intimately connected to the cellular localization 
of FoxO proteins and their interactions with effectors, and therefore are 
considered to be important in regulating the level of activities of these proteins 
(155-156). 
The PI3K/AKT signaling pathway is a major regulator of FoxO proteins 
activation (153). Activation of PI3K leads to phosphorylation and activation of 
AKT. Activated AKT can then directly phosphorylate the three evolutionarily 
conserved sites of FoxO proteins. AKT phosphorylates T24, S256, S319 in 
FoxO1, phosphorylates T32, S253, S315 in FoxO3a, and phosphorylates T28, 
S193, S258 in FoxO4, respectively (Figure 19). The phosphorylation of FoxO 
proteins by AKT within nucleus promotes their shuttling to the cytoplasm, 
thereby inhibiting FoxO proteins-dependent gene transcription (157). The 
constitutively active FoxO proteins (called FoxO-3A), in which three AKT 
phosphorylation sites are mutated to alanine,  predominantly locate in nuclear, 
even in the presence of active PI3K/AKT signaling. This result suggested a 
key role for AKT-directed phosphorylation of FoxO proteins in their 
subcellular localization (136). 
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 !
Figure 19. Conserved AKT phosphorylation sites in FoxO proteins 
(Reference 157). 
!
4.1.4 FoxO Proteins and Autophagy 
FoxO proteins have also been reported to be regulators of autophagy. 
Multiple studies have suggested that FoxO1 and FoxO3a promote the 
expression of autophagy related genes, leading to increased autophagy 
(158-159). These findings have led to the notion that FoxO proteins in general 
are activators of autophagy through their function as transcription factors (62, 
160). In this view, the functions of different FoxO proteins are considered 
similar and overlapping with regard to the promotion of autophagy, with tissue 
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genetic analyses of the C. elegans dauer larval stage [13]. The DAF-16
gene was situated downstream of the pheromone receptor DAF-2 [14].
Subsequent studies also connected this pathway to C. elegans longevity,
showing that mutants of DAF-2, resulting in activation of DAF-16, live
longer thannormal animals [15]. Subsequent cloningof theDAF-16gene
and detailed pathway analysis delineated a signaling pathway starting
from DAF-2 (insulin receptor like gene) and going through AGE1 (PI3-
Kinase) and AKT to DAF-16 [16–18]. These studies underlined the
signiﬁcance of thepathway formetabolismand longevity control aswell
as the key role of DAF-16 in the pathway and the potential of its
mammalian homologues to mediate signals from the insulin receptor.
The studies indicated onnegative control of DAF-16 function byAKT and
also recognized the homology of DAF-16 to themammalian FKHR gene,
identifying three potential AKT phosphorylation sites conserved
between DAF-16 and FKHR (Fig. 1). Since speciﬁc insulin-regulated
transcription factors have not been identiﬁed at that time, the DAF-16
ﬁndings prompted a glut in studies focusing on the regulation of FKHR
(FoxO) proteins by AKT in mammalian systems [19–27].
2. Regulation of FoxO proteins by AKT
2.1. Historical perspective
Theﬁrst study showing regulationof amammalianFoxObyAKTwas a
study by Brunet et al. published in early 1999 [19]. This study
demonstrated that AKT can phosphorylate FoxO3/FKHRL1 on the three
predicted sites: T32, S253 and S315 both in vitro and in vivo and that this
phosphorylation resulted in the nuclear exclusion of FoxO3. Accordingly,
cell treatment with PI3K agonists such as IGF-1 or serum induced FoxO3
phosphorylation and nuclear exclusion while PI3K inhibition induced
FoxO3 dephosphorylation and nuclear accumulation. The study also
demonstrated that T32 and S253 phosphorylations mediated FoxO3
binding to the adapter protein 14-3-3z, suggesting that 14-3-3 proteins
facilitated FoxO3 nuclear/cytoplasmic shuttling. The study also identiﬁed
DNA sequenceswithin the IGFBP1 (insulin responsive sequence, IRS) and
FAS ligand (forkhead responsive element, FHRE) promoters that can
mediate FoxO3 binding and showed that AKT phosphorylation regulates
the transcriptional activity of FoxO3. Finally, the study showed that FoxO3
can mediate survival signaling downstream of AKT and that its over-
activation can induce apoptosis. A study by Kops et al [20], appearing at
the same time as the above study, demonstrated a similar regulation of
FoxO4/AFX phosphorylation and transcriptional activity by AKT. These
studies were followed by numerous studies demonstrating the ability of
AKT to phosphorylate FoxO1/FKHR and the other FoxO members,
corroborating this key regulatory mechanism [21–27]. These studies
were consequently conﬁrmed also with DAF-16 and Drosophila FoxO,
demonstrating the conservation of this regulatory mechanism through
evolution [28–35].
2.2. Mechanistic aspects of FoxO regulation by AKT
As illustrated in Fig. 1, the regulatory AKT phosphorylation sites
are shared by all mammalian FoxO members and are conserved
through evolution. All FoxO proteins, with the exception of FoxO6,
contain three AKT phosphorylation sites (FoxO6 lacks the
carboxy terminal site [12]). Notably however, The AKT consensus
phosphorylation motif deﬁned by Alessy et al, RxRxxS/T [36,37], can
be phosphorylated also by other AGC family kinases [38] such as PKA,
PKC, SGK and PAK family kinases. Indeed, SGK was shown to
phosphorylate FoxO3 on the AKT phosphorylation sites, though
with different site preference than AKT: both phosphorylated the
T32 site equally well, however, SGK showed preference for the S315
site and AKT for the S253 site [39]. PKAa was also shown recently to
phosphorylate FoxO1 on the AKT phosphorylation sites in vascular
endothelial cells [40]. To what extent other AGC family kinases
participate in FoxO regulation through phosphorylation of these sites
and under what cellular conditions remains to be determined.
Regarding the functional consequences of AKT phosphorylation, it
appears that these phosphorylations serve primarily as docking points
for 14-3-3 binding and do not affect protein function directly, e.g. DNA
binding afﬁnity. This notionwas inferred initially from DAF-16 studies
and later from mammalian FoxO studies [28,41–43]. Crystallography
studies also do not suggest direct effect of these phosphorylations on
FoxO protein function [44]. However, since 14-3-3 deﬁcient models
Fig. 1. Conserved AKT phosphorylation sites in FoxO proteins. Depiction of mammalian and C. elegans FoxO isoforms and the corresponding AKT phosphorylation sites. Indicated are
also the locations of the forkhead domain and the nuclear export (NES) and nuclear localization sequence (NLS).
1939G. Tzivion et al. / Biochimica et Biophysica Acta 1813 (2011) 1938–1945
distribution accounting for their differential impact in specific cell contexts. In 
addition, recent findings have also suggested that cytosolic FoxO1 can 
promote autophagy, in response to nutritional stress, by direct interaction with 
Atg7, demonstrating the complicated roles of this group of proteins in 
regulating autophagy (161). 
!
4.2 Results and Discussion 
4.2.1 FoxO proteins might be involved in Rac3-regualted autophagy 
process 
Rac GTPases are involved in multiple signaling processes. They exert 
their diverse cellular functions through interacting and activating a multitude 
of downstream effectors such as MAPK, PAK, Wave1/2, JNK, PI3K-AKT, 
NF-κB and NADPH oxidase etc. (162-166). Given the many connections of 
Rac signaling, it will likely require extensive studies to delineate the complete 
path of Rac3 signaling in exerting control of autophagy. This may involve 
some downstream effectors of Rac or some proteins already linked to the 
autophagy process, for example FoxO proteins. It may also implicate new 
players or new roles of known proteins which transmit or mediate the impact 
of Rac3 function on autophagy. 
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To investigate which downstream effector(s) of Rac or protein(s) already 
known to link to autophagy is involved in the autophagy regulation process of 
Rac3, immunoblot analysis was employed to assess the impact of Rac3 
knockdown on relevant proteins. Inspiringly, immunoblot analysis showed that 
FoxO1, which is a well known positive autophagy regulator, significantly 
increased when autophagy was induced through Rac3 knockdown (Figure 20). 
This phenomena is only shown in Rac3 is knockdown, but not in Rac1 or 
Rac2 knockdown. Very interestingly, FoxO3, the other member of FoxO 
proteins, dramatically decreased upon Rac3 knockdown. Again, this 
phenomena is Rac3 isoform specific. 
Figure 20. Knockdown of Rac3 induces FoxO1 but inhibits FoxO3a. 
Immunoblot analysis of FoxO1 and FoxO3a levels in lysates from PC3 cells 
treated with siRNAs targeting luciferase, Rac1, Rac2, and Rac3, respectively. 
Cell lysates were prepared from PC3 cells 72 h or 96 h after siRNA 
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This data suggested that both FoxO1 and FoxO3a are might be involved 
in Rac3-regulated autophagy process. This finding is very interesting, but we 
met a lot of technical difficulties when we further validated this finding. 
Interestingly, a lot of our data have showed that FoxO1 and FoxO3a may have 
opposite function in autophagy regulation in cancer cells, and this finding are 
novel. Therefore, in my thesis, I will not discuss how FoxO1 and FoxO3a 
regulate Rac3-regulated autophagy process, but discuss how FoxO1 and 
FoxO3a interplay in autophagy regulation in cancer cells. 
!
4.2.2 FoxO3a negatively regulates autophagy, in contrast to FoxO1 which 
promotes autophagy 
To further investigate the role of FoxO1 and FoxO3 in autophagy 
regulation in cancer cells as aforementioned finding, FoxO1 and FoxO3a were 
suppressed by siRNA in PC3 cells, respectively. Suppression of FoxO1 levels 
in PC3 cells by siRNA knockdown inhibited cellular autophagy, both under 
basal conditions and that induced by rapamycin (Figure 21A) or serum and 
glucose deprivation (Figure 21B). Two siRNAs targeting FoxO1 suppressed 
autophagy in PC3 cells, as assessed by LC3-II levels, suggesting a target 
specific effect of this regulation (Figure 21C). These data are consistent with 
the notion that FoxO1 is a positive regulator of autophagy (160-161,167). 
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Similar studies were performed using siRNA targeting FoxO3a to 
investigate the role of FoxO3a in PC3 cells. Surprisingly, an opposite effect 
was observed upon suppression of FoxO3a expression; siRNAs targeting 
FoxO3a enhanced basal autophagy as well as that induced by rapamycin, 
measured by LC3-II levels (Figure 21D). This reduction of FoxO3a expression 
further enhanced autophagy induced by either serum or glucose starvation 
(Figure 21E), suggesting a general involvement of FoxO3a in the regulation of 
autophagy in response to nutrition and growth signals in PC3 cancer cells. The 
induction of autophagy by FoxO3a suppression was validated with two 
FoxO3a targeting siRNAs (Figure 21F), diminishing the likelihood of this 
being an off-target effect. Previous studies in myotubes and fibroblasts have 
shown that FoxO3a plays important roles in promoting autophagy (68, 167); 
therefore this result suggests complex and cell context-specific roles of 
FoxO3a in regulation of autophagy. It seemed likely that there are distinct 
differences between muscle and fibroblast cells and epithelial-derived cancer 






 Figure 21. FoxO3a knockdown induces autophagy while FoxO1 
knockdown inhibits autophagy. (A). Immunoblot analysis of lysates from 
PC3 cells transfected with control siRNA (siLuc) or that targeting FoxO1 
(siFoxO1), with or without rapamycin treatment. PC3 cells were transfected 
with the indicated siRNA for 48 h before subsequent treatment with DMSO, 
20 nM or 100 nm rapamycin (Rapa) for 24 h prior to harvest and processing. 
(B). Immunoblot analysis of lysates from PC3 cells transfected with siLuc or 
siFoxO1 in different conditions. PC3 cells were transfected with the indicated 
siRNA for 48 h prior to media change, whereupon the cells were subjected to 
the indicated growth conditions; these conditions are DMEM in the presence 
(Normal) or absence of 10% FBS (serum (-)), or in the absence of D-glucose 
(D-Glu (-)), as indicated. Cells were harvested 6 h after exposure to these 
conditions, and processed for immunoblot analysis of the indicate proteins. 
(C). Immunoblot analysis of lysates from PC3 cells transfected with two 
siRNAs targeting FoxO1. Cell lysates were prepared from PC3 cells 72 h after 
siRNA transfection. (D, E, F) illustrate similar study procedures as (A, B, C), 
but with siRNAs targeting FoxO3a in PC3 cells. All experiments have been 
performed three times with similar results. 
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FoxO3a in PC3 cells, similar studies were performed using siRNA targeting
FoxO3a. Surprisingly, an opposite effect was observed upon suppression of
FoxO3a expression; siRNAs targeting FoxO3a enhanced basal autophagy as well as
that induced by rapamycin, measured by lipidated LC3 levels (Fig. 1D). This
reduction of FoxO3a expression further enhanced autophagy induced by either
serum or glucose starvation (Fig. 1E), suggesting a general involvement of FoxO3a
in the regulation of autophagy in response to nutrition and growth signals in PC3
cancer cells. The induction of autophagy by FoxO3a suppression was validated
with two FoxO3a targeting siRNAs (Fig. 1F), diminishing the likelihood of this
being an off-target effect. Previous studies in myotubes and fibroblasts have
shown that FoxO3a plays important roles in promoting autophagy [20, 34];
therefore this result suggests complex and cell context-specific roles of FoxO3a in
regulation of autophagy. It seemed likely that there are distinct differences
between muscle and fibroblast cells and epithelial-derived cancer cells in this
regulation. To determine whether the surprising negative regulation of autophagy
by FoxO3a was limited to PC3 prostate cancer cells, we examined the impact of
FoxO3a silencing in HCT116 colon and MDA-MB-231 breast cancer cell lines.
Similar to the observation in PC3 cells, knockdown of FoxO3a led to LC3-II
Fig. 1. FoxO3a knockdown induces, while FoxO1 knockdown inhibits, autophagy. (A) Immunoblot analysis of lysates from PC3 cells transfected with
control siRNA (siLuc) or that targeting FoxO1 (siFoxO1), with or without rapamycin treatment. PC3 cells were transfected with the indicated siRNA for 48 h
before subsequent treatment with DMSO, 20 nM or 100 nm rapamycin (Rap) for 24 h prior to harvest and processing. (B) PC3 cells were transfected with
the indicated siRNA for 48 h prior to media change, whereupon the cells were subjected to the indicated growth conditions; these conditions are DMEM in
the presence (Normal) or absence of 10% FBS (serum -), or in the absence of D-glucose (with 10% FBS), as indicated. Cells were harvested 6 h after
exposure to these conditions, and processed for immunoblot analysis of the indicate proteins. (C) Knockdown of FoxO1 with two targeting siRNAs
suppresses autophagy in PC3 cells. (D, E, F) illustrate similar study procedures as (A, B, C), but with siRNAs targeting FoxO3a in PC3 cells. All experiments
have been performed three times with similar results.
doi:10.1371/journal.pone.0115087.g001
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To determine whether the surprising negative regulation of autophagy by 
FoxO3a was limited to PC3 prostate cancer cells, the impact of FoxO3a 
silencing in HCT116 colon and MDA-MB-231 breast cancer cell lines was 
examed. Similar to the observation in PC3 cells, knockdown of FoxO3a led to 
LC3-II elevation in both cell lines (Figure 22), demonstrating this negative 
regulation of autophagy by FoxO3a is not limited to a single cancer cell line. 
 
Figure 22. FoxO3a knockdown induces autophagy in multiple cancer cell 
lines.  Immunoblot analysis of lysates from MDA-MB-231 and HCT116 cells 
transfected with siFoxO3a. Cell lysates were prepared from cells 72 h after 
siRNA transfection. All experiments have been performed three times with 
similar results. 
!
The pattern of LC3-I and LC3-II levels alone is not sufficient to 
illustrate the actual autophagy process, as aforementioned discussion. To 
clarify the role of FoxO3a in this process, we determined the impact of 
FoxO3a silencing on actual autophagy flux using two approaches. One 
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approach involved treatment of the cells with chloroquine in the presence of 
FoxO3a knockdown, which was performed in all three cancer cell lines, i.e. 
PC3, MDA-MB-231 and HCT116 cells. Suppression of FoxO3a resulted in 
the accumulation of LC3-II in these cells; and the addition of chloroquine 
further increased the LC3-II levels, suggesting that FoxO3a suppression 
increased LC3-II through autophagy induction (Figure 23). 
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Figure 23. FoxO3a knockdown induces autophagy flux. PC3, MDA-
MB-231, and HCT116 cells were transfected with control siRNA (siLuc) or 
that targeting FoxO3a (siFoxO3a). Subsequently, these cells were exposed to 
control vehicle or 50 mM chloroquine 72 h post transfection for 3 h before cell 
lysates preparation for immunoblot analysis of the indicated proteins. The 
LC3-II/GAPDH ratio for each condition is as presented after band 
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The second approach involved the measurement of the progression of 
autophagosomes into the acidic autophagolysosomes by confocal imaging. 
MDA-MB-231 cells stably expressing the tandem florescence protein mRFP-
GFP-LC3 were transfected with FoxO3a siRNA or control siRNA. 
Subsequently, colocalization of GFP with RFP, an indicator of 
autophagosome-lysosome fusion and protein degradation, was examined as 
previous (72). In this system, FoxO3a silencing not only led to increased LC3 
positive foci, but also to significant reduction in GFP colocalization with RFP, 
reflecting the status of increased autophagy flux (Figure 24A, 24B, 24C). 
Further, siRNA mediated reduction of Atg5 levels inhibited autophagy induced 
by FoxO3a knockdown (Figure 24D), providing evidence that suppression of 
FoxO3a promote autophagy induction in an Atg5 dependent manner. These 
data clearly establish that, while FoxO1 promotes autophagy as expected, 








 Figure 24. FoxO3a knockdown increases autophagy flux. (A). Confocal 
microscopy of MDA-MB-231 cell stably expressing tandem fluorescent 
mRFP-GFP-LC3 following transfection by either control or FoxO3a siRNA. 
Images were taken 72 h after transfection of the indicated siRNA. 
(B) .Quantitative analysis of the images from the experiment shown in panel A 
using MetaMorph software to determine the average number of RFP-positive 
particles per cell in control (siLuc) and siFoxO3a treated cells. (C). 
Colocalization analysis of RFP and GFP from experiment described in panel A 
to assess autophagy progression. RFP and GFP colocalization indicated by 
Pearson Coefficients was analyzed by ImageJ software. In both (B) and (C), 
more than 50 cells were analyzed for each condition. Data are presented as 
Mean ± S.E.M. (‘‘**’’, p<0.01). (D). PC3 cells were transfected with control 
siRNA (siLuc) or that targeting Atg5 (siAtg5), FoxO3a (siFoxO3a), or 
combination of both, as indicated. Cells were harvested 72 h after transfection 
and the lysates were processed for analysis. All experiments have been 
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To further test the hypothesis that FoxO3a is a negative regulator of 
autophagy in cancer cell lines, a target-specific rescue study was performed in 
PC3 cells by ectopic expression of FoxO3a(r), which encodes the same protein 
sequence as wild type FoxO3a but contained silent mutations rendering it 
resistant to the FoxO3a siRNA. Immunoblot analysis demonstrated that 
ectopic expression of FoxO3a(r) suppressed both basal autophagy and the 
autophagy induced by FoxO3a knockdown, in comparison to that in the cells 
expressing vector control (Figure 25A). Worth noting, expression of a form of 
FoxO3a, called FoxO3a-3A (unable to be phosphorylated by AKT), which 
exclusively localized to the nucleus (68), inhibited the autophagy as much as 
the wild type FoxO3a that localized both in the nucleus and in cytosol (Figure 
25B). These findings suggested that FoxO3a negatively regulates autophagy 







Figure 25. FoxO3a overexpression inhibits autophagy. (A). PC3 cells were 
transfected with either control siRNA or that targeting FoxO3a. Each group of 
cells was also co-transfected with either ectopic expression vector control or 
that express FoxO3a(r). The cell lysates were harvested for immunoblot 
analysis 72 h post transfection. (B). PC3 cells were transfected with three 
different expression plasmids, which are vector-Flag, Flag-FoxO3a or Flag-
FoxO3a-3A, respectively. The cell lysates were prepared 72 h post transfection 
for immunoblot analysis of the indicated proteins. All experiments have been 
performed three times with similar results. 
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4.2.3 FoxO3a regulation of autophagy is mediated by FoxO1 
It was noted that knockdown of FoxO3a resulted in an increase of 
FoxO1 protein level (Figure 26A), raising the possibility that FoxO1 mediates 
the autophagy induction effect from FoxO3a suppression. To investigate the 








FLAG-vector                  +       -        -        
FLAG-FoxO3a               -        +       - 
FLAG-FoxO3a-3A         -        -        +
siLuc                             +        +       -         - 
siFoxO3a                       -        -        +       + 
FLAG-vector                +       -        +        - 







concurrently suppressed the expression of these two proteins. Concurrent 
knockdown of FoxO1 not only inhibited basal autophagy as expected, but also 
completely abolished the elevation of autophagy induced by FoxO3a 
knockdown (Figure 26A), suggesting that FoxO1 is indispensable in 
autophagy induction resulting from FoxO3a suppression. Transfection of two 
different siRNAs targeting FoxO3a both resulted in elevated FoxO1 protein 
level (Figure 26B), which make the possibility of off-target effects of the 
siRNAs an unlikely scenario. 
 
Figure 26. Negative regulation of autophagy by FoxO3a is indispensable 
of FoxO1. (A). PC3 cells were transfected with siRNA for luciferase (siLuc), 
FoxO1 (siFoxO1), or FoxO3a (siFoxO3a), or combinations, as indicated. Cells 
were harvested 72 h after transfection, and cell lysates processed for 
immunoblot analysis of the indicated proteins. (B). FoxO3a knockdown with 
two FoxO3a targeting siRNA to illustrate the impact on FoxO1 protein level. 
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Consistent to the impact on protein levels, assessment of transcription by 
real-time PCR showed an increase of FoxO1 expression with FoxO3a 
knockdown (Figure 27A), suggesting that FoxO3a transcriptionally regulates 
FoxO1 level. Furthermore, treatment of cells with cycloheximide concurrently 
with FoxO3a knockdown eliminated the increase of FoxO1 protein level 
(Figure 27B), providing further evidence for FoxO3a regulating the 
expression, not stability of FoxO1. Taken together, these data support the 
conclusion that the increase in FoxO1 resulting from FoxO3a knockdown is 
likely the result of the increased transcription and synthesis of FoxO1. 
To further investigate the potential negative transcriptional regulation of 
FoxO1 by FoxO3a, we assessed the impact of FoxO3a overexpression on 
endogenous FoxO1 transcription. When introduced into PC3 cells, direct 
impact of FoxO3a(r) on FoxO1 expression was observed, with or without 
concomitant knockdown of FoxO3a. The inhibitory effect of FoxO3a(r) on 
basal FoxO1 expression was modest, but significant. In contrast, introduction 
of FoxO3a(r) almost completely obliterated the increase of FoxO1 
transcription induced by FoxO3a siRNA, bringing it back to near basal level 
(Figure 27C). This FoxO3a rescue study provides direct evidence for FoxO3a 
inhibition of FoxO1 transcription in PC3 cells. Taken together, these results 
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suggest that FoxO3a negatively regulates cellular autophagy by inhibiting the 
transcription of FoxO1, a positive regulator of autophagy and cell metabolism. 
Figure 27. FoxO3a negatively regulates autophagy through inhibition of 
FoxO1 transcription. (A). RT-PCR analysis of FoxO1 and FoxO3a mRNA 
levels in control siRNA (gray) or FoxO3a siRNA (black) transfected cells. 
Cells were harvested and processed 48 h after transfection; 18S ribosomal 
RNA was analyzed as the normalization control. Data was presented as Mean 
± S.D. (‘‘**’’, p<0.01). (B). PC3 cells were transfected with control siRNA or 
FoxO3a siRNA as indicated. Following 48 h of transfection, cells were treated 
with either DMSO control or 10 mg/ml cycloheximide for 24 h as indicated 
prior to being harvested for immunoblot analysis of the indicated proteins. The 
FoxO1/GAPDH ratio for each condition is as presented after band 
quantification by ImageJ. (C). RT-PCR analysis of endogenous FoxO1 
expression level in PC3 cells transfected with either control plasmid (vector) 
or that expressing FoxO3a(r); in each group of the plasmid transfected cells, 
either control siRNA or FoxO3a siRNA were concurrently introduced. The 
cells are harvested for RNA preparation and RT-PCR analysis 72 h post 
transfection.18S was used as the normalization control. Data was presented as 
Mean ± S.D. (‘‘**’’, p<0.01). All experiments have been performed three 
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4.2.4 Elevation in cytosolic FoxO1 resulting from FoxO3a suppression 
induces autophagy 
It is well-established that FoxO1 positively regulates autophagy by 
increase the transcription of some autophagy genes (69, 160). However, recent 
studies have provided convincing evidence that cytosolic FoxO1 promotes 
autophagy independent of its transcription regulatory activity (161). This 
current study so far has demonstrated that suppression of FoxO3a increased 
the transcription and total FoxO1protein level, which is the cause of elevated 
autophagy. It is unclear, however, whether this FoxO1 dependent autophagy is 
mainly due to its nuclear or cytosolic function. We seek to define this question 
using a few different approaches. Fractionation of PC3 cell lysate following 
knockdown of FoxO3a revealed a significant elevation of cytosolic FoxO1, 
while the quantity of nuclear FoxO1 remain unchanged (Figure 28A). This 
result suggests that the increased FoxO1 resulting from FoxO3a suppression 
mostly accumulates in the cytosol. We speculate that this predominantly 
cytosolic elevation of FoxO1 was the likely culprit for the activation of 
autophagy following FoxO3 knockdown, consistent with some recent reports 
(161). Consistent with the fractionation study, RT- PCR quantitation of known 
FoxO target genes involved in autophagy, such as Atg4c, Atg7, LC3, Atg12, 
and Bnip3, showed no significant increase in expression upon FoxO3a 




Figure 28. Increased cytosolic FoxO1 resulting from FoxO3a knockdown 
leads to the elevated level of autophagy. (A). Cell fractionation of PC3 cells 
transfected with  siRNA for luciferase (-) or FoxO3a (siFoxO3a). PC3 cells 
were transfected with siLuc (-) or siFoxO3a as indicated, and harvested for 
immunoblot analysis of the indicated proteins 72 h after transfection. Histone 
H3 and GAPDH were used as loading control for nuclear and cytosolic 
proteins, respectively. The band quantity ratios, FoxO1/GAPDH and FoxO1/
Histone H3, for each condition were obtained using ImageJ. (B). Real-time 
PCR analysis for the relative expression levels of the indicated autophagy-
related genes. Total mRNA was isolated 48 h after transfection of PC3 cells 
with control siRNA (black) or two different siRNAs targeting FoxO3a (light 
and dark grey, respectively). Data was presented as Mean ± S.D. All 
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To directly assess the impact of cytosolic FoxO1 on autophagy in PC3 
cancer cells, we introduced into cells an expression vector containing Flag-
tagged FoxO1 modified to have a defective DNA binding mutation, FoxO1-
∆DB (161). The FoxO1-∆DB thus expressed is non-functional as a 
transcription factor and, interestingly, almost exclusively localized to the 
cytosol. In both PC3 cells (Figure 29A) and H1299 cells (Figure 29B), Flag-
FoxO1-∆DB protein was exclusively localized to the cytosol as expected and 
Flag-FoxO1-∆DB expressing cells (red) had markedly higher level of 
autophagosomes than that of the un-transfected cells. Image analysis has 
demonstrated statistically significant elevation of autophagosome in cells 
expressing cytosolically localized FoxO1. These data provide direct evidence 
to support the notion that the cytosolic accumulation of FoxO1 in these cancer 




 Figure 29. Over-expression of FoxO1-∆DB increases autophagy. (A). Over-
expression of transcription function inactive/cytosolic form of FoxO1, FoxO1-
∆DB in PC3 cells. The quantities of LC3 positive vesicle of PC3 cells were 
compared in the same analysis between Flag-FoxO1-∆DB over-expressing 
cells and un-transfected cells. (B). Over-expression of FoxO1-∆DB in H1299 
cells. The quantities of LC3 positive vesicle of PC3 cells were compared in the 
same analysis between Flag-FoxO1-∆DB over-expressing cells and un-
transfected cells. FITC and rhodamine tagged secondary antibodies were used 
for the detection of anti-LC3 or anti-Flag tag, respectively. The number of 
LC3 in each cell population was quantified using MetaMorph software; the 
data were plotted on the right side of each panel. More than 50 cells were 
analyzed for each condition. Data was presented as Mean ± S.E.M. (‘‘**’’, 













4.2.5 FoxO1-mediated regulation of autophagy is likely mTORC2 
dependent. 
mTORC1 is a well-recognized sensor for nutrition and growth factor 
signaling; it inhibits autophagy in response to growth signaling. Hence, we 
examined the activity of mTORC1 signaling when FoxO1 or FoxO3a 
expression is suppressed with siRNA. FoxO3a knockdown led to a significant 
elevation of autophagy as seen above; no significant changes in pattern of 
phospho-4EBP1(37/46) and phospho-S6(240/244) were observed in cells with 
FoxO3a knockdown while autophagy was markedly induced (Figure 30A, 
DMSO), suggesting that the elevation of autophagy induced by FoxO3a 
knockdown was likely not through inhibition of mTORC1. Worth noting, 
FoxO1 knockdown-mediated down regulation of autophagy was accompanied 
by an inhibition of mTORC1 signaling, based on both phospho-4EBP1(37/46) 
and phospho-S6(240/244) patterns (Figure 30B, DMSO), which also 
supported the notion that FoxO regulation of autophagy was not mediated 
through the classic mTORC1 signaling in this case. 
To further evaluate the interaction between mTOR signaling and FoxO- 
regulated autophagy, we combined either FoxO3a or FoxO1 knockdown with 
rapamycin treatment in PC3 cells. Rapamycin treatment alone effectively 
blocked mTORC1 function, but induced autophagy to a much less extent than 
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that induced by FoxO3a knockdown. The combination of FoxO3a knockdown 
and rapamycin treatment resulted in a higher level of autophagy induction 
(Figure 30A, Rapamycin). Since the results detailed above indicated that the 
autophagy regulatory effect of FoxO3a was mediated through FoxO1, we 
assessed the impact of FoxO1 suppression in combination with rapamycin on 
mTOR signaling. Consistent with our above results, suppression of FoxO1 
inhibited both basal and rapamycin-induced autophagy. Paradoxically, FoxO1 
down-regulation appeared to inhibit mTOR function, again supporting the 
notion that FoxO1 positively regulates autophagy through a different 
mechanism from that resulting from mTORC1 inhibition (Figure 30B, 
Rapamycin). These observations provide compelling evidence that the 
regulation of autophagy by FoxO proteins is not through the classic 






Figure 30. FoxO3a and FoxO1 regulation of autophagy is unlikely to be 
dependent on mTORC1 activity. (A) PC3 cells were transfected with 
siRNAs targeting FoxO3a as indicated. Following 48 h of transfection, cells 
were subjected to rapamycin treatment for 24 h prior to processing for 
immunoblot analysis of the indicated proteins. (B) PC3 cells underwent 
similar study as described in (A), except siRNA targeting FoxO1 was used as 
indicated. All experiments have been performed three times with similar 
results. 
!
Several studies have linked AKT phosphorylation of FoxO proteins as a 
major element of their cytosolic localization (162).  Hence, we examined the 
activity of AKT and phosphorylation of FoxO1 with FoxO3a knockdown. 
FoxO3a knockdown led to a significant elevation of AKT phosphorylation on 
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Concurrently, Thr24 of FoxO1, a well-recognized target for AKT, was heavily 
phosphorylated upon FoxO3a knockdown. These data suggest that the increase 
in cytosolic FoxO1 that accompanies FoxO3a knockdown is likely mediated 
through phosphorylation and cytosolic retention of this FoxO1. Interestingly, 
concurrent suppression of FoxO1 and FoxO3a abolished the activation of 
AKT, with resultant reduction of both total FoxO1 and Thr24 phosphorylated 
FoxO1. Hence, it seems that FoxO3a down regulation increases transcription 
of FoxO1 with subsequent increase in the protein level (Figure 26A); FoxO1 is 
then involved in the activation of AKT, leading to the phosphorylation and 
cytosolic retention of FoxO1, forming a positive feedback loop between AKT 
and cytosolic FoxO1. Indeed, both p-AKT (S473) and autophagy, induced by 
FoxO3a knockdown are dependent on FoxO1, as the concurrent silencing of 
FoxO1 and FoxO3a eliminated both (Figure 31A).  Worth noting, the finding 
that AKT activation and FoxO1 phosphorylation are associated with 
autophagy induction from FoxO3a knockdown is consistent with the notion 
that it is the cytosolic FoxO1 that promotes autophagy. 
Given that FoxO3a suppression led to AKT(Ser473) phosphorylation, a 
known target of the mTORC2 kinase complex, we suspected that the 
mTORC2 complex could be involved.  To test the hypothesis that mTORC2 
kinase was involved in mediating the induction of autophagy by FoxO3a 
suppression, the impact of co-knockdown of FoxO3a and Rictor, a component 
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of mTORC2 complex, was studied. Both Rictor knockdown alone and co-
knockdown of Rictor and FoxO3a were validated by RT-PCR (not shown). As 
expected as it is a functional component of mTORC2 kinase complex, Rictor 
knockdown reduced AKT(Ser473) phosphorylation (Figure 31B). Consistent 
with the results detailed above, suppression of FoxO3a increased FoxO1 and 
pAKT(Ser473) levels, and promoted autophagy. Co-suppression of Rictor 
reduced the phosphorylation of AKT resulting from FoxO3a knockdown, 
suggesting that the elevation of pAKT473 level is due to mTORC2 activation. 
Most importantly, in addition to reducing pAKT473 level induced by FoxO3a 
knockdown, suppression of Rictor abolished the autophagy induction. These 











 Figure 31. FoxO1-mediated regulation of autophagy might be dependent 
on mTORC2 acitivity. (A). FoxO3a knockdown activates AKT and 
phosphorylates FoxO1. PC3 cells were transfected with siRNAs targeting 
FoxO1, FoxO3a, or in combination, as indicated; cell lysates were prepared 72 
h and 96 h after transfection for immunoblot analysis of the indicated proteins. 
(B). mTORC2 activity mediates the effect of FoxO3a knockdown on 
autophagy induction. PC3 cells were transfected with control siRNA (siLuc), 
or that targeting rictor (siRictor), FoxO3a (siFoxO3a) or the combination of 
siRictor and siFoxO3a, as indicated. Following 72 h of transfection, cells were 
harvested and cell lysates were prepared for immunoblot analysis of the 
indicated proteins. All experiments have been performed three times with 
similar results. !!
In regard to the mechanism of FoxO1 promotion of autophagy, our data 
suggests that the preferential increase in cytosolic localization of FoxO1 is 
achieved through the positive feedback loop of FoxO1 induced AKT 
activation followed by AKT phosphorylation of FoxO1; AKT phosphorylated 
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FIGURE 6. FoxO1 activation of autophagy is dependent on mTORC2, but not mTORC1, 
activity. (A) PC3 cells were transfected with siRNAs targeting FoxO1, FoxO3a, or in 
combination, as indicated; cell lysates were prepared 72 h and 96 h after transfection for 
immunoblot analysis of the indicated proteins. (B) PC3 cells were transfected with either 
control siRNA (siLuc) or siFoxO3a as indicated. Following 48 h of transfection, cells were 
subjected to rapamycin treatment for 24 h prior to processing for immunoblot analysis of the 
indicated proteins. (C) PC3 cells were transfected with either control siRNA (siLuc) or 
siFoxO1 as indicated. Following 48 h of transfection, cells were subjected to rapamycin 
treatment for 24 h prior to processing for immunoblot analysis of the indicated proteins. (D) 
mTORC2 activity mediates the effect of FoxO3a knockdown on autophagy induction. PC3 
cells were transfected with control siRNA (siLuc), or that targeting rictor (siRictor), FoxO3a 
(siFoxO3a) or the combination of siRictor and siFoxO3a, as indicated. Following 72 h of 
transfection, cells were harvested and cell lysates were prepared for immunoblot analysis of 
the indicated proteins. All experiments have been performed three times with similar results. !
that FoxO1 stimulated phosphorylation of Serine 473 of AKT is likely 
mediated through stimulation of mTORC2 kinase activity, which constitutes 
the link of the positive feedback loop between AKT and FoxO1 (Figure 32). 
However, the study on mechanism of FoxO1-mediated regulation of 
autophagy upon FoxO3a suppression is still very preliminary. Much more 
efforts will be needed to investigate which cell signaling is invoked in 




Figure 32. Proposed model for regulation of autophagy by FoxO3a/FoxO1 
function through a FoxO1-mTORC2-AKT positive feedback loop. The 
black lines represent prior established links; the orange lines represent 















FIGURE 7. Proposed model for regulation of autophagy by FoxO3a/FoxO1 function 
through a FoxO1-mTORC2-AKT positive feedback loop. The black lines represent 
prior established links; the orange lines represent elements provided by this study.
4.2.6 Discussion 
A recent study has shown a functional interaction between FoxO3a and 
FoxO1. In that study, FoxO3a promoted cytosolic localization of FoxO1 by 
transcriptionally elevating expression of the PI3-kinase catalytic subunit in 
human embryonic kidney cells and mouse embryonic fibroblast cells (167). 
Therefore, FoxO3a acted as a positive regulator of autophagy in those cell 
types. In our study, our data showed that FoxO3a function as a negative 
regulator of autophagy in multiple cancer cells. The evidence includes: (i) 
multiple siRNAs targeting FoxO3a elicit the autophagy induction, ruling out 
off-target effects, (ii) FoxO3a suppression increased autophagy flux as 
demonstrated by multiple approaches to examine autophagosome to autopha- 
golysosome progression, (iii) autophagy induction by FoxO3 knockdown 
could be rescued by ectopic expression of siRNA resistant wild type FoxO3a, 
and (iv) quantitation of FoxO1 mRNA demonstrated the effect of FoxO3a 
gain- and loss-of function on endogenous FoxO1 expression. 
In regard to the possible mechanism for the difference of FoxO3a 
regulating FoxO1 and autophagy in the two studies, it seems likely that the 
different effects could be because of the cell context differences. In that study, 
immortalized benign HEK293T and MEF cells were used, while our present 
study uses multiple human cancer cells. The point of tissue and cell context 
differences can be illustrated by the example that the expression of atrogin-1 
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and MuRF1 downstream of FoxO are specific to muscle cells, in which these 
proteins regulate both proteasome degradation and autophagy. A scenario that 
could account for the differences observed in FoxO3a function is the 
differential presence of co-repressor(s) or co-activator(s) that assist the 
transcriptional activities of FoxO3a in regulating FoxO1 expression. These 
studies highlight that the regulatory impacts of FoxO proteins can be different 
between different cell types. 
The new information on FoxO regulation of autophagy from our study 
advances the understanding of autophagy regulation. Further investigation of 
the interplay between FoxO3a and FoxO1 in benign and cancer cells, and 
among different cancer cells will not only advance the understanding of 
autophagy regulation but may also provide information for targeting 







CHAPTER 5: DISCUSSION AND FUTURE DIRECTIONS 
!
5.1 Discussion 
Autophagy recently has received increasing attention in both basic 
mechanistic studies as well as for its involvement in multiple 
pathophysiological processes, including cancer and metabolic disorders. The 
regulation of autophagy is essential for the adaptation of cells to its 
extracellular environment, such as nutrient, growth factors, cytokines, oxygen 
status, etc. Dysregulation of autophagy has been recognized to result in 
numerous pathological conditions; hence manipulation of autophagy has 
important therapeutic implications. Studies over the last decade have identified 
many players in the autophagy process and its regulation, but there remain 
many unknowns in the regulation of autophagy. The finding of Rac3 as a 
regulator of autophagy underscores the need to identify novel regulators of the 
autophagy process to advance our understanding for this important cellular 
process, and to pursue tumor-specific targeting. Moreover, it solves a little 
piece of puzzle for autophagy regulation. It is particularly encouraging to find 
that, in the cell lines we surveyed, there is a consistent pattern that the higher 
the expression of Rac3 protein, the lower the basal autophagy. 
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Part of the work in the thesis went beyond CAAX proteins to understand 
the regulation of autophagy. Autophagy is downstream of multiple critical 
signaling pathways, including PI3K/AKT/mTOR and several others that are 
either parallel to, or interactive with, this main axis. PI3K/AKT/mTOR 
signaling is central to cellular response to extracellular environment, and a 
group of the most notable and evolutionarily conserved effectors of this 
pathway are FoxO proteins, which relay signals to different yet connected 
downstream components to provide integrated cellular responses to 
environment. Here, we found that FoxO1 and FoxO3a might be involved in 
Rac3-regulated autophagy process by functioning in opposing ways in 
autophagy regulation. In further studies, we obtained very convincing 
evidence that FoxO3a indeed functions as a negative regulator of autophagy in 
multiple cancer cell, while FoxO1 functions as a positive regulator of 
autophagy. This funding is different from that of earlier studies which implied 
that FoxO1 and FoxO3a function similarly in promoting autophagy. The 
differences of FoxO3a in regulating FoxO1 and autophagy in the two studies 
are likely due to cell context differences. This study has uncovered a new role 
of FoxO3, one of the already-known regulators in autophagy regulation. The 
new information on regulation of autophagy by FoxO1 and FoxO3 has not 
only advanced the understanding of autophagy, but also underscores the 
importance of obtaining a more thorough understanding of the regulatory 
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mechanisms of this process. Further investigation of the interplay between 
FoxO3a and FoxO1 in benign and cancer cells may also provide important 
information for targeting autophagy in therapy. 
!
5.2 Future directions 
Future direction 1: Expanding the siRNA screen to identify additional 
CAAX proteins involved in Icmt inhibitor-mediated autophagy 
regulation. 
Our result showed that ectopic expression of Rac3 only partially 
reversed the effect of cysmethynil treatment in inducing autophagy and cell 
death, and Rac3 knockdown did not generate the same level of autophagy 
induction as cysmethynil treatment (Figure 10). These results encourage us to 
expand the siRNA screen, which may identify additional CAAX protein(s) 
involved in Icmt inhibitor-mediated autophagy regulation. The CAAX 
protein(s) identified through this screen may provide new evidence for their 
function, and new information on autophagy regulation. 
!
Future direction 2: Perform a structure-function analysis of different Rac 
isoforms to identify the structural elements in Rac3 that account for its 
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specific role in autophagy regulation.  
Our aforementioned data have indicated a Rac3-specific role in 
controlling autophagy. Rac3 shares 92% identity with Rac1 and 89% identity 
with Rac2 in overall amino acid, yet it clearly has biological roles not 
associated with the other family members. Several reports have suggested that 
Rac1, Rac2 and Rac3 have different localization, protein-protein interactions 
and functions because of their different amino acid sequence. Therefore, it will 
be important to determine the specific structural elements in Rac3 accounting 
for its distinct role in autophagy regulation, as this will aid in identifying the 
regulatory process that Rac3 engages but the other two isoforms cannot. 
!
Future direction 3: Further elucidate the role of FoxO1 and FoxO3a in 
Rac3-regulated autophagy process. 
Our data indicated that FoxO1 and FoxO3 may be involved in Rac3-
regulated autophagy process, but we need to develop new approaches to 





Future direction 4: Continue to elucidate the mechanism(s) of autophagy 
regulation by Rac3 and delineate the signaling pathway of Rac3 in 
controlling autophagy. 
As aforementioned, Rac proteins are involved in multiple signaling 
processes and they exert their diverse cellular functions through interacting 
and activating a multitude of downstream effectors. Among Rac GTPases, 
Rac1 is the prototypic family member and the focus of most investigations to 
date. All the identified downstream effectors of Rac GTPases have been 
reported to function as effectors of Rac1, but only a few have been also 
studied as downstream effectors of Rac2 and Rac3. Intriguingly, Rac1, Rac2 
and Rac3 have identical so-called “effector binding loops” in their structures, 
suggesting that they bind and activate the same set of effectors. However, as 
noted above, there are functional differences in these Rac isoforms, which 
could be because their different localization in cells. It is conceivable that the 
localization of Rac3 could put it in close proximity to a particular effector 
although the effector binding properties are the same of Rac GTPases. 
Therefore, it is important to not only study which effector(s) Rac3 may 
specifically activate,  but also whether the different cell localization affects the 
interaction of Rac3 with specific effectors in autophagy regulation. These 
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